

CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

- This application claims the benefit under 35 U.S.C. § 119(e) of U.S.
5 Provisional Patent Application No. 61/190,067 filed April 11, 2008, where this
provisional application is incorporated herein by reference in its entirety.

STATEMENT REGARDING SEQUENCE LISTING

- The Sequence Listing associated with this application is provided in
text format in lieu of a paper copy, and is hereby incorporated by reference into
10 the specification. The name of the text file containing the Sequence Listing is
910180_420PC_SEQUENCE_LISTING.txt. The text file is 286 KB, was created
on April 10, 2009, and is being submitted electronically via EFS-Web, concurrent
with the filing of the specification.

BACKGROUND

15 Technical Field

- The present disclosure generally provides compositions and
methods for treating B-cell disorders and, more specifically, a humanized anti-
CD37 small modular immunopharmaceutical (SMIP) molecule, as well as
synergistic combination therapies of CD37-specific binding molecules with
20 bifunctional chemotherapeutics for use in treating or preventing B-cell related
autoimmune, inflammatory, or hyperproliferative diseases.

Description of the Related Art

- The human immune system generally protects the body from
invading foreign substances and pathogens. One component of the immune
25 system is B lymphocytes, also referred to as B-cells, which produce antibodies
that protect the body by binding to, and in some cases mediating destruction of, a
foreign substance or pathogen. In some instances, however, the immune system

functions can go awry and disease results. For example, there are numerous cancers, autoimmune diseases, and inflammatory diseases that involve uncontrolled proliferation of B-cells.

B-cells can be identified by molecules on their cell surface, such as

5 CD37. CD37 is a heavily glycosylated 40-52 kDa protein that belongs to the tetraspanin transmembrane family of cell surface antigens, which is highly expressed on normal antibody-producing B-cells but not on pre-B-cells or plasma cells. In addition to normal B-cells, almost all malignancies of B-cell origin are positive for CD37 expression, including chronic lymphocytic leukemia (CLL), non-

10 Hodgkins lymphoma (NHL), and hairy cell leukemia (Moore *et al.*, J. Pathol. 152:13 (1987); Merson and Brochier, Immunol. Lett. 19:269 (1988); and Faure *et al.*, Am. J. Dermatopathol. 12:122 (1990)).

A few CD37 specific immunotherapies have been developed. An IgG1 murine monoclonal antibody specific for CD37, MB-1, was labeled with ¹³¹I

15 and tested in a clinical trial in the treatment of NHL (see Press *et al.*, J. Clin. Oncol. 7:1027 (1989); Bernstein *et al.*, Cancer Res. (Suppl.) 50:1017 (1990); Press *et al.*, Front. Radiat. Ther. Oncol. 24:204 (1990); Press *et al.*, Adv. Exp. Med. Biol. 303:91 (1991) and Brown *et al.*, Nucl. Med. Biol. 24:657 (1997)). The MB-1 antibody lacks Fc effector functions, such as antibody-dependent cellular

20 cytotoxicity (ADCC), and the naked MB-1 antibody did not inhibit tumor growth in an *in vivo* xenograft model (Buchsbaum *et al.*, Cancer Res. 52:6476 (1992)). In addition, an immunoconjugate having adriamycin linked to G28-1, another murine monoclonal anti-CD37, was administered to mice and shown to be internalized with adriamycin being released intracellularly (see, Braslawsky *et al.*, Cancer

25 Immunol. Immunother. 33:367 (1991)). An engineered fusion protein, termed a small modular immunopharmaceutical (SMIP™) product, directed to CD37 is currently being tested in humans (see, e.g., US Patent Application Publications 2003/0133939 and 2007/0059306).

Although there has been extensive research carried out on

30 antibody-based therapies, there remains a need in the art for alternative or improved compositions and methods for treating B-cell associated disorders or diseases.

BRIEF SUMMARY

In one aspect, the present disclosure provides humanized CD37-specific binding molecules and a method for reducing B-cells or treating a disease associated with aberrant B-cell activity comprising administering to a
5 subject in need thereof an effective amount of a humanized CD37-specific binding molecule provided herein.

In certain embodiments, the present disclosure provides a humanized CD37-specific binding molecule, comprising from amino terminus to carboxyl terminus: (i) a humanized heavy chain variable region, (ii) a linker as set
10 forth in SEQ ID NO:229, (iii) a humanized light chain variable region, (iv) an IgG1 hinge, (v) human IgG1 CH2 region, and (vi) human IgG1 CH3 region, wherein (a) the humanized heavy chain variable region comprises from amino terminus to carboxyl terminus: a humanized heavy chain FR1, a heavy chain CDR1 as set forth in SEQ ID NO:63, a humanized heavy chain FR2, a heavy chain CDR2 as
15 set forth in SEQ ID NO:65, a humanized heavy chain FR3, a heavy chain CDR3 as set forth in SEQ ID NO:67, 68 or 69, and a humanized heavy chain FR4, and (b) the humanized light chain variable region comprises from amino terminus to carboxyl terminus: a humanized light chain FR1, a light chain CDR1 as set forth in SEQ ID NO:61 or 62, a humanized light chain FR2, a light chain CDR2 as set
20 forth in SEQ ID NO:64, a humanized light chain FR3, and a light chain CDR3 as set forth in SEQ ID NO:66, and a humanized light chain FR4.

In certain embodiments of the above humanized CD37-specific binding molecules, the humanized heavy chain FR1 comprises SEQ ID NO:144, the humanized heavy chain FR2 comprises SEQ ID NO:151, the heavy chain
25 FR3 comprises SEQ ID NO:158, and the heavy chain FR4 comprises SEQ ID NO:161 or 162.

In certain embodiments of any one of the above humanized CD37-specific binding molecules, the humanized light chain FR1 comprises SEQ ID NO:171, the light chain FR2 comprises SEQ ID NO:182, the light chain FR3
30 comprises SEQ ID NO:195, and the light chain FR4 comprises SEQ ID NO:206.

In a related aspect, the present disclosure provides a CD37-specific binding molecule that comprises the amino acid sequence as set forth in SEQ ID NO:253.

In certain embodiments, the CD37-specific binding molecule
5 consists essentially of the amino acid sequence as set forth in SEQ ID NO:253.

In certain embodiments, the CD37-specific binding molecule consists of the amino acid sequence as set forth in SEQ ID NO:253.

In a related aspect, the present disclosure also provides an isolated nucleic acid molecule that comprises a nucleotide sequence encoding a
10 humanized CD37-specific binding molecule provided herein.

In another related aspect, the present disclosure provides a vector that comprises an isolated nucleic acid molecule that encodes a humanized CD37-specific binding molecule provided herein.

In another related aspect, the present disclosure provides a host
15 cell that comprises the above-described vector.

The present disclosure also provides a composition that comprises a humanized CD37-specific binding molecule provided herein and a pharmaceutically acceptable carrier.

In another aspect, the present disclosure provides a method for
20 reducing B-cells or treating a disease associated with aberrant B-cell activity, comprising administering to a subject in need thereof an effective amount of a humanized CD37-specific binding molecule provided herein.

In certain embodiments, the disease associated with aberrant B-cell activity is a B-cell lymphoma, a B-cell leukemia, a B-cell myeloma, a disease
25 characterized by autoantibody production, or a disease characterized by inappropriate T-cell stimulation associated with a B-cell pathway.

In certain embodiments, the disease characterized by autoantibody production is idiopathic inflammatory myopathy, rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis, an
30 autoimmune disease, dermatomyositis, polymyositis, or Waldenstrom's macroglobinemia.

In certain embodiments, the disease associated with aberrant B-cell activity is chronic lymphocytic leukemia (CLL).

In another aspect, the present disclosure provides compositions and methods for the combined use of CD37-specific binding molecules and bifunctional chemotherapeutics to reduce B-cells or treat a disease associated with aberrant B-cell activity. A surprising result of this combination is that these compounds act synergistically, which results in an increased B-cell reduction.

For example, the present disclosure provides a composition that comprises a CD37-specific binding molecule and bendamustine.

In certain embodiments, the CD37-specific binding molecule is a CD37-specific antibody or SMIP, such as a humanized antibody or humanized SMIP.

In certain embodiments, the CD37-specific binding molecule competes with G28-1 mAb in CD37-specific binding.

In certain embodiments, the CD37-specific binding molecule is a humanized CD37-specific binding molecule provided herein, such as a humanized CD37-specific binding molecule that comprises, consists essentially of, or consists of, the amino acid sequence as set forth in SEQ ID NO:253.

In a related aspect, the present disclosure provides a method for reducing B-cells or treating a disease associated with aberrant B-cell activity, comprising administering to a subject in need thereof an effective amount of a CD37-specific binding molecule and bendamustine.

In certain embodiments, the disease associated with aberrant B-cell activity is a B-cell lymphoma, a B-cell leukemia, a B-cell myeloma, a disease characterized by autoantibody production, or a disease characterized by inappropriate T-cell stimulation associated with a B-cell pathway.

In certain further embodiments, the disease characterized by autoantibody production is idiopathic inflammatory myopathy, rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis, an autoimmune disease, dermatomyositis, polymyositis, or Waldenstrom's macroglobinemia.

In certain other embodiments, the disease associated with aberrant B-cell activity is chronic lymphocytic leukemia (CLL).

In certain embodiments, the CD37-specific binding molecule and bendamustine are administered concurrently.

5 In certain other embodiments, the CD37-specific binding molecule and bendamustine are administered sequentially.

In certain embodiments, the CD37-specific binding molecule and bendamustine are formulated together.

In certain embodiments, the CD37-specific binding molecule is a
10 CD37-specific antibody or SMIP, such as a humanized antibody or a humanized SMIP.

In certain embodiments, the CD37-specific binding molecule competes with G28-1 mAb in CD37-specific binding.

In certain embodiments, the CD37-specific binding molecule is a
15 humanized CD37-specific binding molecule provided herein, such as a humanized CD37-specific binding molecule that comprises, consists essentially of, or consists of, the amino acid sequence as set forth in SEQ ID NO:253.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows heavy and light chain variable region amino acid
20 sequence alignments of mouse G28.1 and CAS-024 sequences, along with a consensus identity sequence.

Figures 2A-2D show the size exclusion chromatography (SEC) chromatograms of CAS-001, CAS-002, CAS-003, and CAS-024. The peaks of interest (POI) have 98-99% of the SMIP molecules being purified. CAS-024 has
25 a very sharp and symmetrical peak (indicating homogeneity), whereas CAS-001, CAS-002, and CAS-003 peaks have a slight shoulder (where upon integration, the shoulder accounts for about 35% of the POI), which indicates a heterogeneous population of molecules.

Figure 3 is graph showing how various anti-CD37 specific SMIP
30 proteins compete with the parent CAS-006 molecule (chimeric anti-CD37 SMIP protein, mVLmVH) for binding to CD37 on Ramos cells, which provides an

indication on the affinity of binding as compared to the parent molecule. CAS-024 (hVHhVL) has substantially the same affinity for CD37 as does CAS-006, whereas the other molecules (CAS-001, CAS-002, and CAS-003, all hVLhVH) have a 2- to 4-fold decrease in affinity.

5 Figures 4A and 4B are graphs of additional binding competition assays against CAS-006 (labeled as SMIP-016 in these graphs). Here, mouse-human hybrid SMIP molecules (CAS-014 mVHhVL and CAS-017 hVLmVH) have an affinity that is higher than CAS-006, whereas CAS-024 shows the same binding affinity as CAS-006 and CAS-003 (hVLhVH) has a lower binding affinity.

10 Figures 5A-5E show competitive binding between various different anti-CD37 antibodies and CAS-006 (a chimeric anti-CD37 SMIP molecule).

 Figures 6A and 6B show that CAS-024 was statistically superior to Rituxan® in the *in vivo* treatment of an animal model of follicular lymphoma as shown by (A) survival rate and (B) tumor-free percentage.

15 Figure 7 shows that CAS-024 acts synergistically with chemotherapeutic agents fludarabine and vincristine to kill mantle cell lymphoma (MCL) cells, Rec-1 cells.

 Figure 8 is a bar graph showing the level of depletion of peripheral blood lymphocytes in human patients treated with an anti-CD37 SMIP molecule
20 of this disclosure.

 Figure 9 shows the lymphocyte depletion and course of treatment for patient BJB. BJB (part of Cohort 7) was treated with 3.0 mg/kg on days 1, 3 and 5 the first week followed by 3 weekly doses in the first cycle, and this same treatment was administered in a second cycle. Patient BJB showed a dramatic
25 drop in lymphocytes (within 48 hrs), showed a decrease in palpable lymph nodes by day 4, and continues to respond to treatment.

 Figure 10 shows the lymphocyte depletion and course of treatment for patient GRP. GRP (part of Cohort 4) was treated with 1.0 mg/kg once a week for four weeks as the first cycle, and then two months later was treated in the
30 same way in a second cycle. Patient GRP showed a dramatic drop in lymphocytes (within 2 weeks), showed a 36% decrease in lymph node size by CT

scan, a decrease in spleen size, improved hemoglobin level, and continues to respond to treatment.

Figure 11 shows a combination index (CI) plot for inhibitory effects of CAS-024 and bendamustine against Rec-1 cell growth.

5 Figure 12 shows inhibitory effects of chlorambucil alone and in combination with CAS-024 on SU-DHL-6 cell growth.

Figure 13 shows a combination index plot for inhibitory effects of CAS-024 and chlorambucil on SU-DHL-6 cell growth.

Figure 14A shows tumor volume comparisons in tumor-bearing
10 mice resulted from injections of DOHH2 cells and subsequently treated with hulgG (Human IgG, R&D Systems), CAS-024, bendamustine, and the combination of CAS-024 and bendamustine. Figure 14B shows tumor volume of individual mice on day 13 relative to day 0.

Figure 15 shows mean tumor volumes over time in tumor-bearing
15 mice resulted from injections of DOHH2 cells and subsequently treated with hulgG, CAS-024, bendamustine, and the combination of CAS-024 and bendamustine. Values are the mean $\pm$ the standard error of the mean for each measurement day. Curves for each group end after one or more of the mice in the group were euthanized.

20 Figure 16 shows survival percentages over time of tumor-bearing mice resulted from injections of DOHH2 cells and subsequently treated with hulgG, CAS-024, bendamustine, and the combination of CAS-024 and bendamustine.

Figure 17 shows incidence of tumor free mice over time after
25 treatments with hulgG, CAS-024, bendamustine, and the combination of CAS-024 and bendamustine.

DETAILED DESCRIPTION

In one aspect, the present disclosure provides the CD37-specific binding molecule CAS-024 (SEQ ID NO:253), which is a humanized version of
30 CAS-006 (a small modular immunopharmaceutical (SMIP) protein having the immunoglobulin variable regions from mouse anti-human CD37 monoclonal

antibody G28-1). The CAS-024 SMIP protein is unexpectedly (1) expressed at up to about 25-fold higher levels than other humanized versions of CAS-006 (such as CAS-002, CAS-003; see Examples 2 and 5), (2) capable of binding CD37 as well as CAS-006 while other humanized versions do not (see Examples 4 and 5), and (3) produced as a homogenous population of molecules as compared the heterogenous nature of other humanized versions (see Example 3). Additionally, the instant disclosure provides the CD37-specific binding molecule CAS-024 (SEQ ID NO:253) for use in methods for reducing B-cells or treating disease associated with aberrant B-cell activity comprising administering to a subject in need thereof an effective amount of CAS-024 provided herein.

In another aspect, the present disclosure provides compositions and methods for the combined use of any CD37-specific binding molecule and bifunctional chemotherapeutics (such as bendamustine) to reduce B-cells or treat a disease associated with aberrant B-cell activity. A surprising result of this combination is that this combination of compounds acts synergistically and results in a substantially more effective therapeutic regimen.

Prior to setting forth this disclosure in more detail, it may be helpful to an understanding thereof to provide definitions of certain terms to be used herein. Additional definitions are set forth throughout this disclosure.

In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Also, any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated. As used herein, "about" or "consisting essentially of" mean $\pm 20\%$ of the indicated range, value, or structure, unless otherwise indicated. It should be understood that the terms "a" and "an" as used herein refer to "one or more" of the enumerated components. The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms "include" and "comprise" are used synonymously. In addition, it should be understood that the

individual compounds, or groups of compounds, derived from the various combinations of the structures and substituents described herein, are disclosed by the present application to the same extent as if each compound or group of compounds was set forth individually. Thus, selection of particular structures or particular substituents is within the scope of the present disclosure.

A "binding domain" or "binding region" according to the present disclosure may be, for example, any protein, polypeptide, oligopeptide, or peptide that possesses the ability to specifically recognize and bind to a biological molecule (e.g., CD37) or complex of more than one of the same or different molecule or assembly or aggregate, whether stable or transient. A binding region includes any naturally occurring, synthetic, semi-synthetic, or recombinantly produced binding partner for a biological molecule or other target of interest. A variety of assays are known for identifying binding domains of the present disclosure that specifically bind a particular target, including Western blot, ELISA, or Biacore analysis.

Binding domains and fusion proteins thereof of this disclosure can be capable of binding to a desired degree, including "specifically or selectively binding" a target while not significantly binding other components present in a test sample, if they bind a target molecule with an affinity or K_a (i.e., an equilibrium association constant of a particular binding interaction with units of $1/M$) of, for example, greater than or equal to about $10^5 M^{-1}$, $10^6 M^{-1}$, $10^7 M^{-1}$, $10^8 M^{-1}$, $10^9 M^{-1}$, $10^{10} M^{-1}$, $10^{11} M^{-1}$, $10^{12} M^{-1}$, or $10^{13} M^{-1}$. "High affinity" binding domains refers to those binding domains with a K_a of at least $10^7 M^{-1}$, at least $10^8 M^{-1}$, at least $10^9 M^{-1}$, at least $10^{10} M^{-1}$, at least $10^{11} M^{-1}$, at least $10^{12} M^{-1}$, at least $10^{13} M^{-1}$, or greater. "Low affinity" binding domains refers to those binding domains with a K_a of up to $5 \times 10^7 M^{-1}$, up to $10^7 M^{-1}$, up to $10^6 M^{-1}$, up to $10^5 M^{-1}$, or less. Alternatively, affinity may be defined as an equilibrium dissociation constant (K_d) of a particular binding interaction with units of M (e.g., $10^{-5} M$ to $10^{-13} M$). Affinities of binding domain polypeptides and fusion proteins according to the present disclosure can be readily determined using conventional techniques (see, e.g., Scatchard *et al.* (1949) Ann. N.Y. Acad. Sci. 51:660; and U.S. Patent Nos. 5,283,173, 5,468,614, or the equivalent).

The term "CD37-specific binding molecules" refer to a protein, polypeptide, oligopeptide or peptide that specifically binds to CD37 with a K_a of at least about 10^6 M^{-1} (e.g., at least about 10^7 M^{-1} , 10^8 M^{-1} , 10^9 M^{-1} , 10^{10} M^{-1} , 10^{11} M^{-1} , 10^{12} M^{-1} , or 10^{13} M^{-1}).

5 The term "CD37-specific binding domain" refers to a portion or a domain of a CD37-specific binding molecule responsible for the specific CD37 binding of the molecule. A CD37-specific binding domain itself (*i.e.*, without any other portion of the CD37-specific binding molecule) binds to CD37 with a K_a of at least about 10^6 M^{-1} (e.g., at least about 10^7 M^{-1} , 10^8 M^{-1} , 10^9 M^{-1} , 10^{10} M^{-1} , 10^{11}
10 M^{-1} , 10^{12} M^{-1} , or 10^{13} M^{-1}). A CD37-specific binding domain itself may be sufficient as a CD37-specific binding molecule. Exemplary CD37-specific binding domains include CD37-specific scFv and Fab fragments, which can be derived from anti-CD37 antibodies, such as monoclonal antibody G28-1.

 Terms understood by those in the art as referring to antibody
15 technology are each given the meaning acquired in the art, unless expressly defined herein. For example, the terms " V_L " and " V_H " refer to the variable binding region derived from an antibody light and heavy chain, respectively. The variable binding regions are made up of discrete, well-defined sub-regions known as "complementarity determining regions" (CDRs) and "framework regions" (FRs).
20 The terms " C_L " and " C_H " refer to an "immunoglobulin constant region," *i.e.*, a constant region derived from an antibody light or heavy chain, respectively, with the latter region understood to be further divisible into C_{H1} , C_{H2} , C_{H3} and C_{H4} constant region domains, depending on the antibody isotype (IgA, IgD, IgE, IgG, IgM) from which the region was derived. A portion of the constant region
25 domains makes up the Fc region (the "fragment crystallizable" region), which contains domains responsible for the effector functions of an immunoglobulin, such as ADCC (antibody-dependent cell-mediated cytotoxicity), CDC (complement-dependent cytotoxicity) and complement fixation, binding to Fc receptors, greater half-life *in vivo* relative to a polypeptide lacking an Fc region,
30 protein A binding, and perhaps even placental transfer (see Capon *et al.*, Nature, 337:525 (1989)). Further, a polypeptide containing an Fc region allows for dimerization or multimerization of the polypeptide.

A "hinge region" is an amino acid sequence interposed between and connecting a CD37-specific binding domain and another region (e.g., a CH2 region) in a fusion protein so that the fusion protein is still capable of specific binding to CD37 (*i.e.*, with a K_a of at least about 10^6 M^{-1} , 10^7 M^{-1} , 10^8 M^{-1} , 10^9 M^{-1} , 10^{10} M^{-1} , 10^{11} M^{-1} , 10^{12} M^{-1} , or 10^{13} M^{-1}). In certain embodiments, a hinge region is an immunoglobulin hinge region.

An "immunoglobulin hinge region" refers to a wild type immunoglobulin hinge region or an altered wild type immunoglobulin hinge region.

10 According to crystallographic studies, the immunoglobulin hinge region can be further subdivided functionally into three regions: the upper hinge region, the core region, and the lower hinge region. The upper hinge region includes amino acids from the carboxyl end of CH1 to the first residue in the hinge that restricts motion, generally the first cysteine residue that forms an
15 interchain disulfide bond between the two heavy chains. The length of the upper hinge region correlates with the segmental flexibility of the antibody. The core hinge region contains the inter-heavy chain disulfide bridges, and the lower hinge region joins the amino terminal end of the CH2 domain and includes residues in CH2. *Id.* The core hinge region of human IgG1 contains the sequence Cys-Pro-Pro-Cys (SEQ ID NO:264) which, when dimerized by disulfide bond formation,
20 results in a cyclic octapeptide believed to act as a pivot, thus conferring flexibility.

A "wild type immunoglobulin hinge region," as used herein refers to a naturally occurring amino acid sequence interposed between and connecting CH1 and CH2 regions of a single chain of an antibody. It contains the upper
25 hinge region, the core hinge region, and the portion of the lower hinge region that is not part of CH2 region. An exemplary wild type immunoglobulin hinge region is human IgG1 hinge region as set forth in SEQ ID NO:90, in which from its amino terminus to its carboxyl terminus, the first ten amino acids (EPKSCDKTHT, SEQ ID NO:263) form the upper hinge region, the next four amino acids (CPPC, SEQ
30 ID NO:264) form the core hinge region, and the last amino acid (*i.e.*, proline) is the first amino acid in the lower hinge region and is not part of CH2.

An "altered wild type immunoglobulin hinge region" or "altered immunoglobulin hinge region" refers to (a) a wild type immunoglobulin hinge region with up to 30% amino acid changes (*e.g.*, up to 25%, 20%, 15%, 10%, or 5% amino acid substitutions or deletions), (b) a portion of a wild type immunoglobulin hinge region that is at least 10 amino acids (*e.g.*, at least 12, 13, 14 or 15 amino acids) in length with up to 30% amino acid changes (*e.g.*, up to 25%, 20%, 15%, 10%, or 5% amino acid substitutions or deletions), or (c) a portion of a wild type immunoglobulin hinge region that comprises the core hinge region (which may be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, or at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in length). When an altered wild type immunoglobulin hinge region is interposed between and connecting a CD37-specific binding domain and another region (*e.g.*, a CH2 region) in a fusion protein, it allows the fusion protein to specifically bind to CD37 (*i.e.*, with a K_a of at least about 10^6 M^{-1} , 10^7 M^{-1} , 10^8 M^{-1} , 10^9 M^{-1} , 10^{10} M^{-1} , 10^{11} M^{-1} , 10^{12} M^{-1} , or 10^{13} M^{-1}). In certain embodiments, one or more cysteine residues in a wild type immunoglobulin hinge region may be substituted by one or more other amino acid residues (*e.g.*, one or more serine residues). An altered immunoglobulin hinge region may alternatively or additionally have a proline residue of a wild type immunoglobulin hinge region substituted by another amino acid residue (*e.g.*, a serine residue).

A "linker" refers to an amino acid sequence that connects a heavy chain variable region and a light chain variable region together and provides a spacer function compatible with interaction of the two sub-binding domains so that the resulting polypeptide is capable of CD37-specific binding.

"Derivative" as used herein refers to a chemically or biologically modified version of a compound that is structurally similar to a parent compound and (actually or theoretically) derivable from that parent compound. Generally, a "derivative" differs from an "analogue" in that a parent compound may be the starting material to generate a "derivative," whereas the parent compound may not necessarily be used as the starting material to generate an "analogue." A derivative may have different chemical or physical properties from the parent compound. For example, a derivative may be more hydrophilic or it may be a

mutated sequence having altered reactivity (e.g., a CDR having an amino acid change that alters its affinity for a target) as compared to the parent compound or sequence.

“B-cell associated disorder or disease” refers to aberrant B-cell activity or activity that deviates from the normal, proper, or expected course. For example, a B-cell associated disorder or disease may include inappropriate proliferation of cells that have damaged or defective DNA or other cellular components. Aberrant B-cell activity may include cell proliferation characterized by inappropriately high levels of cell division, inappropriately low levels of apoptosis, or both. Such diseases may have, for example, single or multiple local abnormal proliferations of cells, groups of cells or tissue(s), whether cancerous or non-cancerous, benign or malignant. A B-cell associated disorder or disease may also include aberrant antibody production, such as production of autoantibodies, or overproduction of antibodies more desirable when produced at normal levels. It is also contemplated herein that aberrant B-cell activity may occur in certain subpopulations of B-cells and not in other subpopulations, or may include inappropriate stimulation of T-cells, such as by inappropriate antigen presentation to T-cells or by other B-cells pathway.

“Treatment” or “treating” refers to either a therapeutic treatment or prophylactic/preventative treatment. A therapeutic treatment may improve at least one symptom of disease in an individual receiving treatment or may delay worsening of a progressive disease in an individual, or prevent onset of additional associated diseases.

A “therapeutically effective amount (or dose)” or “effective amount (or dose)” of a specific binding molecule or compound refers to that amount of the compound sufficient to result in amelioration of one or more symptoms of the disease being treated. When applied to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered serially or simultaneously. The invention specifically

contemplates that one or more specific binding molecules may be administered according to methods of the invention, each in an effective dose.

“An individual having, or suspected of having, a disease associated with aberrant B-cell activity” is an individual in whom a disease or a symptom of a disorder may be caused by aberrant B-cell activity or B-cell proliferation, may be exacerbated by aberrant B-cell activity, or may be relieved by regulation of B-cell activity. Examples of such diseases are a B-cell malignancy or B-cell cancer (for example, B-cell lymphoma, a B-cell leukemia or a B-cell myeloma), a disease characterized by autoantibody production or a disease characterized by inappropriate T-cell stimulation caused by inappropriate B-cell antigen presentation to T-cells or caused by other pathways involving B-cells.

Additional definitions are provided in the following detailed description of the present disclosure.

Humanized CD37-Specific Binding Molecules

In one aspect, the present disclosure provides humanized CD37-specific binding molecules. These molecules may be in any form that contains a humanized CD37-specific binding domain, including a humanized anti-CD37 antibody, an Fab fragment of a humanized anti-CD37 antibody, a humanized CD37-specific single chain Fv (scFv), a humanized CD37-specific SMIP protein, a humanized CD37-specific PIMS protein (a fusion protein comprising the components of SMIP in the reverse orientation), a humanized CD37-specific SCORPION protein, and other bi- or multi-specific binding proteins that comprise at least one humanized CD37-specific binding domain. Detailed description of SMIP proteins and methods for making the same may be found, for example, in U.S. Patent Publication Nos. 2003/0133939, 2003/0118592, and 2005/0136049 and WO 2005017148. Constructs and methods for making PIMS proteins are described in U.S. Application No. 12/168,875. Methods for making SCORPION proteins may be found, for example, in PCT Application Publication No. WO 2007/146968. Other exemplary multi-functional fusion proteins may be found, for example, in U.S. Patent Application Publication No. 2006/0051844 and U.S. Patent No. 7,166,707. Certain bi- or multi-specific binding proteins may

comprise a CD37-specific scFv and one or more other binding domains that are not derived from an immunoglobulin.

Humanized CD37-Specific Binding Domains

An exemplary “humanized CD37-specific binding domain” is an
5 immunoglobulin variable region specific for CD37 that comprises at least one human framework region.

A “human framework region” refers to a wild type (*i.e.*, naturally occurring) framework region of a human immunoglobulin variable region, an altered framework region of a human immunoglobulin variable region with less
10 than about 50% (*e.g.*, preferably less than about 45%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%) of the amino acids in the region are deleted or substituted (*e.g.*, with one or more amino acid residues of a nonhuman immunoglobulin framework region at corresponding positions), or an altered framework region of a nonhuman immunoglobulin variable region with less than about 50% (*e.g.*, less
15 than 45%, 40%, 30%, 25%, 20%, 15%, 10%, or 5%) of the amino acids in the region deleted or substituted (*e.g.*, at positions of exposed residues and/or with one or more amino acid residues of a human immunoglobulin framework region at corresponding positions) so that, in one aspect, immunogenicity is reduced.

In certain embodiments, a human framework region is a wild type
20 framework region of a human immunoglobulin variable region. In certain other embodiments, a human framework region is an altered framework region of a human immunoglobulin variable region with amino acid deletions or substitutions at one, two, three, four or five positions. In yet certain other embodiments, a human framework region is an altered framework region of a non-human
25 immunoglobulin variable region with amino acid deletions or substitutions at one, two, three, four or five positions.

In certain embodiments, a humanized CD37-specific binding domain comprises at least one, two, three, four, five, six, seven or eight human framework regions (FR) selected from human light chain FR1, human heavy
30 chain FR1, human light chain FR2, human heavy chain FR2, human light chain

FR3, human heavy chain FR3, human light chain FR4, and human heavy chain FR4.

Exemplary human FRs are set forth in SEQ ID NOS:140-146 (human heavy chain FR1), SEQ ID NOS:147, 150 and 151 (human heavy chain FR2), SEQ ID NO:154-160 (human heavy chain FR3), SEQ ID NOS: 161-163, 168 and 169 (human heavy chain FR4), SEQ ID NOS:170-172, 175, and 177-181 (human light chain FR1), SEQ ID NOS:182, 184-188 and 191 (human light chain FR2), SEQ ID NOS:194-198, 203 and 205 (human light chain FR3), and SEQ ID NOS:206-210 (human light chain FR4). Additional exemplary human FR regions may be found in FR regions of the CD37-specific SMIP proteins provided herein, such as CAS-001, CAS-002, CAS-003, or CAS-024.

Human FRs that may be present in CD37-specific binding domains also include variants of the exemplary FRs provided herein in which one or two amino acids of the exemplary FRs have been substituted or deleted.

In certain embodiments, a humanized CD37-specific binding domain comprises (a) a humanized light chain variable region that comprises a human light chain FR1, a human light chain FR2, a human light chain FR3, and a human light chain FR4, and (b) a humanized heavy chain variable region that comprises a human heavy chain FR1, a human heavy chain FR2, a human heavy chain FR3, and a human heavy chain FR4.

CD37-specific binding domains provided herein also comprise one, two, three, four, five, or six CDRs. Such CDRs may be nonhuman CDRs or altered nonhuman CDRs selected from CDR1, CDR2 and CDR3 of the light chain and CDR1, CDR2 and CDR3 of the heavy chain. In certain embodiments, a CD37-specific binding domain comprises (a) a light chain variable region that comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3, and (b) a heavy chain variable region that comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3.

Exemplary CDRs include CDR1 of the light chain as set forth in SEQ ID NO:61 (RASENVYSYLA) or SEQ ID NO:62 (RTSENVYSYLA), CDR1 of the heavy chain as set forth in SEQ ID NO:63 (GYNMN), CDR2 of the light chain as set forth in SEQ ID NO:64 (FAKTLAE), CDR2 of the heavy chain as set forth

in SEQ ID NO:65 (NIDPYYGGTTYNRKFKG), CDR3 of the light chain as set forth in SEQ ID NO:66 (QHHSDNPWT), CDR3 of the heavy chain as set forth in SEQ ID NO:67 (SVGPFDY), CDR3 of the heavy chain as set forth in SEQ ID NO:68 (SVGPFDS), and CDR3 of the heavy chain as set forth in SEQ ID NO:69 (SVGPMDY). Preferred light chain CDR1 is SEQ ID NO:61 (RASENVYSYLA) and preferred heavy chain CDR3 include SEQ ID NO:68 (SVGPFDS) or SEQ ID NO:69 (SVGPMDY).

Additional exemplary CDRs include CDR1 of the light chain as set forth in SEQ ID NO:128 (RTSQNVYSYLA), 129 (RTSESVYSYLA), 130 (RASQSVYSYLA), 131 (RASQSVSSYLA) and 132 (RASQSVSYLA), CDR1 of the heavy chain as set forth in SEQ ID NOS:133 (SYMNM) and 134 (SYWIG), CDR2 of the light chain as set forth in SEQ ID NOS:135 (AASSLQS), 136 (GASTRAT) and 137 (DASNRAT), CDR2 of the heavy chain as set forth in SEQ ID NOS:138 (IIPGDS DTRYSPSFQG) and 139 (RIDPSDSYTNYS PSFQG), CDR3 of the light chain as set forth in SEQ ID NO:220 (QHHSDNPWT), and CDR3 of the heavy chain as set forth in SEQ ID NOS:211 (SVGPMDY), 212 (SVGPFDY), 213 (SVGPMDV), 214 (SVGPFDS), 215 (SVGPFDV), 216 (SVGPFDY), 217 (SVGPFDV), 218 (SVGPFDI) and 219 (SVGPFDL). Further exemplary CDRs include the CDRs in the CD37-specific SMIP proteins provided herein.

In certain embodiments, CD37-specific binding domains comprise a humanized light chain variable region that comprises from its amino terminus to carboxyl terminus: human light chain FR1, light chain CDR1, human light chain FR2, light chain CDR2, human light chain FR3, light chain CDR3, and human light chain FR4.

In certain embodiments, CD37-specific binding domains comprise a humanized light chain variable region that comprises from its amino terminus to carboxyl terminus: human light chain FR1, light chain CDR1 as set forth in SEQ ID NO:61 or 62, human light chain FR2, light chain CDR2 as set forth in SEQ ID NO:64, human light chain FR3, light chain CDR3 as set forth in SEQ ID NO:66, and human light chain FR4. In further embodiments, CD37-specific binding domains comprise, consist essentially of, or consist of a humanized light chain

variable region that comprises from its amino terminus to carboxyl terminus:
human light chain FR1 as set forth in SEQ ID NO:171, light chain CDR1 as set
forth in SEQ ID NO:61, human light chain FR2 as set forth in SEQ ID NO:182,
light chain CDR2 as set forth in SEQ ID NO:64, human light chain FR3 as set
5 forth in SEQ ID NO:195, light chain CDR3 as set forth in SEQ ID NO:66, and
human light chain FR4 as set forth in SEQ ID NO:206. Additional exemplary
humanized light chains are set forth in SEQ ID NOS:237-240 and include the light
chains in humanized CD37-specific SMIP proteins provided herein.

In certain embodiments, CD37-specific binding domains comprise a
10 humanized heavy chain variable region that comprises from its amino terminus to
carboxyl terminus: human heavy chain FR1, heavy chain CDR1, human heavy
chain FR2, heavy chain CDR2, human heavy chain FR3, heavy chain CDR3, and
human heavy chain FR4.

In certain embodiments, CD37-specific binding domains comprise a
15 humanized heavy chain variable region that comprises from its amino terminus to
carboxyl terminus: human heavy chain FR1, heavy chain CDR1 as set forth in
SEQ ID NO:63, human heavy chain FR2, heavy chain CDR2 as set forth in SEQ
ID NO:65, human heavy chain FR3, heavy chain CDR3 as set forth in SEQ ID
NO:67, 68 or 69, and human heavy chain FR4. In further embodiments, CD37-
20 specific binding domains comprise consist essentially of, or consist of a
humanized heavy chain variable region that comprises from its amino terminus to
carboxyl terminus: human heavy chain FR1 as set forth in SEQ ID NO:144,
heavy chain CDR1 as set forth in SEQ ID NO:63, human heavy chain FR2 as set
forth in SEQ ID NO:151, heavy chain CDR2 as set forth in SEQ ID NO:65, human
25 heavy chain FR3 as set forth in SEQ ID NO:158, heavy chain CDR3 as set forth
in SEQ ID NO:67, 68 or 69, and human heavy chain FR4 as set forth in SEQ ID
NO:161. Additional exemplary humanized light chains are set forth in SEQ ID
NOS:242-245 and include the light chains in humanized CD37-specific SMIP
proteins provided herein.

30 In certain embodiments, CD37-specific binding domains may be in
the form of a Fab or scFv fragment. In a preferred embodiment, the CD37-
specific binding domain is a humanized CD37-specific scFv that comprises a light

chain variable region and a heavy chain variable region joined together via a linker. In further embodiments, both the light and heavy chain variable regions are humanized, and may comprise both a humanized light chain variable region as set forth in SEQ ID NO:238 and a humanized heavy chain variable region as
5 set forth in SEQ ID NO:245.

In still further embodiments, only the light or heavy chain variable region is humanized. For example, CD37-specific binding domains may comprise a humanized light chain variable region (*i.e.*, a light chain variable region that comprises at least one human FR) and a nonhuman heavy chain
10 variable chain region (*e.g.*, mouse or rat). Alternatively, CD37-specific binding domains may comprise a nonhuman light chain variable region (*e.g.*, mouse or rat) and a humanized heavy chain variable chain region (*i.e.*, a heavy chain variable region that comprises at least one human FR). Both types of CD37-specific binding domains may be referred to as a "hybrid human-nonhuman
15 CD37-specific binding domain" or as a "chimeric CD37-specific binding domains."

In certain embodiments, the carboxyl terminus of the light chain variable region in a humanized CD37-specific scFv is linked to the amino terminus of the heavy chain variable region via a linker. Thus, the resulting scFv has from its amino terminus to its carboxyl terminus: the light chain variable
20 region, the linker, and the heavy chain variable region. In certain other embodiments, the carboxyl terminus of the heavy chain variable region in a humanized CD37-specific scFv is linked to the amino terminus of the light chain variable region via a linker. Thus, the resulting scFv has from its amino terminus to its carboxyl terminus: the heavy chain variable region, the linker, and the heavy
25 chain variable region.

In certain embodiments, the linkers have 5-30 amino acids, such as 15-25 amino acids. In certain embodiments, the linkers comprises $(\text{Gly}_n\text{Ser})_m$, wherein n and m may be an integer independently selected from 1 to 5. For example, in certain embodiments, n is 4, and m is 1, 2, 3, 4 or 5. In certain
30 embodiments, one or two amino acids other than Gly or Ser may be present at the amino terminus, carboxyl terminus or both termini. In certain other embodiments, one or two amino acids other than Gly or Ser may be used to

substitute a Gly or Ser in a linker that comprises $(\text{Gly}_n\text{Ser})_m$ with m and n as defined above. An exemplary linker has the sequence $(\text{Gly}_4\text{S})_5$ as set forth in SEQ ID NO:229. Additional exemplary linker sequences are set forth in SEQ ID NOS:225-228.

5 In certain embodiments, humanized CD37-specific binding domains or CD37-specific binding molecules competes with G28-1 mAb for binding to CD37. In other words, in such embodiments, CD37 binding of G28-1 mAb is reduced in the presence of other CD37-specific binding domains (such as anti-CD37 monoclonal antibodies) or CD37-specific binding molecules compared to
10 CD37 binding of G28-1 mAb in the absence of CD37-specific binding domains or CD37-specific binding molecules. Competitive binding assays are known in the art, such as those described in the Examples 4-6, and may be used to determine whether a given CD37-specific binding domain or CD37-specific binding molecule is capable of competing with G28-1 mAb for binding to CD37.

15 *Humanized CD37-Specific SMIP Polypeptides*

 In certain embodiments, CD37-specific binding molecules are CD37-specific small modular immunopharmaceutical (SMIP) polypeptides. SMIP proteins are binding domain-immunoglobulin fusion proteins that typically comprise from their amino termini to carboxyl termini: a binding domain derived
20 from an immunoglobulin (e.g., a scFv), a hinge region, and an effector domain (e.g., IgG CH2 and CH3 regions). In preferred embodiments, the CD37-specific binding SMIP polypeptides are humanized.

 The hinge region of a humanized CD37-specific binding SMIP polypeptide may be an immunoglobulin hinge region. In certain embodiments,
25 the hinge region is a wild type immunoglobulin hinge region, such as an IgG hinge, IgA hinge, IgD hinge, IgE hinge or a fragment thereof (e.g., 4 to 20 or 5 to 15 amino acids in length) that comprises a core hinge region. In certain preferred embodiments, a hinge region may be an antibody hinge region selected from human IgG1, human IgG2, human IgG3, human IgG4, or fragments or variants
30 thereof. In some embodiments, the hinge region is a wild type immunoglobulin hinge region or portion thereof, such as a human immunoglobulin hinge region.

Exemplary hinges for such embodiments are wild type human IgG1 hinge region as set forth in SEQ ID NO:90, wild type human IgA1 hinge as set forth in SEQ ID NO:115, wild type human IgA2 hinge as set forth in SEQ ID NO:116, wild type human IgG3 hinge as set forth in SEQ ID NO:118, a portion of human IgG3 hinge as set forth in SEQ ID NO:258, and human IgD hinge as set forth in SEQ ID NO:127. In certain embodiments, one or more amino acid residues may be added at the amino- or carboxy- terminus of a wild type immunoglobulin hinge region as part of fusion protein construct design. Such amino acid residues are referred to as "junction amino acids" (see Table 4).

In certain embodiments, the hinge region is an altered (mutated) wild type immunoglobulin hinge region, such as an altered wild type IgG immunoglobulin hinge region, or an altered portion of a wild type immunoglobulin hinge region. For example, the wild type human IgG1 hinge region contains three cysteine residues – the most N-terminal cysteine is referred to the first cysteine, whereas the most C-terminal cysteine in the hinge region is the third cysteine. In certain embodiments, the mutated human IgG1 hinge region has only two cysteine residues, such as a human IgG1 hinge region with the first cysteine substituted by a serine. In certain other embodiments, the mutated human IgG1 hinge region has only one cysteine residue. In certain embodiments, the proline C-terminal to the third cysteine in the human IgG1 hinge region is substituted, for example, by a serine. Exemplary mutated human IgG1 hinge regions are as set forth in SEQ ID NOS:92, 94, 102, 104, 255, 256, 106, 108, 257, 96, 110, 112, 98, and 100. Exemplary mutated portions of human IgG3 hinge regions are as set forth in SEQ ID NOS:120, 126, 259-261, 122, and 124. In certain embodiments, one or more amino acid residues may be added at the amino-or carboxy-terminus of a mutated immunoglobulin hinge region as part of fusion protein construct design. Examples of such modified hinge regions are indicated in italics in SEQ ID NOS:231-235.

In certain embodiments, a hinge region comprises or has a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least

96%, at least 97%, at least 98%, at least 99% identical to a wild type immunoglobulin hinge region, such as a wild type human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD and IgE hinges.

In further embodiments, altered hinge regions can be based on a wild type immunoglobulin hinge region (e.g., an IgG1 hinge region) and contain one or more (e.g., 1, 2, 3, or 4) insertions, one or more (e.g., 1, 2, 3, or 4) deletions, one or more (e.g., 1, 2, 3, or 4) amino acid substitutions (e.g., conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above-noted mutations, when compared with the wild type immunoglobulin hinge region, but provided that the modified hinge retains the flexibility or rigidity suitable for properly orienting the binding domain of a fusion binding protein to interact with its target. The insertion(s), deletion(s) or substitution(s) may be anywhere in the wild type immunoglobulin hinge region, including at the amino- or carboxy-terminus or both.

As described herein, CD37-specific SMIP polypeptides may comprise an immunoglobulin C_{H2} region. In certain embodiments, the immunoglobulin C_{H2} region is a wild type immunoglobulin C_{H2} region, such as a wild type human immunoglobulin C_{H2} region, including wild type human IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4 and IgM C_{H2} regions. In certain embodiments, the immunoglobulin C_{H2} region is a human IgG1 C_{H2} region.

In certain other embodiments, the immunoglobulin C_{H2} region is an altered wild type immunoglobulin C_{H2} region. For example, the altered wild type immunoglobulin C_{H2} region may be a human IgG1 C_{H2} region but with one, two, three, four or five mutations at positions 234 to 238, 253, 279, 310, 318, 320, 322, and 331 (EU numbering, Ward *et al.*, 1995 *Therap. Immunol.* 2:77-94). The mutations in such positions reduce or eliminate the antibody-dependent cell-mediated cytotoxicity (ADCC) activity, Fc receptor-binding capability, and/or complement fixation.

As described herein, a humanized CD37-specific SMIP polypeptides may comprise an immunoglobulin C_{H3} region. In certain embodiments, an immunoglobulin C_{H3} region polypeptide is a wild type immunoglobulin C_{H3} region polypeptide, including a wild type C_{H3} region of any

one of the various immunoglobulin isotypes (*e.g.*, IgA, IgD, IgG1, IgG2, IgG3, IgG4, IgE, or IgM) from various species (*i.e.*, human, mouse, rat or other mammals). In other embodiments, an immunoglobulin C_{H3} region polypeptide is a mutated immunoglobulin C_{H3} region polypeptide. The mutations in the
5 immunoglobulin C_{H3} region may be at one or more positions that are involved in complement fixation, such as at H433 or N434.

In certain embodiments, a humanized CD37-specific SMIP polypeptides may contain one or more additional regions. Such additional regions may be a leader sequence at the amino-terminus for secretion of an
10 expressed SMIP polypeptide, an additional Fc sub-region (*e.g.*, a wild type or mutated C_{H4} region of IgM or IgE), a tail sequence at its carboxy-terminus for identification or purification purposes (*e.g.*, epitope tags for detection or purification, including a 6-Histidine tag or a FLAG epitope), or additional amino acid residues that arise from use of specific expression systems. Exemplary
15 leader peptides of this disclosure include natural leader sequences or others, such as those as set forth in SEQ ID NOS:223 and 224.

This disclosure includes CD37-specific SMIP polypeptides that exhibit at least 80 percent identity (*e.g.*, 82%, 84%, 85%, 86%, 88%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99%) to the polypeptide set forth in SEQ ID NO:2,
20 wherein the CD37-specific SMIP polypeptide binds CD37. In further embodiments, such polypeptides having at least 80% identity with SEQ ID NO:2 may be further humanized. Exemplary humanized CD37-specific SMIP polypeptides comprise, consist essential of, or consist of any amino acid sequence selected from the group consisting of SEQ ID NOS:6, 8, 10, 12, 14, 16,
25 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 52, 80, 82, 84, 86, 88, and 222 in which the leader sequences are deleted, as well as SEQ ID NOS:247-254 and 266-269.

"Sequence identity," as used herein, refers to the percentage of amino acid residues in one sequence that are identical with the amino acid
30 residues in another reference polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the

sequence identity. The percentage sequence identity values are generated by the NCBI BLAST2.0 software as defined by Altschul *et al.* (1997) "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402, with the parameters set to default values.

5 In a preferred embodiment, the present disclosure provides a humanized CD37-specific SMIP polypeptide that comprises from amino terminus to carboxyl terminus: a humanized heavy chain variable region (V_H), a (G₄S)₅ linker (SEQ ID NO:229), a humanized light chain variable region (V_L), an altered IgG1 hinge, a human IgG1 CH2 region, and a human IgG1 CH3 region. The
10 humanized heavy chain variable region comprises from its amino terminus to its carboxyl terminus: a human heavy chain FR1, a heavy chain CDR1 as set forth in SEQ ID NO:63, a human heavy chain FR2, a CDR2 as set forth in SEQ ID NO:65, a human heavy chain FR3, CDR3 as set forth in SEQ ID NO:67, 68 or 69, and a human heavy chain FR4. The humanized light chain variable region
15 comprises from its amino terminus to its carboxyl terminus: a human light chain FR1, a light chain CDR1 as set forth in SEQ ID NO:61 or 62, a human light chain FR2, a light chain CDR2 as set forth in SEQ ID NO:64, a human light chain FR3, and a light chain CDR3 as set forth in SEQ ID NO:66, and a human light chain FR4.

20 In some of the above preferred embodiments, the human heavy chain FR1, FR2, and FR3 comprise SEQ ID NOS:144, 151, and 158, respectively, and the heavy chain FR4 comprises SEQ ID NO:161 or 162. In further preferred embodiments, the human light chain FR1, FR2, FR3, and FR4 comprise SEQ ID NOS:171, 182, 195, and 206, respectively. Alternatively, both
25 the heavy and light chains contain these sequences.

 The CAS-024 SMIP protein is unexpectedly (1) expressed at up to about 25-fold higher levels than other humanized versions of CAS-006 (such as CAS-002, CAS-003; see Examples 2 and 5), (2) capable of binding CD37 as well as CAS-006 while other humanized versions do not (see Examples 4 and 5), and
30 (3) produced as a homogenous population of molecules as compared the heterogenous nature of other humanized versions (see Example 3) In a preferred embodiment, the instant disclosure provides a CD37-specific binding protein that

comprises or consists of CAS-024 (SEQ ID NO:253). In particular, this humanized CD37-specific binding molecule has substantially the same CD37 binding affinity as its parent chimeric molecule (CAS-006, SMIP protein having the immunoglobulin variable regions from mouse anti-human CD37 monoclonal antibody G28-1) in contrast to other humanized molecules, is expressed at high levels compared to other humanized molecules, and/or shows a high degree of homogeneity when purified, for example, via size exclusion chromatography (SEC) in contrast to other humanized molecules. In addition, this CAS-024 CD37-specific binding molecule has been shown to be effective in inhibiting tumor growth and causing long term tumor regression.

The disclosure also includes an isolated nucleic acid molecule comprising a nucleotide sequence encoding humanized CD37-specific binding molecules and the components thereof, including human or humanized FRs, CDRs, humanized light chain variable regions, humanized heavy chain variable regions, humanized scFv, and humanized SMIP polypeptides. Exemplary isolated nucleic acid molecules that encode humanized CD37-specific SMIP polypeptides include those that comprise SEQ ID NOS:5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 51, 79, 81, 83, 85, 87, and 221. In one embodiment, the disclosure includes vectors that comprise these nucleic acid molecules and host cells that comprise the vectors.

The disclosure also includes processes of producing the polypeptides described herein, comprising culturing the host cells under suitable conditions to express the polypeptides, and optionally isolating the polypeptides from the culture.

Compounds Useful for Combination Therapy

The present disclosure also provides a combination therapy using any of the CD37-specific binding molecules known in the art or disclosed herein and bifunctional chemotherapeutics (e.g., bendamustine).

The CD37-specific binding molecules useful for the combination therapy may be in any forms that contain a CD37-specific binding domain, including an anti-CD37 antibody, an Fab fragment of anti-CD37 antibody, a

CD37-specific single chain Fv (scFv), a CD37-specific SMIP, a CD37-specific PIMS, a CD37-specific SCORPION, and other bi- or multi-specific binding proteins that comprise at least one CD37-specific binding protein.

In certain embodiments, the CD37-specific binding molecules useful for combination therapy with a bifunctional chemotherapeutic are CD37-specific antibodies. Such antibodies include those used for characterizing the CD37 antigen in the Thrid HLDA Workshop, *i.e.*, HD28, G28-1, HH1, BI14, WR17 and F93G6 (see, Ling and MacLennan, pp. 302-335 in *Leucocyte Typing III. White Cell Differentiation Antigens*, Oxford University Press (1987)). Other CD37-specific antibodies useful for the combination therapy include RFB-7, Y29/55, MB-1, M-B371, M-B372 and IPO-24 (see, Moldenhauer, *J. Biol. Regul. Homeost. Agents*, 14: 281-283 (2000), stating that all these antibodies recognize only one CD37 epitope, and Schwartz-Albiez *et al.*, 14: 905-914 (1988), indicating that the epitope is situated in the carbohydrate moiety of CD37). Another CD37-specific antibody that may be used in combination therapy is S-B3 (Biosys).

In certain embodiments, the CD37-specific binding molecules useful for combination therapy with a bifunctional chemotherapeutic are CD37-specific SMIP polypeptides. An exemplary SMIP polypeptide comprises SEQ ID NO:2. Additional exemplary SMIP polypeptides include those described in WO 2005017148, such as (1) G28-1 scFv (SSS-S) H WCH2 WCH3 comprising a G28-1 scFv, an altered human IgG1 hinge in which all three cysteine residues and a proline carboxyl terminus to the third cysteine in a human IgG1 hinge region are mutated to serine residues, and wild type human IgG1 CH2 and CH3 domains; (2) G28-1 scFv IgAH WCH2 WCH3 comprising a G28-1 scFv, a portion of human IgA hinge, and human IgG1 CH2 and CH3 domains; (3) G28-1 scFv VHL11S (SSS-S) H WCH2 CH3 comprising a G28-1 scFv, an altered human IgG1 hinge in which all three cysteine residues and a proline carboxyl terminus to the third cysteine in the hinge region are mutated to serine residues, and human IgG1 CH2 and CH3 domains, wherein the leucine at position 11 of the heavy chain variable region is substituted with a serine; (4) G28-1 scFv VH L11S (CSS-S) H WCH2 CH3 comprising a G28-1 scFv, an altered human IgG1 hinge in

which the cysteine residues at the second and third positions and a proline
 carboxyl terminus to the third cysteine are substituted with serine residues, and
 human IgG1 CH2 and CH3 domains, wherein the leucine at position 11 of the
 heavy chain variable region is substituted with a serine; (5) G28-1 scFv VHL11S
 5 (CSC-S) H WCH2 CH3 comprising a G28-1 scFv, an altered human IgG1 hinge
 in which the cysteine residue at the second position and a proline carboxyl
 terminus to the cysteine at the third position were substituted with serine
 residues, and human IgG1 CH2 and CH3 domains, wherein the leucine at
 position 11 of the heavy chain variable region is substituted with a serine; (6)
 10 G28-1 scFv VH11S (SSC-P) H WCH2 WCH3 comprising a G28-1 scFv, an
 altered human IgG1 hinge in which the first and second cysteine residues in the
 hinge region are mutated to serine residues, and human IgG1 CH2 and CH3
 domains, wherein the leucine at position 11 of the heavy chain variable region is
 substituted with a serine; (7) G28-1 scFv VH11S (SCS-S) H WCH2 WCH3
 15 comprising a G28-1 scFv, an altered human IgG1 hinge in which the first and
 third cysteine residues and a proline carboxyl terminus to the third cysteine in the
 hinge regions are mutated to serine residues, and human IgG1 CH2 and CH3
 domains, wherein the leucine at position 11 of the heavy chain variable region is
 substituted with a serine; (8) G28-1 scFv VHL11S (CCS-P) H WCH2 WCH3
 20 comprising a G28-1 scFv, an altered human IgG1 hinge in which the third
 cysteine residue in the hinge region is substituted with a serine, and human IgG1
 CH2 and CH3 domains, wherein the leucine at position 11 of the heavy chain
 variable region is substituted with a serine (9) G28-1scFv VHL11S (SCC-P) H
 WCH2 WCH3 comprising a G28-1 scFv, an altered human IgG1 hinge in which
 25 the first cysteine is substituted with a serine, and human CH2 and CH3 domains,
 wherein the leucine at position 11 of the heavy chain variable region is
 substituted with a serine; (10) G28-1 scFv VH L11S mIgE CH2 CH3 CH4,
 comprising a G28-1 scFv and mouse IgE CH2, CH3 and CH4 regions, wherein
 the leucine at position 11 of the heavy chain variable region is substituted with a
 30 serine; (11) G28-1 scFv VH L11S mIgA WlgACH2 T4CH3, comprising a G28-1
 scFv, a mouse IgA hinge, and a wild type IgA CH2 and a truncated IgA CH3
 domain lacking the 4 carboxy amino acids GTCY (SEQ ID NO:265); (12) G28-1

scFv VHL11S hIgE CH2 CH3 CH4, comprising a G28-1 scFv and human IgE CH2, CH3 and CH4 regions, wherein the leucine at position 11 of the heavy chain variable region is substituted with a serine; and (13) G28-1 scFv VHL11S hIgAH WlgACH2 TCH3 comprising a G28-1 scFv, a portion of human IgA hinge,
5 a wild type IgA CH2 and a truncated IgA CH3 domain lacking the 4 carboxy amino acids GTCY (SEQ ID NO:265), wherein the leucine at position 11 of the heavy chain variable region is substituted with a serine.

In certain embodiments, CD37-specific binding molecules useful for combination therapy with a bifunctional chemotherapeutic are humanized CD37-
10 specific binding molecules described herein, including humanized anti-CD37 antibodies, Fab fragments of humanized anti-CD37 antibody, humanized CD37-specific PIMS protein, humanized CD37-specific SCORPION protein, and other bi- or multi-specific binding proteins that comprise at least one humanized CD37-specific binding protein, especially humanized CD37-specific single chain Fv
15 (scFv) and humanized CD37-specific SMIP polypeptides.

Certain CD37-specific binding molecules contemplated in this disclosure have affinities for CD37 of about 0.5 to about 10 nM. Another characteristic of certain CD37-binding molecules contemplated in this disclosure is that they exhibit a half life in circulation of about 5 to about 30 days.

20 In certain embodiments, CD37-specific binding molecules are capable of competing with G28-1 mAb in CD37-specific binding.

Bendamustine (4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid) is a nitrogen mustard with alkylator and antimetabolite activities. Bendamustine has both an alkylating group and a
25 benzimidazole ring. The alkylating group allows bendamustine metabolites to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and subsequently apoptosis. The benzimidazole ring may allow bendamustine to act as a purine analogue. Bendamustine hydrochloride has trade names TREANDA® and RIBOMUSTIN®.

30 Although bendamustine or its salts are preferred therapeutic agents that may be used in combination with CD37-specific binding molecules, other therapeutic agents that both comprise one or more alkylating groups and are

capable of functioning as a purine analogue may also be used in combination with CD37-specific binding molecules according to the present disclosure.

The term "alkylating group," as used herein, refers to a group that enables the compound comprising this group to attach an alkyl group to DNA.

- 5 The compound that comprises an alkylating group may be referred to as an "alkylating agent." In certain embodiments, alkylating agents are nitrogen mustards.

- The term "purine analogue" refers to an antimetabolite that mimics the structure of metabolic purines (*e.g.*, adenine and guanine) and has one, two, 10 three or four substituents at the purine ring that differ from metabolic purines. Exemplary purine analogues include azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin and cladribine.

- A therapeutic agent is "capable of functioning as a purine analogue" if it possesses at least one function of a purine analogue. Exemplary functions of 15 purine analogues include interference with or inhibition of purine nucleotide synthesis, purine nucleotide metabolism, nucleic acid synthesis, nucleic acid processing, or nucleic acid function, such as inhibiting ribonucleotide reductase, DNA polymerase, adenosine deaminase, and being incorporated into DNA or RNA.

20 Compositions and Methods

- In one aspect, the present disclosure provides a method for reducing B cells or treating a disease associated with aberrant B cell activity comprising administering to a subject in need thereof (*i.e.*, an individual having or 25 suspected of having a disease associated with aberrant B-cell activity) an effective amount of a humanized CD37-specific binding molecule provided herein (*e.g.*, CAS-024).

- In another aspect, the present disclosure provides a method for reducing B cells or treating a disease associated with aberrant B cell activity comprising administering to a subject in need thereof an effective amount of a 30 CD37-specific binding molecule (*e.g.*, CAS-024) and a bifunctional chemotherapeutic (*e.g.*, bendamustine). As described above, CD37-specific

binding molecules useful for combination therapy with a bifunctional chemotherapeutic are not limited to humanized CD37-specific binding molecules, but include other CD37-specific binding molecules that have not been humanized.

5 In one embodiment, a composition comprising a CD37 therapeutic and a bifunctional chemotherapeutic act synergistically in reducing B cells or treating a disease associated with aberrant B cell activity. Two or more compounds that act synergistically interact such that the combined effect of the compounds is greater than the sum of the individual effects of each compound
10 when administered alone (see, e.g., Berenbaum, *Pharmacol. Rev.* 41:93, 1989). For example, an interaction between small modular immunopharmaceutical that targets CD37 and another agent or compound may be analyzed by a variety of mechanistic and empirical models (see, e.g., Ouzounov et al., *Antivir. Res.* 55:425, 2002). A commonly used approach for analyzing the interaction between
15 a combination of agents employs the construction of isoboles (iso-effect curves, also referred to as isobolograms), in which the combination of agents (d_a , d_b) is represented by a point on a graph, the axes of which are the dose-axes of the individual agents (see, e.g., Ouzounov *et al.*, *supra*; see also Tallarida, J. *Pharmacol. Exp. Therap.* 298:865, 2001).

20 Another method for analyzing drug-drug interactions (antagonism, additivity, synergism) known in the art includes determination of combination indices (CI) according to the median effect principle to provide estimates of IC_{50} values of compounds administered alone and in combination (see, e.g., Chou. In *Synergism and Antagonism Chemotherapy*. Eds. Chou and Rideout. Academic
25 Press, San Diego Calif., pages 61-102, 1991; CalcuSynTM software). A CI value of less than one represents synergistic activity, equal to one represents additive activity, and greater than one represents antagonism.

 Still another exemplary method is the independent effect method (Pritchard and Shipman, *Antiviral Res.* 14:181, 1990; Pritchard and Shipman,
30 *Antiviral Therapy* 1:9, 1996; MACSYNERGYTM II software, University of Michigan, Ann Arbor, Mich.). MACSYNERGYTM II software allows a three-dimensional (3-D) examination of compound interactions by comparing a calculated additive

surface to observed data to generate differential plots that reveal regions (in the form of a volume) of statistically greater than expected (synergy) or less than expected (antagonism) compound interactions. For example, a composition comprising a CD37-specific binding molecule and a bifunctional
5 chemotherapeutic alters viral replication will be considered to have synergistic activity or have a synergistic effect when the volume of synergy produced as calculated by the volume of the synergy peaks is preferably about 15% greater than the additive effect (that is, the effect of each agent alone added together), or preferably about a 2-fold to 10-fold greater than the additive effect, or preferably
10 about a 3-fold to 5-fold or more greater than the additive effect.

In further embodiments, a CD37-specific binding molecule and a bifunctional chemotherapeutic can be administered to act synergistically in the treatment of B-cell malignancies or B-cell cancers. B-cell malignancies or B-cell cancers include B-cell lymphomas [such as various forms of Hodgkin's disease,
15 non-Hodgkins lymphoma (NHL) or central nervous system lymphomas], leukemias [such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hairy cell leukemia and chronic myoblastic leukemia] and myelomas (such as multiple myeloma). Additional B cell cancers include small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic
20 lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, solitary plasmacytoma of bone, extraosseous plasmacytoma, extra-nodal marginal zone B-cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large
25 B-cell lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia, B-cell proliferations of uncertain malignant potential, lymphomatoid granulomatosis, and post-transplant lymphoproliferative disorder.

Burkitt's lymphoma (or "Burkitt's B cell malignancy", or "Burkitt's tumor", or "Malignant lymphoma, Burkitt's type") is a cancer of the lymphatic
30 system (in particular, B lymphocytes). It can be divided into three main clinical variants: the endemic, the sporadic and the immunodeficiency-associated variants.

Non-Burkitt's B cell malignancies include, but are not limited to, B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, B-cell prolymphocytic leukemia, an acute lymphoblastic leukemia (ALL), lymphoplasmacytic lymphoma (including, but not limited to, Waldenstrom's
5 macroglobulinemia), marginal zone lymphomas (including, but not limited to, splenic marginal zone B-cell lymphoma, nodal marginal zone lymphoma, and extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type), hairy cell leukemia, plasma cell myeloma/plasmacytoma, follicular
10 lymphoma, mantle cell lymphoma (MCL), diffuse large cell B-cell lymphoma, transforming large B cell lymphoma, mediastinal large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, and non-Burkitt's non-Hodgkins lymphoma (NHL).

Disorders characterized by autoantibody production are often considered autoimmune diseases. Autoimmune diseases include, but are not
15 limited to: arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, polychondritis, psoriatic arthritis, psoriasis, dermatitis, polymyositis/dermatomyositis, inclusion body myositis, inflammatory myositis, toxic epidermal necrolysis, systemic scleroderma and sclerosis, CREST syndrome, responses associated with inflammatory bowel disease, Crohn's
20 disease, ulcerative colitis, respiratory distress syndrome, adult respiratory distress syndrome (ARDS), meningitis, encephalitis, uveitis, colitis, glomerulonephritis, allergic conditions, eczema, asthma, conditions involving infiltration of T cells and chronic inflammatory responses, atherosclerosis, autoimmune myocarditis, leukocyte adhesion deficiency, systemic lupus
25 erythematosus (SLE), subacute cutaneous lupus erythematosus, discoid lupus, lupus myelitis, lupus cerebritis, juvenile onset diabetes, multiple sclerosis, allergic encephalomyelitis, neuromyelitis optica, rheumatic fever, Sydenham's chorea, immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes, tuberculosis, sarcoidosis, granulomatosis
30 including Wegener's granulomatosis and Churg-Strauss disease, agranulocytosis, vasculitis (including hypersensitivity vasculitis/angiitis, ANCA and rheumatoid vasculitis), aplastic anemia, Diamond Blackfan anemia, immune

hemolytic anemia including autoimmune hemolytic anemia (AIHA), pernicious anemia, pure red cell aplasia (PRCA), Factor VIII deficiency, hemophilia A, autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocyte diapedesis, central nervous system (CNS) inflammatory disorders,

5 multiple organ injury syndrome, myasthenia gravis, antigen-antibody complex mediated diseases, anti-glomerular basement membrane disease, anti-phospholipid antibody syndrome, allergic neuritis, Behcet disease, Castleman's syndrome, Goodpasture's syndrome, Lambert-Eaton Myasthenic Syndrome, Reynaud's syndrome, Sjorgen's syndrome, Stevens-Johnson syndrome, solid

10 organ transplant rejection, graft versus host disease (GVHD), pemphigoid bullous, pemphigus, autoimmune polyendocrinopathies, seronegative spondyloarthropathies, Reiter's disease, stiff-man syndrome, giant cell arteritis, immune complex nephritis, IgA nephropathy, IgM polyneuropathies or IgM mediated neuropathy, idiopathic thrombocytopenic purpura (ITP), thrombotic

15 thrombocytopenic purpura (TTP), Henoch-Schonlein purpura, autoimmune thrombocytopenia, autoimmune disease of the testis and ovary including autoimmune orchitis and oophoritis, primary hypothyroidism; autoimmune endocrine diseases including autoimmune thyroiditis, chronic thyroiditis (Hashimoto's Thyroiditis), subacute thyroiditis, idiopathic hypothyroidism,

20 Addison's disease, Grave's disease, autoimmune polyglandular syndromes (or polyglandular endocrinopathy syndromes), Type I diabetes also referred to as insulin-dependent diabetes mellitus (IDDM) and Sheehan's syndrome; autoimmune hepatitis, lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant) vs NSIP, Guillain-Barre' Syndrome, large vessel

25 vasculitis (including polymyalgia rheumatica and giant cell (Takayasu's) arteritis), medium vessel vasculitis (including Kawasaki's disease and polyarteritis nodosa), polyarteritis nodosa (PAN) ankylosing spondylitis, Berger's disease (IgA nephropathy), rapidly progressive glomerulonephritis, primary biliary cirrhosis, Celiac sprue (gluten enteropathy), cryoglobulinemia, cryoglobulinemia associated

30 with hepatitis, amyotrophic lateral sclerosis (ALS), coronary artery disease, familial Mediterranean fever, microscopic polyangiitis, Cogan's syndrome, Whiskott-Aldrich syndrome and thromboangiitis obliterans, autoimmune thyroid

disease (such as Graves' disease and Hashimoto's thyroiditis), Sjogren's syndrome, and idiopathic inflammatory myopathy (IIM), including dermatomyositis (DM) and polymyositis (PM). The above autoimmune diseases may also be treated with humanized CD37-specific binding molecules or with the
5 combination of CD37-specific binding molecules and a bifunctional chemotherapeutic.

In one aspect of the disclosure, a humanized CD37-specific binding molecule or a combination of a CD37-specific binding molecule with a bifunctional chemotherapeutic is administered in a pharmaceutical composition.

10 To administer a humanized CD37-specific binding molecule or a combination of a CD37-specific binding molecule with a bifunctional chemotherapeutic to human or test animals, it is preferable to formulate the binding molecule or the combination in a composition comprising one or more pharmaceutically acceptable carriers. The phrase "pharmaceutically or pharmacologically acceptable" refer to
15 molecular entities and compositions that do not produce allergic, or other adverse reactions when administered using routes well-known in the art, as described below. "Pharmaceutically acceptable carriers" include any and all clinically useful solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. In addition, compounds may form
20 solvates with water or common organic solvents. Such solvates are contemplated as well.

Pharmaceutical compositions of the present disclosure containing a humanized CD37-specific binding molecule or a combination of a CD37-specific binding molecule with a bifunctional chemotherapeutic used in a method of the
25 disclosure may contain pharmaceutically acceptable carriers or additives depending on the route of administration. Examples of such carriers or additives include water, a pharmaceutical acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran,
30 carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, gelatin, agar, diglycerin, glycerin, propylene glycol, polyethylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum

albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like. Additives used are chosen from, but not limited to, the above or combinations thereof, as appropriate, depending on the dosage form of the present disclosure.

5 Formulation of the pharmaceutical composition will vary according to the route of administration selected (e.g., solution, emulsion). An appropriate composition comprising the antibody to be administered can be prepared in a physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions
10 or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers

 A variety of aqueous carriers, e.g., water, buffered water, 0.4%
15 saline, 0.3% glycine, or aqueous suspensions may contain the active compound in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or
20 wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty
25 acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate.

30 A CD37-specific binding molecule, a combination of a CD37-specific binding molecule with a bifunctional chemotherapeutic, or a composition comprising the binding molecule or the combination can be lyophilized for storage

and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immunoglobulins. Any suitable lyophilization and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution can
5 lead to varying degrees of activity loss and that use levels may have to be adjusted to compensate.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more
10 preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.

The concentration of CD37-specific binding molecule or bifunctional chemotherapeutic in these formulations can vary widely, for example from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by
15 weight and will be selected primarily based on fluid volumes, viscosities, *etc.*, in accordance with the particular mode of administration selected. Thus, a typical pharmaceutical composition for parenteral injection could be made up to contain 1 mL sterile buffered water, and 50 mg of antibody. A typical composition for intravenous infusion could be made up to contain 250 mL of sterile Ringer's
20 solution, and 150 mg of antibody. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa. (1980). An effective dosage of CD37-specific binding molecules (including humanized CD37-specific
25 binding molecules) is within the range of 0.01 mg to 1000 mg per kg of body weight per administration.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous, oleaginous suspension, dispersions or sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The
30 suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution

or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, vegetable oils, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

10 In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. It must be stable under the conditions of manufacture and storage and must be preserved
15 against the contaminating action of microorganisms, such as bacteria and fungi. The prevention of the action of microorganisms can be brought about by various antibacterial or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, or the like. In many cases, it will be desirable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of
20 the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Compositions useful for administration may be formulated with uptake or absorption enhancers to increase their efficacy. Such enhancers include for example, salicylate, glycocholate/linoleate, glycholate, aprotinin,
25 bacitracin, SDS, caprate and the like. See, e.g., Fix (J. Pharm. Sci., 85:1282-1285, 1996) and Oliyai and Stella (Ann. Rev. Pharmacol. Toxicol., 32:521-544, 1993).

In addition, the properties of hydrophilicity and hydrophobicity of the compositions contemplated for use in the disclosure are well balanced, thereby
30 enhancing their utility for both in vitro and especially in vivo uses, while other compositions lacking such balance are of substantially less utility. Specifically, compositions contemplated for use in the disclosure have an appropriate degree

of solubility in aqueous media which permits absorption and bioavailability in the body, while also having a degree of solubility in lipids which permits the compounds to traverse the cell membrane to a putative site of action. Thus, antibody compositions contemplated are maximally effective when they can be
5 delivered to the site of target antigen activity.

In one aspect, methods of the disclosure include a step of administration of a CD37-specific binding molecule composition. In certain embodiments, the combinations of compounds may be administered concurrently, together in the same pharmaceutically acceptable carrier, or
10 separately (but concurrently). In other embodiments, the CD37 immunotherapeutic (*i.e.*, the CD37-specific binding molecule) and a bifunctional chemotherapeutic can be administered sequentially, in any order and in any combination.

The binding molecule, bifunctional chemotherapeutic, or
15 combination compositions may be administered orally, topically, transdermally, parenterally, by inhalation spray, vaginally, rectally, or by intracranial injection, or any combination thereof. In one embodiment, both the CD37-specific binding molecule and the bifunctional chemotherapeutic are administered parenterally, either concurrently or sequentially. The term parenteral, as used herein, includes
20 subcutaneous injections, intravenous, intramuscular, intracisternal injection, or infusion techniques. Administration by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, intrathecal, retrobulbar, intrapulmonary injection and or surgical implantation at a particular site is contemplated as well. Generally, compositions are essentially free of pyrogens, as well as other
25 impurities that could be harmful to the recipient. Injection, especially intravenous, is preferred.

In one embodiment, administration is performed at the site of a cancer or affected tissue needing treatment by direct injection into the site or via a sustained delivery or sustained release mechanism, which can deliver the
30 formulation internally. For example, biodegradable microspheres or capsules or other biodegradable polymer configurations capable of sustained delivery of a

composition (e.g., a soluble polypeptide, antibody, or small molecule) can be included in the formulations of the disclosure implanted near the cancer.

Therapeutic compositions may also be delivered to the patient at multiple sites. The multiple administrations may be rendered simultaneously or
5 may be administered over a period of time. In certain cases it is beneficial to provide a continuous flow of the therapeutic composition. Additional therapy may be administered on a period basis, for example, hourly, daily, weekly or monthly.

Binding molecule, bifunctional chemotherapeutic, or combination compositions of this disclosure may comprise one or more than one binding
10 molecule, bifunctional chemotherapeutic, or any combination thereof. Also contemplated by the present disclosure is the administration of binding molecule, bifunctional chemotherapeutic, or combination compositions in conjunction with a further therapeutic agent. Further therapeutic contemplated by the disclosure are listed in paragraphs below.

15 A further therapeutic agent may be a B-cell-associated molecule. Other B-cell-associated molecules contemplated by the disclosure include binding molecules which bind to B-cell surface molecules that are not CD37. B-cell-associated molecules, include CD19 (B-lymphocyte antigen CD19, also referred to as B-lymphocyte surface antigen B4, or Leu-12), CD20, CD21, CD22
20 (B-cell receptor CD22, also referred to as Leu-14, B-lymphocyte cell adhesion molecule, or BL-CAM), CD23, CD40 (B-cell surface antigen CD40, also referred to as Tumor Necrosis Factor receptor superfamily member 5, CD40L receptor, or Bp50), CD80 (T lymphocyte activation antigen CD80, also referred to as Activation B7-1 antigen, B7, B7-1, or BB1), CD86 (T lymphocyte activation
25 antigen CD86, also referred to as Activation B7-2 antigen, B70, FUN-1, or BU63), CD137 (also referred to as Tumor Necrosis Factor receptor superfamily member 9), CD152 (also referred to as cytotoxic T-lymphocyte protein 4 or CTLA-4), L6 (Tumor-associated antigen L6, also referred to as Transmembrane 4 superfamily member 1, Membrane component surface marker 1, or M3S1), CD30
30 (lymphocyte activation antigen CD30, also referred to as Tumor Necrosis Factor receptor superfamily member 8, CD30L receptor, or Ki-1), CD50 (also referred to as Intercellular adhesion molecule-3 (ICAM3), or ICAM-R), CD54 (also referred to

as Intercellular adhesion molecule-1 (ICAM1), or Major group rhinovirus receptor), B7-H1 (ligand for an immunoinhibitory receptor expressed by activated T cells, B-cells, and myeloid cells, also referred to as PD-L1; see Dong, et al., "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion," *Nat. Med.*, 5:1365-1369 (1999), CD134 (also referred to as Tumor Necrosis Factor receptor superfamily member 4, OX40, OX40L receptor, ACT35 antigen, or TAX-transcriptionally activated glycoprotein 1 receptor), 41BB (4-1BB ligand receptor, T-cell antigen 4-1BB, or T-cell antigen ILA), CD153 (also referred to as Tumor Necrosis Factor ligand superfamily member 8, CD30 ligand, or CD30-L), CD154 (also referred to as Tumor Necrosis Factor ligand superfamily member 5, TNF-related activation protein, TRAP, or T cell antigen Gp39), Toll receptors, or the like.

Examples of chemotherapeutic agents contemplated as further therapeutic agents include alkylating agents, such as nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, ifosfamide, melphalan, and chlorambucil); nitrosoureas (e.g., carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU)); ethyleneimines and methyl-melamines (e.g., triethylenemelamine (TEM), triethylene thiophosphoramidate (thiotepa), and hexamethylmelamine (HMM, altretamine)); alkyl sulfonates (e.g., busulfan); and triazines (e.g., dacabazine (DTIC)); antimetabolites, such as folic acid analogues (e.g., methotrexate, trimetrexate, and pemetrexed (multi-targeted antifolate)); pyrimidine analogues (such as 5-fluorouracil (5-FU), fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, and 2,2'-difluorodeoxycytidine); and purine analogues (e.g., 6-mercaptopurine, 6-thioguanine, azathioprine, 2'-deoxycoformycin (pentostatin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, 2-chlorodeoxyadenosine (cladribine, 2-CdA)); Type I topoisomerase inhibitors such as camptothecin (CPT), topotecan, and irinotecan; natural products, such as epipodophylotoxins (e.g., etoposide and teniposide); and vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine); anti-tumor antibiotics such as actinomycin D, doxorubicin, and bleomycin; radiosensitizers such as 5-bromodeoxyuridine, 5-iododeoxyuridine, and bromodeoxycytidine; platinum

coordination complexes such as cisplatin, carboplatin, and oxaliplatin; substituted ureas, such as hydroxyurea; and methylhydrazine derivatives such as N-methylhydrazine (MIH) and procarbazine.

Further therapeutic agents contemplated by this disclosure for
5 treatment of autoimmune diseases are referred to as immunosuppressive agents, which act to suppress or mask the immune system of the individual being treated. Immunosuppressive agents include, for example, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, glucocorticoids, disease-modifying antirheumatic drugs (DMARDs) for the treatment of arthritis, or biologic response modifiers.
10 Compositions in the DMARD description are also useful in the treatment of many other autoimmune diseases aside from RA.

Exemplary NSAIDs are chosen from the group consisting of ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors such as Vioxx and Celebrex, and sialylates. Exemplary analgesics are chosen from the group
15 consisting of acetaminophen, oxycodone, tramadol or propoxyphene hydrochloride. Exemplary glucocorticoids are chosen from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone. Exemplary biological response modifiers include molecules directed against cell surface markers (e.g., CD4, CD5, etc.), cytokine inhibitors,
20 such as the TNF antagonists (e.g. etanercept (Enbrel), adalimumab (Humira) and infliximab (Remicade)), chemokine inhibitors and adhesion molecule inhibitors. The biological response modifiers include monoclonal antibodies as well as recombinant forms of molecules. Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide,
25 sulfasalazine, hydroxychloroquine, Gold (oral (auranofin) and intramuscular) and minocycline.

It is contemplated the binding molecule composition and the further therapeutic agent may be given simultaneously in the same formulation. Alternatively, the agents are administered in a separate formulation but
30 concurrently, with concurrently referring to agents given, for example, within minutes, hours or days of each other.

In another aspect, the further therapeutic agent is administered prior to administration of the binding molecule, bifunctional chemotherapeutic, or combination composition. Prior administration refers to administration of the further therapeutic agent within the range of minutes, hours, or one week prior to treatment with the binding molecule, bifunctional chemotherapeutic, or combination composition. It is further contemplated that the further therapeutic agent is administered subsequent to administration of the binding molecule composition. Subsequent administration is meant to describe administration more than minutes, hours, or weeks after binding molecule, bifunctional chemotherapeutic, or combination composition treatment or administration.

It is further contemplated that when the binding molecule is administered in combination with a further therapeutic agent, wherein the further therapeutic agent is a cytokine or growth factor, or a chemotherapeutic agent, the administration may also include use of a radiotherapeutic agent or radiation therapy. The radiation therapy administered in combination with an antibody composition is administered as determined by the treating physician, and at doses typically given to patients being treated for cancer.

These compositions may be administered in a single dose or in multiple doses. Standard dose-response studies, first in animal models and then in clinical testing, reveal optimal dosages for particular disease states and patient populations.

The administration of the binding molecule, bifunctional chemotherapeutic or combination composition decreases the B-cell population by at least 20% after a single dose of treatment. In one embodiment, the B-cell population is decreased by at least about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, or about 100%. B-cell reduction is defined as a decrease in absolute B-cell count below the lower limit of the normal range. B-cell recovery is defined as a return of absolute B-cell count to, for example, 70%, 80%, 90% of a subject's baseline value or normal range. Further, the administration of binding molecule, bifunctional chemotherapeutic, or combination composition of this disclosure results in desired clinical effects in the disease or disorder being treated.

In some embodiments, patients suffering from a disease associated with aberrant B cell activity who receive treatment according to the disclosure may demonstrate an overall beneficial response to the treatment, based on clinical criteria well known and commonly used in the art and as described below.

5 For example, in patients affected by rheumatoid arthritis, the administration may improve the patient's condition by a clinically significant amount [e.g., achieves the American College of Rheumatology Preliminary Detection of Improvement (ACR20)], and/or an improvement of 20% in tender and swollen joint and 20% improvement in 3/5 remaining ACR measures (Felson
10 et al., *Arthritis Rheum.* 1995, 38:727-35). Biological measures for improvement in an RA patient after administration of CD37-specific and CD20-specific binding molecules include measurement of changes in cytokine levels, measured via protein or RNA levels. Cytokines of interest include, but are not limited to, TNF- α , IL-1, interferons, Blys, and APRIL. Cytokine changes may be due to reduced B
15 cell numbers or decreased activated T cells. In RA patients, markers relevant to bone turnover (bone resorption or erosion) are measured before and after administration of CD20-specific binding molecules. Relevant markers include, but are not limited to, alkaline phosphatase, osteocalcin, collagen breakdown fragments, hydroxyproline, tartrate-resistant acid phosphatase, and RANK ligand
20 (RANKL). Other readouts relevant to the improvement of RA include measurement of C reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), rheumatoid factor, CCP (cyclic citrullinated peptide) antibodies and assessment of systemic B cell levels and lymphocyte count via flow cytometry. Specific factors can also be measured from the synovium of RA patients,
25 including assessment of B cell levels in synovium from synovium biopsy, levels of RANKL and other bone factors and cytokines set out above.

 In a related aspect, the effects of combination administration on other diseases may be measured according to standards known in the art. For example, it is contemplated that Crohn's disease patients treated according to the
30 invention achieve an improvement in Crohn's Disease Activity Index (CDAI) in the range of about 50 to about 70 units, wherein remission is at 150 units (Simonis et al., *Scand. J Gastroent.* 1998, 33:283-8). A score of 150 or 200 is considered

normal, while a score of 450 is considered a severe disease score. It is further desired that administration of the CD37-specific and CD20-specific binding molecules results in a reduction in perinuclear anti-neutrophil antibody (pANCA) and anti-Saccharomyces cervisiae antibody (ASCA) in individuals affected by
5 inflammatory bowel disease.

It is further contemplated that adult and juvenile myositis patients treated according to the disclosure may achieve an improvement in core set of evaluations, such as 3 out of 6 of the core set measured improved by approximately 20%, with not more than 2 of the core measurements worse by
10 approximately 25% (see Rider et al., *Arthritis Rheum.* 2004, 50:2281-90).

It is further contemplated that SLE patients treated according to the disclosure may achieve an improvement in Systemic Lupus Activity Measure (SLAM) or SLE Disease Activity Index (SLEDAI) score of at least 1 point (Gladman et al, *J Rheumatol* 1994, 21:1468-71) (Tan et al., *Arthritis Rheum.*
15 1982, 25:1271-7). A SLAM score of >5, or SLEDAI score >2, is considered clinically active disease. A response to treatment may be defined as improvement or stabilization over the in 2 disease activity measures (the SLE Disease Activity Index [SLEDAI] and the Systemic Lupus Activity Measure) and 2 quality of life measures (patient's global assessment and the Krupp Fatigue Severity Scale)
20 (Petri et al., *Arthritis Rheum.* 2004, 50:2858-68.) It is further contemplated that administration of the binding molecule to SLE patients results in a reduction in anti-double-stranded DNA antibodies. Alternatively, improvement may be gauged using the British Isles Lupus Assessment Group Criteria (BILAG).

It is further contemplated that multiple sclerosis patients treated
25 according to the disclosure may achieve an improvement in clinical score on the Kurtzke Expanded Disability status scale (EDSS) (Kurtzke, F., *Neurology* 1983, 33:1444-52) of at least 0.5, or a delay in worsening of clinical disease of at least 1.0 on the Kurtzke scale (Rudick et al., *Neurology* 1997, 49:358-63).

It is further contemplated that patients suffering from IIM treated
30 according to the disclosure may achieve a reduction in at least one of five criteria set out in the Idiopathic Inflammatory Myopathy Criteria (IIMC) assessment (Miller, F., *supra*). It is further contemplated that administration to IIM patients

may result in a reduction in IIM associated factors selected from the group consisting of creatine kinase (CK), lactate dehydrogenase, aldolase, C-reactive protein, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and antinuclear autoantibody (ANA), myositis-specific antibodies (MSA), and antibody
5 to extractable nuclear antigens. Alternatively, patients meet 3 out of 6 of the criteria set out in Rider et al., Arthritis Rheum., 50(7):2281-2290 (2004), with worsening in no more than 2 criteria.

In some embodiments, patients suffering from a B cell cancer that receive treatment according to the disclose may demonstrate an overall
10 beneficial response to the treatment, based on clinical criteria well-known and commonly used in the art, and as described below, such as a decrease in tumor size, decrease in tumor number and/or an improvement in disease symptoms.

Exemplary clinical criteria are provided by the U.S. National Cancer Institute (NCI), which has divided some of the classes of cancers into the clinical
15 categories of "indolent" and "aggressive" lymphomas. Indolent lymphomas include follicular cell lymphomas, separated into cytology "grades," diffuse small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL), lymphoplasmacytoid/Waldenstrom's Macroglobulinemia, Marginal zone lymphoma and Hairy cell leukemia. Aggressive lymphomas include diffuse mixed
20 and large cell lymphoma, Burkitt's lymphoma/diffuse small non-cleaved cell lymphoma, Lymphoblastic lymphoma, Mantle cell lymphoma and AIDS-related lymphoma. In some cases, the International Prognostic Index (IPI) is used in cases of aggressive and follicular lymphoma. Factors to consider in the IPI include age (<60 years of age versus >60 years of age), serum lactate
25 dehydrogenase (levels normal versus elevated), performance status (0 or 1 versus 2-4) (see definition below), disease stage (I or II versus III or IV), and extranodal site involvement (0 or 1 versus 2-4). Patients with 2 or more risk factors have less than a 50% chance of relapse-free and overall survival at 5 years.

30 Performance status in the aggressive IPI is defined as follows:
Grade Description: 0 Fully active, able to carry on all pre-disease performance without restriction; 1 Restricted in physically strenuous activity but ambulatory

and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 Ambulatory and capable of all selfcare but unable to carry out any work activities, up to and about more than 50% of waking hours; 3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4
5 Completely disabled, unable to carry on any selfcare, totally confined to bed or chair; and, 5 Dead. (See, The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. *N. Engl. J. Med.* 329:987–94, 1993.)

Typically, the grade of lymphoma is clinically assessed using the
10 criterion that low-grade lymphoma usually presents as a nodal disease and is often indolent or slow-growing. Intermediate- and high-grade disease usually presents as a much more aggressive disease with large extranodal bulky tumors.

The Ann Arbor classification system is also used to measure progression of tumors, especially non-Hodgkin's lymphomas. In this system,
15 stages I, II, III, and IV of adult NHL can be classified into A and B categories depending on whether the patient has well-defined generalized symptoms (B) or not (A). The B designation is given to patients with the following symptoms: unexplained loss of more than 10% body weight in the 6 months prior to diagnosis, unexplained fever with temperatures above 38° C. and drenching night
20 sweats. Definitions of the stages are as follows: Stage I-involvement of a single lymph node region or localized involvement of a single extralymphatic organ or site. Stage II-involvement of two or more lymph node regions on the same side of the diaphragm or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node
25 regions on the same side of the diaphragm. Stage III-involvement of lymph node regions on both sides of the diaphragm, possibly accompanying localized involvement of an extralymphatic organ or site, involvement of the spleen, or both. Stage IV-disseminated (multifocal) involvement of one or more extralymphatic sites with or without associated lymph node involvement or
30 isolated extralymphatic organ involvement with distant (non-regional) nodal involvement. For further details, see The International Non-Hodgkin's Lymphoma

Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma, *New England J. Med.* (1993) 329:987-994.

In one aspect, a therapeutic effect of the methods according to the disclosure is determined by the level of response, for example, a partial response
5 is defined as tumor reduction to less than one-half of its original size. A complete response is defined as total elimination of disease confirmed by clinical or radiological evaluation. In one embodiment, the individual receiving treatment according to the invention demonstrates at least a partial response to treatment.

According to the Cheson criteria for assessing NHL developed in
10 collaboration with the National Cancer Institute (Cheson et al., *J Clin Oncol.* 1999, 17:1244; Grillo-Lopez et al., *Ann Oncol.* 2000, 11:399-408), a complete response is obtained when there is a complete disappearance of all detectable clinical and radiographic evidence of disease and disease-related symptoms, all lymph nodes have returned to normal size, the spleen has regressed in size, and
15 the bone marrow is cleared of lymphoma.

An unconfirmed complete response is obtained when a patient shows complete disappearance of the disease and the spleen regresses in size, but lymph nodes have regressed by more than 75% and the bone marrow is indeterminate. An unconfirmed complete response meets and exceeds the
20 criteria for partial response. An overall response is defined as a reduction of at least 50 percent in overall tumor burden.

Similar criteria have been developed for various other forms of cancers or hyperproliferative diseases and are readily available to a person of skill in the art. See, e.g., Cheson et al., *Clin Adv Hematol Oncol.* 2006, 4:4-5,
25 which describes criteria for assessing CLL; Cheson et al., *J Clin Oncol.* 2003, 21:4642-9, which describes criteria for AML; Cheson et al., *Blood* 2000, 96:3671-4, which describes criteria for myelodysplastic syndromes.

In another aspect, a therapeutic response in patients having a B cell cancer is manifest as a slowing of disease progression compared to patients not
30 receiving therapy. Measurement of slowed disease progression or any of the above factors may be carried out using techniques well-known in the art,

including bone scan, CT scan, gallium scan, lymphangiogram, MRI, PET scans, ultrasound, and the like.

As an additional aspect, the disclosure includes kits which comprise one or more compounds or compositions useful in the methods of this disclosure

5 packaged in a manner which facilitates their use to practice methods of the disclosure. In a simplest embodiment, such a kit includes a compound or composition described herein as useful for practice of a method of the disclosure packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or

10 composition to practice the method of the disclosure. Preferably, the compound or composition is packaged in a unit dosage form. The kit may further include a device suitable for administering the composition according to a preferred route of administration or for practicing a screening assay. The kit may include a label that describes use of the binding molecule composition(s) in a method of the

15 disclosure.

EXAMPLES

EXAMPLE 1

CD37-SPECIFIC BINDING MOLECULES

5

Various CD37-specific binding proteins can be made with exemplary components provided in Tables 2-4. For example, antibodies or SMIP molecules can be made, and these molecules can be chimeric, humanized, or human. More specifically, preferred light chain variable region CDRs are found in
10 SEQ ID NOS:236-240 and 247-254 and preferred heaving chain variable domain CDRs include SEQ ID NOS:241-245 and 247-254. Also, preferred light and heavy chain variable regions are provided in SEQ ID NOS:236-240 and SEQ ID NOS:241-245, respectively. Preferred light and heavy chain variable regions may also be found in SEQ ID NOS:247-254. Preferred variable domain linkers
15 include SEQ ID NOS:225-229, while preferred hinges include SEQ ID NOS:230-235.

A particularly preferred embodiment is CAS-024 [G28-1 VH (M99F, Y102S) – VL (T25A) scFv (SSC-P) H WCH2 WCH3], which is a recombinant, 483 amino acid single-chain fusion protein that binds to human CD37. The binding
20 domain comprises a humanized scFv based on the G28-1 antibody variable region CDRs, including mutations in the heavy chain CDR3 and in the light chain CDR1. The variable domains are linked by a (G₄S)₅ (25 amino acid) sequence (SEQ ID NO:229), which is connected via a three amino acid junction (GDQ) to the amino terminus of a modified upper and core IgG1 hinge region (wherein the
25 first two of three cysteines found in these hinge regions are each substituted with a serine). The carboxy-terminus of the hinge is fused to an effector domain comprising CH2 and CH3 domains of IgG₁. The amino acid sequence of CAS-024 is set out in SEQ ID NO:253. Figure 1 shows heavy and light chain variable region amino acid sequence alignments of mouse G28.1 and CAS-024
30 sequences, along with a consensus identity sequence.

Table 1.
Exemplary CD-37 Specific SMIP Constructs

Construct	Description†	Linker	Hinge*	AA SEQ ID NO.
CAS-001	Vk3:VH5-51	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	6
CAS-002	Vk3:VH5 JH4 <i>CDRL1 (T25A);</i> <i>CDRH3 (M99F)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	48
CAS-003	Vk3:VH5 JH5a <i>CDRL1 (T25A);</i> <i>CDRH3 (M99F; Y102S)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	52
CAS-007	Vk3:VH5-51 (<i>Linker TG→SS</i>)	16aa (G ₄ S) ₃ S	SSC-P	8
CAS-008	Vk3:VH5-51 <i>VH VIIIS</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	10
CAS-009	Vk3:VH5-51 <i>CDRL1 (E27Q)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	12
CAS-010	Vk3:VH5-51 <i>CDRL1 (N28S)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	14
CAS-011	Vk3:VH5-51 <i>CDRL1 (T25A)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	16
CAS-012	mVk:VH5-5a	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	18
CAS-013	Vk3:VH5 <i>VH3 FW1</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	22
CAS-014	mVH:Vk3	22aa (G ₄ S) ₄ AS	SSC-P	24
CAS-015	Vk3:mVH (<i>2H7 Leader</i>)	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	26
CAS-016	mVH:Vk3	22aa (G ₄ S) ₄ AS	SCC-P	28
CAS-017	Vk3:mVH	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	30
CAS-018	Vk3:mVH	16aa (G ₄ S) ₂ (G ₄ A)S	SCC-P	32
CAS-019	Vk3:VH5 <i>VH3 FW1</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SCC-P	34
CAS-020	Vk3:VH5 <i>VH3-13 FW1</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	38
CAS-021	Vk3:VH5 <i>VH3-13 FW1</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SCC-P	40
CAS-022	Vk3:VH5 <i>VH3-13 VIIIS FW1</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	42
CAS-023	Vk3:VH5 <i>VH3-13 VIIIS FW1</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SCC-P	44
CAS-024	VHVL	25aa (G ₄ S) ₅	SSC-P	253
CAS-060	Vk3:VH5 <i>VH3 FW1</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	36
CAS-061	Vk3:VH5 <i>CDRL1 (T25A, E27Q)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	46
CAS-062	Vk3:CDR-H3 JH6 <i>CDRL1 (T25A);</i>	16aa	SSC-P	254

Construct	Description†	Linker	Hinge*	AA SEQ ID NO.
	<i>CDRH3 (Y102V)</i>	(G ₄ S) ₂ (G ₄ T)G		
CAS-063	Vk3:VH5 JH5b <i>CDRL1 (T25A); CDRH3 (M99F; Y102P)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	266
CAS-064	Vk3:VH5 JH1 <i>CDRL1 (T25A) CDRH3 (D101E; Y102H)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	267
CAS-065	Vk3:CDR-H3 JH3a <i>CDRL1 (T25A) CDRH3 (M99F; Y102V)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	268
CAS-066	Vk3:CDR-H3 JH3b <i>CDRL1 (T25A) CDRH3 (M99F; Y102I)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	269
CAS-067	Vk3:CDR-H3 JH2 <i>CDRL1 (T25A) CDRH3 (M99F; Y102L)</i>	16aa (G ₄ S) ₂ (G ₄ T)G	SSC-P	80
CAS-068	Vk3:VH5 JH2 <i>CDRL1 (T25A) CDRH2 (T59N; N61A; R62Q; K65Q)</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	82
CAS-069	Vk3:VH5 JH2 <i>CDRL1 (T25A) CDRH2 (T59G; N61A; R62Q; K65Q)</i>	16aa (G ₄ S) ₂ (G ₄ A)S	SSC-P	262
CAS-070	Vk3:VH5 JH5a <i>CDRL1 (T25A); CDRH3 (M99F; Y102S)</i>	20aa (G ₄ S) ₃ (G ₃ A)S	CPPCP	84

* Entries represent abbreviations regarding IgG1 hinges having mutations in only the first or the first and second cysteines found within the upper and core regions. The only exception is SEQ ID NO:84, which depicts the full-length hinge amino acid (CPPCP, SEQ ID NO:230) sequence used (essentially, only the core IgG1 sequence with a proline at the end).

5 † CDR mutation numbering is based on the Kabat numbering scheme.

Additional hinge regions that may be used in CD-37 specific binding molecules, such as SMIP molecules or antibodies, are provided in the following table.

Table 2.
Exemplary Hinge Regions for CD37-Specific Binding Proteins

Hinge description	Amino Acid Sequence	SEQ ID NO:
ccc(p)-hIgG1	EPKSCDKTHTCPPCP	90
scc(p)-hIgG1	EPKSSDKTHTCPPCP	92
scc(s)-hIgG1	EPKSSDKTHTCPPCS	94
csc(p)-hIgG1	EPKSCDKTHTSPPCP	102
csc(s)-hIgG1	EPKSCDKTHTSPPCS	104
ccs(p)-hIgG1	EPKSCDKTHTCPPSP	255
ccs(s)-hIgG1	EPKSCDKTHTCPPSS	256
ssc(p)-hIgG1	EPKSSDKTHTSPPCP	106
ssc(s)-hIgG1	EPKSSDKTHTSPPCS	108
scs(p)-hIgG1	EPKSSDKTHTCPPSP	257

Hinge description	Amino Acid Sequence	SEQ ID NO:
scs(s)-hIgG1	EPKSSDKTHTCPPSS	96
css(p)-hIgG1	EPKSCDKTHTSPPSP	110
css(s)-hIgG1	EPKSCDKTHTSPPSS	112
sss(p)-hIgG1	EPKSSDKTHTSPPSP	98
sss(s)-hIgG1	EPKSSDKTHTSPPSS	100
hIgA1	VPSTPPTSPSTPPTSPS	115
hIgA2	VPPPPP	116
hIgG3	ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKS CDTPPPCPRCPEPKSCDTPPPCPRCP	118
hIgG3(ccc)	EPKSCDTPPPCPRCP	258
hIgG3(scc)	EPKSSDTPPPCPRCP	120
hIgG3(csc)	EPKSCDTPPPSPRCP	126
hIgG3(ccs)	EPKSCDTPPPCPRSP	259
hIgG3(ssc)	EPKSCDTPPPSPRCP	260
hIgG3(scs)	EPKSCDTPPPCPRSP	261
hIgG3(css)	EPKSCDTPPPSPRSP	122
hIgG3(sss)	EPKSSDTPPPSPRSP	124
hIgD	ESPKAQASSVPTAQPAEGSLAKATTAPATTRNTG RGGEEKKKKEKEKEEQUEERETKTP	127

Additional framework regions that may be used in CD-37 specific binding molecules, such as SMIP molecules or antibodies, are provided in the following tables.

TABLE 3A.

5 Human Heavy Chain Framework Regions for CD37-Specific Binding Proteins

V-region	Human VH Framework Regions	SEQ ID NO.
	FR1	
VH1	QVQLVQSGAEVKKPGASVKVSCKASGYTFT	140
VH1	QVQLVQSGAEVKKPGSSVKVSCKASGGTFS	141
VH1	EVQLVQSGAEVKKPGATVKISCKVSGYTFT	143
VH5	EVQLVQSGAEVKKPGESLKISCKGSGYSFT	144
VH5	EVQLVQSGAEVKKPGESLRISCKGSGYSFT	145
VH7	QVQLVQSGSELKKPGASVKVSCKASGYTFT	146
	FR2	

V-region	Human VH Framework Regions	SEQ ID NO.
VH1	WVRQAPGQGLEWMG	147
VH1	WVQQAPGKGLEWMG	150
VH5	WVRQMPGKGLEWMG	151
	FR3	
VH1	RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR	154
VH1	RVTITADESTSTAYMELSSLRSEDVAVYYCAR	155
VH1	RVTITADKSTSTAYMELSSLRSEDVAVYYCAR	156
VH1	RVTITADTSTDVAVYYMELSSLRSEDVAVYYCAT	157
VH5	QVTISADKSISTAYLQWSSLKASDTAMYYCAR	158
VH5	HVTISADKSISTAYLQWSSLKASDTAMYYCAR	159
VH7	RFVFSLDTSVSTAYLQISSLKAEDTAVYYCAR	160
	FR4	
JH1, JH4, JH5a, JH5b	WGQGTLLTVSS	161
JH2	WGRGTLTVSS	162
JH3a, JH3b	WGQGTMTVSS	163
JH6	WGQGTTVTVSS	168
	WGKGTTVTVSS	169

TABLE 3B.

Human Light Chain Framework Regions for CD37-Specific Binding Proteins

V-region	Human VK Framework Regions	SEQ ID NO.
	FR1	
VK3	EIVMTQSPATLSVSPGERATLSC	170
VK3	EIVLTQSPATLSLSPGERATLSC	171
VK1	DIQMTQSPSSLSASVGDRVTITC	172
VK1	NIQMTQSPSAMSASVGDRVTITC	175
VK1	AIQLTQSPSSLSASVGDRVTITC	177
VK1	DIQLTQSPSFLSASVGDRVTITC	178
VK1	AIRMTQSPFSLASVGDRVTITC	179
VK1	AIQMTQSPSSLSASVGDRVTITC	180
VK1	DIQMTQSPSTLSASVGDRVTITC	181
	FR2	
VK3	WYQQKPGQAPRLLIY	182
VK1	WYQQKPGKAPKLLIY	184

V-region	Human VK Framework Regions	SEQ ID NO.
VK1	WYQQKPGKVPKLLIY	185
VK1	WYQQKPGKAPKRLIY	186
VK1	WFQQKPGKVPKHLIY	187
VK1	WFQQKPGKAPKSLIY	188
VK1	WYQQKPAKAPKLFYIY	191
	FR3	
VK3	GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC	194
VK3	GIPARFSGSGSGTDFTLTISSLQPEDFAVYYC	195
VK1	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC	196
VK1	GVPSRFSGSGSGTDFTLTISSLQPEDVATYYC	197
VK1	GVPSRFSGSGSGTEFTLTISSLQPEDFATYYC	198
VK1	GVPSRFSGSGSGTDYTLTISSLQPEDFATYYC	203
VK1	GVPSRFSGSGSGTEFTLTISSLQPDDEFATYYC	205
	FR4	
JK1	FGQGTKVEIK	206
	FGQGTKLEIK	207
	FGPGTKVDIK	208
	FGGGTKVEIK	209
	FGQGTRLEIK	210

Preferred exemplary component parts of CD-37 specific SMIP molecules (including leader sequences used for expression and export, but which are removed from the mature fusion protein when exported from a cell; linker sequences used to join light and heavy chain variable domains to form scFv binding domains; hinges used to join scFv binding domains to effector domains; and effector domains), as well as certain CD-37 specific SMIP molecules, including the preferred CAS-024 fusion protein, are provided in Table 4.

Table 4.

SMIP Component Parts and Select CD37-Specific SMIP Polypeptides

Construct No.	SEQ ID NO.	Amino Acid Sequence
Leader Sequence	223	MDFQVQIFSLLISASVIIARGV
Leader Sequence	224	MEAPAQLLFLLLLWLPDTTG

Construct No.	SEQ ID NO.	Amino Acid Sequence
Variable Domain Linker	225	GGGGSGGGSGGGSS
Variable Domain Linker	226	GGGGSGGGSGGGGAS
Variable Domain Linker	227	GGGGSGGSGSGGGGAS
Variable Domain Linker	228	GGGGSGGGSGGGGTG
Variable Domain Linker	229	GGGGSGGGSGGGSGGGSGGGSS
Hinge	230	CPPCP
Hinge (junction amino acid italicized)	231	SEP K SSDKTHTSPPCP
Hinge (junction amino acids italicized)	232	DLE PKSSDKTHTSPPCP
Hinge (junction amino acids italicized)	233	DQE PKSSDKTHTSPPCP
Hinge (junction amino acids italicized)	234	GDQE PKSSDKTHTSPPCP
Hinge (junction amino acids italicized)	235	GS SE PKSSDKTHTSPPCP
Mouse CD37 VL (CDRs highlighted)	236	DIQMTQSPASLSASVGETVTITC RTSENVYSYLAWYQQKQ GKSPQLLV SFAKTLA EGVPSRFSGSGSGTDFTLTIS SLEPEDF DSGSYFC QHHS DNPWTFGGGTELEIK
Humanized CD37 VL (CDRs highlighted)a	237	EIVLTQSPATLSLSPGERATLSC RTSENVYSYLAWYQQKPG QAPRLLIY FAKTLA EGIPARFSGSGSGTDFTLTIS SLEPEDF AVYYC QHHS DNPWTFGQGTKVEIK
Humanized CD37 VL (CDRs highlighted)b	238	EIVLTQSPATLSLSPGERATLSC RASENVYSYLAWYQQKPG QAPRLLIY FAKTLA EGIPARFSGSGSGTDFTLTIS SLEPEDF AVYYC QHHS DNPWTFGQGTKVEIK
Humanized CD37 VL (CDRs highlighted)c	239	EIVLTQSPATLSLSPGERATLSC RTSQNVYSYLAWYQQKPG QAPRLLIY FAKTLA EGIPARFSGSGSGTDFTLTIS SLEPEDF AVYYC QHHS DNPWTFGQGTKVEIK
Humanized CD37 VL (CDRs)	240	EIVLTQSPATLSLSPGERATLSC RTSESVYSYLAWYQQKPG QAPRLLIY FAKTLA EGIPARFSGSGSGTDFTLTIS SLEPEDF

Construct No.	SEQ ID NO.	Amino Acid Sequence
highlighted)d		AVYYCQHSDNPWTFGQGTKVEIK
Mouse CD37 VH (CDRs highlighted)	241	AVQLQQSGPESEKPGASVKISCKASGYSTGYNMNWVKQ NNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTA YMLKSLTSEDSAVYYCARSVGPMDYWGQGTSTVTVSS
Humanized CD37 VH (CDRs highlighted)a	242	EVQLVQSGAEVKKPGESLKISCKGSGYSTGYNMNWVRQ MPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTA YLQWSSLKASDTAMYYCARSVGPMDYWGQGTSLTVTVSS
Humanized CD37 VH (CDRs highlighted)a	243	EVQLVQSGAEVKKPGESLKISCKGSGYSTGYNMNWVRQ MPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTA YLQWSSLKASDTAMYYCARSVGPMDYWGQGTSLTVTVSS
Humanized CD37 VH (CDRs highlighted)b	244	EVQLVQSGAEVKKPGESLKISCKGSGYSTGYNMNWVRQ MPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTA YLQWSSLKASDTAMYYCARSVGPFDYWGQGTSLTVTVSS
Humanized CD37 VH (CDRs highlighted)c	245	EVQLVQSGAEVKKPGESLKISCKGSGYSTGYNMNWVRQ MPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTA YLQWSSLKASDTAMYYCARSVGPFDYWGQGTSLTVTVSS
IgG1 CH2CH3	246	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTKAKAGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFV MHEALHNHYTQKSLSLSPGK
CAS-006 (chimeric anti-CD37 SMIP)	247	DIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQKQ GKSPQLLVSAFATLAEGVPSRFSGSGSGTQFSLKISSLQPE DSGSYFCQHSDNPWTFGGGTELEIKGGGGSGGGSGGG GSSAVQLQQSGPESEKPGASVKISCKASGYSTGYNMNWV KQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSS TAYMLKSLTSEDSAVYYCARSVGPMDYWGQGTSTVTVS SDLEPKSSDKTHTSPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLT VDKSRWQQGNVFCFVSMHEALHNHYTQKSLSLSPGK

Construct No.	SEQ ID NO.	Amino Acid Sequence
CAS-001	248	EIVLTQSPATLSLSPGERATLSCRTSENVYSYLAWYQQKPG QAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTSSLEPEDF AVYYCQHHSNDNPWTFGQGTKVEIKGGGGSGGGSGGGG TGEVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWV RQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSI STAYLQWSSLKASDTAMYYCARSVGPMDYWGRGTLVTV SSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
CAS-002	249	EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPG QAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTSSLEPEDF AVYYCQHHSNDNPWTFGQGTKVEIKGGGGSGGGSGGGG TGEVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWV RQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSI STAYLQWSSLKASDTAMYYCARSVGPFDYWQGTTLVTV SSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
CAS-003	250	EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPG QAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTSSLEPEDF AVYYCQHHSNDNPWTFGQGTKVEIKGGGGSGGGSGGGG TGEVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWV RQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSI STAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTTLVTV SSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKL TVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

Construct No.	SEQ ID NO.	Amino Acid Sequence
CAS-014 (mouse-human hybrid)	251	AVQLQQSGPESEKPGASVKISCKASGYSTFTGYNMNWVKQ NNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTA YMLKSLTSEDSAVYYCARSVGPMGYWGQGTSTVTVSSG GGGSGGGSGGGSGGGSGGGGSAEIVLTQSPATLSLSPGERAT LSCRTSENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPA RFGSGSGGTDFTLTISSELPEDFAVYYCQHHSNPNWTFGQ GTKVEIKGSSEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKP KDTLMISRTPVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFF LYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLS PGK
CAS-017 (human-mouse hybrid)	252	EIVLTQSPATLSLSPGERATLSCRTSENVYSYLAWYQQKPG QAPRLLIYFAKTLAEGIPARFGSGSGGTDFTLTISSELPEDF AVYYCQHHSNPNWTFGQGTKVEIKGGGSGGGSGGGG ASAVQLQQSGPESEKPGASVKISCKASGYSTFTGYNMNWV KQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSS TAYMLKSLTSEDSAVYYCARSVGPMGYWGQGTSTVTVS SSEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKDTLMISR TPVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTV DKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
CAS-024	253	EVQLVQSGAEVKKKPGESLKISCKGSGYSTFTGYNMNWVRQ MPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTA YLQWSSLKASDTAMYYCARSVGPFDSWGQGTSTVTVSSG GGGSGGGSGGGSGGGSGGGGSEIVLTQSPATLSLSPG ERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAE GIPARFGSGSGGTDFTLTISSELPEDFAVYYCQHHSNPNWT FGQGTKVEIKGDQEPKSSDKTHTSPPCPAPELLGGPSVFLF PPKPKDTLMISRTPVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSD GSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKS LSLSPGK

EXAMPLE 2

EXPRESSION OF CAS-024 AND OTHER CD37-SPECIFIC BINDING PROTEINS

5 CAS-024 and other CD37-specific binding SMIP molecules were cloned into a Chinese Hamster Ovary (CHO) mammalian cell expression system. Transfected CHO cells that produced the SMIP molecules were cultured in shake flasks and harvested cell culture supernatants were titrated using Octec Q Protein A sensor.

10 Table 5 shows that the CAS-024 construct (VHVL format with 25 amino acid variable domain linker) had an unexpectedly superior expression level, up to about 10-fold better, than the other humanized anti-CD37 SMIP molecules (mostly VLVH format with 15 amino acid variable domain linker). Indeed, all fully humanized VLVH constructs expressed poorly (data not shown),
15 as did mouse-human hybrid molecules in either orientation (see Example 5).

Table 5.
SMIP Expression

SMIP Protein	Clones Screened	Protein Titer Range (µg/ml)
CAS-001	492	65 – 80
CAS-002	425	200 – 280
CAS-003	611	300 – 360
CAS-024	203	500 – 650

EXAMPLE 3

20 PURIFICATION AND SIZE EXCLUSION CHROMATOGRAPHY OF CAS-024 AND OTHER CD37-SPECIFIC BINDING PROTEINS

To produce more protein, nucleic acid encoding CAS-024 and several other CD37-specific binding SMIP molecules were cloned into a Chinese
25 Hamster Ovary (CHO) mammalian cell expression system. Transfected CHO cells that produced the SMIP molecules were cultured in shake flasks.

All of the CD37-specific binding SMIP molecules were purified from CHO culture supernatants by Protein A affinity chromatography. A 50 mL rProtein A FF sepharose column (GE Healthcare) was equilibrated at 5.0 mls/min (150 cm/hr) for 1.5 column volumes (CV) with dPBS. The culture supernatant
5 was loaded onto the rProtein A Sepharose FF column at a flow rate of 1.7mls/min using the AKTA Explorer 100 Air (GE healthcare), capturing the recombinant SMIP molecules. The column was washed with dPBS for 5 Column Volumes (CV), then 1.0 M NaCl, 20mM Sodium Phosphate, pH 6.0, and then with 25 mM NaCl, 25mM NaOAc, pH 5.0. The recombinant CD37-specific binding molecules
10 were eluted from the column with 100mM glycine, pH 3.5. Fractions (10mL) of the eluted product were recovered and then brought to pH 5.0 with 20% of the eluted volume of 0.5 M 2-(N-morpholino)ethanesulfonic acid (MES), pH6.0. This eluted product was concentrated to approximately 25 mg/mL protein and filter sterilized.

15 This concentrated and sterilized protein was further purified by GPC size exclusion chromatography (SEC) to achieve separate SMIP (dimer) molecule from higher molecular weight aggregates. An XK 50/100 column (GE healthcare) containing 1 L of Superdex 200 FF sepharose was equilibrated at 12.6 ml/min (38cm/hr) for 1.5 column volumes (CV) with dPBS. A maximum
20 volume of 54 mls (3% CV) of sample was applied to the column. The column continued to run at 12.6 ml/min and the eluted protein was fractionated in 40 mL fractions. Each fraction was analyzed for product quality using an analytic HPLC, and the eluted fractions were pooled to greater than about 95% protein of interest (non-aggregated). The resultant pool was filter sterilized at 0.22 μ m,
25 concentrated, and then formulated with 20 mM sodium phosphate, 240 mM sucrose, pH 6.0.

The SEC traces showing the peaks containing the protein of interest (POI) for CAS-001 (SEQ ID NO:6), CAS-002 (SEQ ID NO:48), CAS-003 (SEQ ID NO:52), and CAS-024 (SEQ ID NO:253) are shown in Figures 2A-2D,
30 respectively. The CAS-024 peak is narrower and more symmetric than the CAS-001, CAS-002, and CAS-003 samples (broader and asymmetric). The CAS-006 (chimeric) molecule produces a sharp peak similar to CAS-024. The CAS-001,

CAS-002, and CAS-003 samples all had a slight tailing shoulder, which if integrated, accounts for about 35% of the POI area. This 'shoulder' would be difficult to separate from the POI and probably represents either misfolded conformers or a heterogenous population of molecules (e.g., have different levels of glycosylation). This indicates that CAS-024 was not only expressed better, but this construct also produces a more homogenous population of molecules.

EXAMPLE 4

CELL BINDING BY CAS-024 IS UNEXPECTEDLY SUPERIOR TO OTHER CD37-SPECIFIC BINDING PROTEINS

A competition assay was used to compare the binding affinity of different anti-CD37 specific small modular immunopharmaceutical (SMIP) molecules to CD-37 found on Ramos cells (a B-lymphoblastoid cell line derived from a Burkitt lymphoma). An SEC purified chimeric anti-CD37 SMIP molecule (CAS-006, SEQ ID NO:247) was labeled with the FMAT Blue® fluorescence dye (Applied Biosystems) and used as the standard to compete with purified unlabeled chimeric anti-CD37 SMIP molecule (positive control) and purified unlabeled humanized anti-CD37 SMIP test molecules. Higher affinity showed up as a weaker fluorescence signal and an FL1 fluorescence value was used to generate the competition curve. Briefly, the reagent FMAT Blue® labeled chimeric anti-CD37 SMIP molecule was diluted to 2µg/ml in FACS blocking buffer and the purified protein samples (CAS-001 (SEQ ID NO:6), CAS-002 (SEQ ID NO:48), CAS-003 (SEQ ID NO:52), and CAS-024 (SEQ ID NO:253)) were serially diluted 1:2 to concentrations ranging from 50 µg/ml to 0.02 µg/ml. Ramos cells were harvested at 1,000 rpm for 5 minutes and resuspend in FACS blocking buffer at 4×10^6 cells/10 ml buffer. To each well of a black 96-well plate the following was added: 50 µl sample, 50 µl FMAT Blue® labeled chimeric anti-CD37 SMIP molecule, and 50 µl Ramos cells (4×10^4 /well). The plates were incubated at room temperature for 30 min and read on an 8200 Cellular Detection System (Applied Biosystems) gated for middle cell size and low signal.

This FMAT competition assay showed that CAS-024 (humanized anti-CD37 SMIP molecule having a VHVL scFv with a 25 amino acid variable domain linker) has the same affinity for CD37 as the parent chimeric anti-CD37 SMIP molecule and, in contrast, has an unexpectedly up to a 4-fold greater
5 affinity for CD37 than the humanized anti-CD37 SMIP molecules having the reverse VLVH structure and a shorter 16 amino acid variable domain linker (see Figure 3). The best binding, although still significantly less than CAS-006 or CAS-024, was found in a VLVH construct that does not have any CDR mutations (CAS-001). However, CAS-001 was consistently the worst expressing construct
10 and produced a non-homogenous population of purified molecules – even for this construct, CAS-024 bound from 1.5- to 2-fold better than CAS-001.

This result was also surprising because M99 and Y102 in the heavy chain CDR3 of CAS-024 are mutated – the Y102 position is generally conserved and it would be expected that a change at this position alone would diminish or
15 even abolish binding (e.g., CAS-062, mutated at position Y102, has detectable but severely decreased binding compared to CAS-001 or CAS-024, while CAS-063 to CAS-067 each have barely detectable to no binding activity in this assay when a mutation at position M99 or D101 is added, data not shown). Thus, the structure of CAS-024 provided a molecule that surprisingly bound as well as the
20 chimeric molecule, CAS-006.

EXAMPLE 5

EXPRESSION AND CELL BINDING OF CAS-024 COMPARED TO MOUSE-HUMAN HYBRID CD37-SPECIFIC BINDING PROTEINS

25

CAS-024 and other CD37-specific binding SMIP molecules were produced by recombinant DNA technology and transfected into HEK293 cells for 7 days. Cell culture supernatants were harvested on day 7 and titered using Octec Q Protein A sensor.

30

Similar to the results found in Example 2, here Table 6 shows that CAS-024 (VHVL format with 25 amino acid variable domain linker) expressed from about 5-fold to about 27-fold better than the other humanized or mouse-

human hybrid anti-CD37 SMIP molecules. The mouse-human hybrid molecules did not express well regardless of the VHVL or VLVH orientation.

Table 6.
SMIP Expression

SMIP Protein	Protein Titer (µg/ml)
CAS-002 (hVLhVH)	0.47
CAS-003 (hVLhVH)	2.39
CAS-014 (mVHhVL)	2.16
CAS-017 (hVLmVH)	0.70
CAS-006 (mVLmVH)	9.3
CAS-024 (hVHhVL)	12.7

5

A competition assay as described in Example 4 was used to compare the binding affinity of different mouse-human hybrid anti-CD37 SMIP molecules compared to CAS-024 binding to Ramos cells. An SEC purified chimeric anti-CD37 SMIP molecule (CAS-006, SEQ ID NO:247) was labeled with the FMAT Blue® fluorescence dye (Applied Biosystems) and used as the standard to compete with purified unlabeled chimeric anti-CD37 SMIP molecule (CAS-006, positive control) and purified unlabeled humanized anti-CD37 SMIP test molecules – CAS-002 (SEQ ID NO:48), CAS-003 (SEQ ID NO:52), CAS-014 (SEQ ID NO:251), CAS-017 (SEQ ID NO:252), and CAS-024 (SEQ ID NO:253).

15

This FMAT competition assay again showed that CAS-024 (VHVL humanized molecule with a 25 amino acid linker) has the same affinity for CD37 as the parent chimeric anti-CD37 SMIP molecule (CAS-006), whereas CAS-002 and CAS-003 (VLVH humanized molecules with a 16 amino acid linker) did not bind as well (showing a 2- to 3-fold reduction) (see Figure 4A). The mouse-

20

human hybrid molecules, regardless of variable domain orientation (mouseVH-humanizedVL with a 22 amino acid linker or humanizedVL-mouseVH with a 16 amino acid linker), bound as well as or even better than (1.5- to 2-fold) CAS-006 and CAS-024 (see Figure 4B). These data show that a mouse-human hybrid molecule without mutations binds as well as or better than CAS-006,

25

regardless of orientation, and that a fully humanized VLVH construct with no CDR

mutations binds better than other humanized molecules but still has diminished binding compared to CAS-006 or CAS-024. Together, these data suggest that no mutations in CDRs for this molecule would be better binders. Also, the particular order (VLVH or VHVL) did not seem to solve the expression problem, even when
5 a longer variable domain linker is used (see CAS-014). Thus, it was unpredictable to select a molecule with the CAS-024 structure and properties similar to the parent molecule CAS-006.

EXAMPLE 6

10 CAS-006 AND VARIOUS CD37-SPECIFIC ANTIBODIES BIND SAME OR AN OVERLAPPING EPI TOPE ON CD37

Experiments were performed to identify the CD37 epitope bound by CAS-006 and other previously described CD37-specific antibodies.

15 Unconjugated MB371 (#555457) and FITC-conjugated MB371 (#555456) were obtained from BD Pharmingen (San Jose, CA), FITC-conjugated BL14 (#0457) from Immunotech/Beckman Coulter (Fullerton, CA), FITC-conjugated NMN46 (#RDI-CBL 136FT) and unconjugated NMN46 (#RDI-CBL 136) from RDI (Flanders, NJ), FITC-conjugated IPO24 (#186-040) and unconjugated IPO-24
20 (#186-020) from Ancell Corporation (Bayport, MN), FITC-conjugated HHI (#3081) and unconjugated HH1 (#3080) from DiaTec.Com (Oslo, Norway) and FITC-conjugated WR17 (YSRTMCA483F) and unconjugated WR17 (YSRTMCA483S) from Accurate Chemical & Scientific (Westbury, NY). CAS-006 SMIP protein was produced as described in Example 2.

25 CAS-006 was conjugated to FITC using a Molecular Probes Fluororeporter FITC Labeling Kit (F6434) according to manufacturer's instructions as follows: CAS-006 protein peak of interest (POI) at 13.5 mg/mL was adjusted to 5 mg/mL with PBS. One mg (200 ul) was added to kit tubes with a stirbar, and 1M NaHCO₃ (adjusted to pH 8.5 with 6N NaOH), was added to a final
30 concentration of 0.1M. 50 ul DMSO was added to 370 ug of FITC and was added to the tubes at molar ratios of 15, 20, 30 and 40 FITC: protein using the following formula to determine the ul of FITC to add: [ul of FITC solution to add =

5 mg/mL protein x 0.2 mL x 389 x 100 x desired molar ratio/Molecular weight of CAS-006 (110,000)].

Reactions were shielded from light and stirred continuously for 75 minutes at room temperature. Reactions were added to spin columns prepared as described in the kit and spun at 1100 g for 5 minutes to buffer exchange into PBS with azide and remove unconjugated FITC. The OD at 280 nM and 494 nM was determined with 2 ul drops on the Nanodrop; the extinction coefficient for CAS-016 was experimentally determined for this instrument by reading dilutions of the starting unconjugated SMIP molecule, the concentration of each of the conjugates was 4.25 mg/ml and the following FITC:protein ratios were determined: 2.7 FITC/CAS-016 at a ratio of 15; 3.7 FITC/CAS-016 at a ratio of 20; 4.4 FITC/CAS-016 at a ratio of 30; and 5.1 FITC/CAS-016 at a ratio of 40.

BSA was added to 3 mg/mL to help stabilize the protein. Binding of each fraction was assessed at dilutions ranging from 100-24,300x on Ramos and 3200-25,600 on human PBMC. All bound, but the MR30 ratio was chosen for further use since it gave a high MFI that was well maintained over the titration range used, indicating that binding avidity was least affected in this reaction.

FITC labeled antibody conjugates were titrated from 10 ng/mL to 10 µg/mL in an initial binding study to determine the optimal amount to use in the blocking studies. The level chosen was just below saturating amounts, and was kept constant in the subsequent assays, while levels of blocking antibody were increased over a 10-fold range. Data were plotted as percent of maximal binding versus concentration of blocking antibody, so that higher levels indicate less efficient blocking, while lower levels indicate more efficient blocking activity. All of the antibodies tested showed blocking activity of the maximal binding observed without unlabeled reagents (Figure 5).

BJAB-cells, a lymphoblastoid B-cell line were then stained with a panel of various clones of anti-CD37 mAbs, including MB371, BL14, NMN46, IPO24, HH1, WR17, and chimeric CAS-006 SMIP.

For competitive binding assays, 2.5×10^5 BJAB cells were incubated in 96-well V-bottom plates in staining media (PBS with 2% mouse sera) with the FITC-conjugated anti-CD37 mAbs at 1.25 µg/mL in the presence of

unconjugated anti-CD37 MAb at the indicated concentrations (2.5, 1.25, 0.6, or 0.3 µg/ml) or staining media for 45 minutes on ice in the dark. Blocking antibodies and FITC labeled antibody conjugates were added to reactions prior to addition of cells. The cells were then washed 2.5 times with PBS and fixed with
5 1% paraformaldehyde (USB, Cleveland, Ohio). The treated cells were analyzed by flow cytometry using a FACsCalibur instrument and CellQuest software (BD Biosciences, San Jose, CA).

For FACs cross blocking assays, 2.5×10^5 BJAB cells were incubated in 96-well V-bottom plates in staining media (PBS with 2% mouse
10 sera) in the presence of unconjugated anti-CD37 MAb at 5 µg/mL staining media for 45 minutes at room temperature in the dark. FITC-conjugated anti-CD37 mAbs were added to a final concentration of 2 µg/ml, resulting in a dilution of the unlabelled reagents to 3.3 µg/ml. The reactions were further incubated for 45 minutes at room temperature in the dark, then washed 2.5 times with PBS, and
15 finally fixed in 1% paraformaldehyde in PBS (USB, Cleveland, Ohio). Cells were analyzed by flow cytometry on a FACsCalibur instrument using Cell Quest software (BD Biosciences, San Jose, CA).

For cell binding assays, cells were suspended in PBS (Gibco/Invitrogen, Grand Island NY) containing 2% FBS (Gibco/Invitrogen),
20 (staining media) at a concentration of approximately 4×10^6 cells/mL. Cells were then plated and test samples, diluted in staining media, were then added 1:1 to the final designated concentrations. Reactions were incubated for 45 minutes on ice. Samples were centrifuged and washed 2 times with PBS. FITC goat anti-human IgG (CalTag, Burlingame CA) was added at a final dilution of 1:50, and
25 incubated 45 minutes on ice. Samples were centrifuged, washed in PBS, then fixed in 200 µl 1% paraformaldehyde in PBS (USB, Cleveland, Ohio). Cells were analyzed by flow cytometry on a FACsCalibur instrument using Cell Quest software (BD Biosciences, San Jose, CA).

Each antibody showed dose dependent inhibition of binding,
30 indicating that all the molecules tested bind to an identical or closely related epitope. A different potency for inhibition of binding was observed for each antibody. CAS-006 SMIP had the highest level of blocking activity of all

molecules tested, while HH1 gave an intermediate level of blocking activity, and WR17, IPO24 blocked better than MB371, but showed less effective blocking than the other two unlabeled molecules (Figure 5).

In addition to analysis of blocking activity, a similar series of experiments was performed in which various CD37 targeted antibodies were tested for their ability to compete with one another for binding to the CD37 receptor. The results from these experiments, like results obtained in the blocking studies for all the molecules tested, indicated that the various CD37 targeted antibodies and CAS-006 have the same or closely overlapping epitopes.

EXAMPLE 7

DOSE RESPONSE OF CAS-024 IN AN ESTABLISHED SUBCUTANEOUS HUMAN TUMOR (DOHH2) XENOGRAFT MODEL IN SCID MICE

The objective of this experiment was to examine the dose response to treatment with CAS-024 in a model of established subcutaneous human tumor (DOHH2) xenograft model in SCID mice. DOHH2 is a CD20⁺CD37⁺ human B-lymphoblastoid cell line derived from a patient with follicular lymphoma (Kluin-Nelemans *et al.*, Leukemia 5:221, 1991). Thus, DOHH2 was derived from a patient with a non-Burkitt's NHL.

Five million DOHH2 cells were injected subcutaneously into the flank of female CB-17SCID mice (Harlan, Somerville, NJ) at 6.5 weeks of age and at a mean weight of 18.0 ± 0.1 g (ranging from 14.6 to 22.6 g). On day 8 post-tumor inoculation, palpable tumors were apparent in a majority of mice. The tumor-bearing mice were sorted into four groups with equivalent mean tumor volumes (n=14 per group; 2 cages of 5 mice and 1 cage of 4 mice for each group). The day of the sort was defined as day 0. Tumor diameters were determined with a pair of calipers and tumor volumes were calculated using the formula: $V = \frac{1}{2} [\text{length} \times (\text{width})^2]$. The baseline mean tumor volume was 228 mm³, the median baseline tumor size was 224 mm³, and the range was 179 to 284 mm³.

Table 7.
Reagents for In Vivo Use

Reagent	% POI	Concentration and Endotoxin	Preparation for Injection
PBS	NA	1X Endotoxin <0.03 EU/mg	NA
Human IgG (huIgG)	Not tested	10 mg/mL Endotoxin = 10 EU/mg	Diluted to 1.0 mg/mL PBS
CAS-024	100	9.6 mg/mL Endotoxin = 0.01 EU/mg	Diluted to 1.0 mg/mL PBS for 200 µg dose; then diluted 1:2 to prepare 100 µg dose, then serially diluted 1:3 to prepare the other dose solutions.

Tumor-bearing groups of SCID mice were treated on days 0, 4, and 8 via IP injection of 0.2 mL of PBS containing 200 µg of huIgG (negative control) or 200, 100, 30, 10, or 3 µg of CAS-024. The two lowest dose solutions of CAS-024 were prepared on the day of injection to avoid the need to add a carrier protein to the most dilute solutions. Drug solutions were color-coded as described below (see Table 8 below).

Table 8.
Experimental Design

Group ID	No. Mice, Route of Injection, and Treatment Days	Dose per injection (µg)	mg/kg per Injection ^a	Cumulative Dose (µg)	Cumulative Dose (~mg/kg) ^a
huIgG	14 per group IP injection Days 0, 4, 8	200	11.1	600	33
CAS-024 200		200	11.1	600	33
CAS-024 100		100	5.6	300	16.7
CAS-024 30		30	1.7	90	5.0
CAS-024 10		10	0.6	30	1.7
CAS-024 3		3	0.2	9	0.5

^aNote that huIgG and CAS-024 were delivered in µg per mouse, not in mg/kg. The approximate mg/kg is noted for convenience, and is based on the mean weight (18.0 ± 0.1 g) of mice on day 0. The weight range in this experiment was 14.6 to 22.6 g.

Dose solutions were prepared in similar volumes and the contents of the tubes were noted on removable labels. An investigator who was not treating or assessing the mice placed a color code on each tube and noted the code and identity of the tube contents in a laboratory notebook. Mice were monitored daily by visual inspection. Weights were determined weekly, and tumor diameters were determined at least 3 times per week (M, W, F) by an observer blinded (see above) to the treatment groups. Tumor volumes were calculated as described above. Mice were euthanized if their tumor volume reached more than 1500 mm³ (or 1200 mm³ on Fridays). Death was not an endpoint in the tumor protocols and, unless noted otherwise, "survival" of a mouse was determined by the time it was euthanized due to its tumor volume reaching the predetermined limits. (The protocol called for mice to be euthanized if (1) their tumor volume exceeded the parameters noted above, (2) ulceration of a tumor occurred, (3) the tumor inhibited the mobility of the mouse, and (4) weight loss exceeded 20% of body weight.)

One mouse in the CAS-024 100 µg treatment group was euthanized on day 35 due to weight loss >20%. This mouse had a tumor volume of 266 mm³ at that time, and was treated as censored data for the survival analysis (not euthanized as of day 35 due to tumor growth). For the calculation of tumor-free incidence at the end of the study, this mouse was classified as one that was euthanized during the study due to growth of its tumor (its tumor was growing back at the time of its death). No other mice were found dead and none were euthanized due to weight loss, tumor ulceration, or impaired mobility. No overt signs of toxicity or weight loss were observed in any of the treatment groups (data not shown).

All statistical analyses were performed using GraphPad Prism software. Significant differences in mean tumor volumes and mean relative tumor volumes were determined using a one-way ANOVA for nonparametric data (Kruskal-Wallis test) with Dunn's multiple comparison post test. To examine differences between each of the CAS-024 treated groups and the hulG group, all groups were compared. For comparisons between the CAS-024 groups only, the hulG group was excluded. In addition, the high and middle dose (200, 100,

and 30 µg) groups were analyzed as a one data set, and the middle and low dose (30, 10, and 3 µg) groups were analyzed as another data set. Significant differences in survival of mice over time were determined using Kaplan-Meier survival analysis with a log-rank test for comparing survival curves. Significant differences in the incidence of tumor-free mice were determined using Fisher's exact test. p values <0.05 were considered significant.

CAS-024 had a dose-dependent inhibitory effect on the growth of DOHH2 tumors. With the exception of the low (3 µg) dose regimen group, the mean tumor volume of each CAS-024 treated group was significantly lower than that of the human IgG treated group as early as day 5, and remained lower through day 12. The hulG treated mice were euthanized starting on day 12; therefore, comparisons of tumor volumes of the CAS-024 treated groups to the hulG group were not performed for later time points. In terms of a dose response, there was no significant difference in the mean tumor volumes of the two highest dose groups at any point in the study. In contrast, the mean tumor volumes of these two groups differed significantly from those of each of the three lower dose groups from days 12 through 16 (day 16 was the last evaluable timepoint for the low dose group). Similarly, the mean tumor volumes in mice of the 30 µg and 10 µg dose groups differed from each other and from the low dose group over this same period.

The tumors in the mice treated with hulG grew rapidly, and all of the mice in this group were euthanized by day 19. As summarized in Tables 9 and 10 below, the survival of mice treated with any of the CAS-024 dose regimens was prolonged relative to the hulG treated group ($p < 0.0001$ in all cases). In terms of a dose response, there was no significant difference in the survival curves of mice treated with the highest (200 and 100 µg) dose regimens ($p = 0.7091$). With the exception of this group comparison, there was a significant difference between the survival curve of each dose group and the survival curve of each of the groups treated with a lower dose regimen (p values ranged from 0.0132 to < 0.0001).

Table 9.
Median Survival Time and Incidence of Tumor-Free Mice

Treatment Group ^a	Cumulative Dose	Median Survival Time (Days) ^b	Death (Not Due to Large Tumor Volume)	Tumor-Free Incidence at End of Study ^c	p Value for Fischer's Exact Test (comparison of tumor-free incidence) ^d
HuIgG 200	600 µg	14	0/14	0/14 (0%)	NA
CAS-024 200	600 µg	Undefined ^{ef}	0/14	11/14 (79%)^g	<0.0001
CAS-024 100	300 µg	Undefined	1/14 ^h	11/14 (79%)	<0.0001
CAS-024 30	90 µg	35	0/14	5/14 (36%)	0.0407
CAS-024 10	30 µg	28	0/14	0/14 (0%)	NA
CAS-024 3	9 µg	19	0/14	0/14 (0%)	NA

^a Mice were treated with the indicated protein via IP injection on days 0, 4, and 8. The numbers indicate the amount of protein (µg) injected per day.

5 ^b "Survival" of a mouse was determined by the day it was euthanized due to tumor growth. One mouse in the CAS-024 100 µg dose group was euthanized on day 35 due to >20% weight loss. The mouse had a tumor volume of 266 mm³ at that time, and was treated as censored data (tumor volume did not reach predetermined limit by day 35) for the Kaplan Meier analysis. No other mice were euthanized for reasons other than its tumor volume reaching the predetermined limit.

10 ^c "Tumor-free" mice had no palpable SC tumors. The absence of tumor cells was not confirmed by histology. The study ended on day 61.

^d Each group was compared with the HuIgG treated control group.

15 ^e The median survival time is undefined when >50% of the mice are alive at the end of the observation period.

^f Values in bold face indicate that the survival curves of the indicated group are significantly different from those of HuIgG control (p<0.0001 in each case, log rank test).

^g Values in bold face are significantly different from the huIgG treated control group.

20 ^h One mouse was euthanized on day 35 due to >20% weight loss. The mouse had a tumor volume of 266 mm³ at that time and was treated as censored data for the Kaplan Meier analysis.

Table 10.
p-Values for Comparison of Survival Curves and Tumor-Free Incidence
Between CAS-024 Treated Groups

Group Comparison ^a	p Values for Indicated Comparisons	
	Log rank test (comparison of survival curves)	Fisher's exact test (comparison of tumor- free incidence)
200 vs 100	0.7091	1.0000
200 vs 30	0.0132^b	0.0542
200 vs 10	<0.0001	<0.0001
200 vs 3	<0.0001	<0.0001
100 vs 30	0.0035	0.0542
100 vs 10	<0.0001	<0.0001
100 vs 3	<0.0001	<0.0001
30 vs 10	0.0002	0.0407
30 vs 3	<0.0001	0.0407
10 vs 3	<0.0001	NA

^aSee legend to Table 7 for information on the groups.

^bp values <0.05 are in bold face for emphasis.

5 All of the mice in the hulgG treated group and in the two lowest (10 and 3 µg) CAS-024 dose groups were euthanized due to growth of their tumors. In contrast, the majority of tumors in the groups of mice treated with 200 or 100
10 µg of CAS-024 regressed to the point that no palpable tumor was present. By the end of the study, 11/14 (79%) of the mice in each of the two highest dose groups and 5/14 (36%) of the mice in the 30 µg dose group remained tumor-free (p<0.0001 and 0.0407, respectively, vs. hulgG group).

Thus, CAS-024 exhibited dose-dependent inhibitory effects on the
15 growth of established subcutaneous human tumor (DOHH2) xenografts in SCID mice. The two highest dose regimens (100 or 200 µg per IP injection; cumulative dose of 300 or 600 µg, which corresponds to about 16.7 or 33 mg/kg, respectively) had similar inhibitory effects and were the most efficacious of the regimens tested in terms of inhibiting tumor growth, prolonging survival, and
20 inducing complete tumor regression.

EXAMPLE 8

EFFICACY OF CAS-024 AND RITUXAN® AS SINGLE AGENTS IN AN ESTABLISHED HUMAN TUMOR (DOHH2) XENOGRAFT MODEL IN SCID MICE

5 The objective of this study was to examine the efficacy of CAS-024 and Rituxan as single agents in a model of established human tumor (DOHH2) xenografts in SCID mice. As set out above, DOHH2 is a CD20⁺CD37⁺ human B-lymphoblastoid cell line derived from a patient with follicular lymphoma.

10 Five million DOHH2 cells were injected subcutaneously into the flank of female CB-17SCID mice (Harlan, Somerville, NJ) at 6.5 weeks of age. On day 8 post-tumor inoculation, palpable tumors were apparent in a majority of the mice. The tumor-bearing mice were sorted into four groups (n=15 per group; 3 cages of 5 mice for each group) with equivalent mean tumor volumes. The day of the sort was defined as day 0 of the study. Tumor diameters were determined
15 with a pair of calipers and tumor volumes were calculated using the formula: $V = \frac{1}{2} [\text{length} \times (\text{width})^2]_3$. The baseline mean tumor volume was 228 mm³; the median baseline tumor size was 227 mm; and the range was 181 to 272 mm³. Mice (15 per treatment group) were treated on days 0, 4, and 8 via IP injection of 0.2 mL of PBS containing 200 µg human IgG, CAS-024, or Rituxan® (for a total of 600 µg
20 after the three treatments). For the hulgG, CAS-024, and Rituxan® IP treated groups, solutions were prepared in similar volumes and the contents of the tubes were noted on removable labels. An investigator who was not treating or assessing the mice placed a color code on each tube and noted the code and identity of the tube contents in a laboratory notebook.

25 Mice were monitored daily by visual inspection. Weights were determined weekly, and tumor diameters were determined at least 3 times per week (M, W, F) by an observer blinded (see above) to the treatment groups. Tumor volumes were calculated as described above. Tumor volumes on the last day that all mice were alive in each group were also expressed in terms of tumor
30 volumes relative to day 0, using the formula:

$$\text{Relative tumor volume on day of interest} = \frac{(\text{volume on day of interest} - \text{volume on day 0})}{\text{volume on day 0}}$$

volume on day 0

Mice were euthanized if their tumor volume reached more than 1500 mm³ (or 1200 mm³ on Fridays). Death is not an endpoint in our tumor protocols, and unless noted otherwise, "survival" of a mouse was determined by the time it was euthanized due to its tumor volume reaching the predetermined limits. (Our protocol calls for mice to be euthanized if their tumor volume exceeds the parameters noted above, ulceration of a tumor occurs, the tumor inhibits the mobility of the mouse, or if weight loss exceeds 20%.)

All statistical analyses were performed using GraphPad Prism software. Significant differences in mean tumor volumes and mean relative tumor volumes were determined using a one-way ANOVA for nonparametric data (Kruskal-Wallis test) with Dunn's multiple comparison post test. Significant differences in survival of mice over time were determined using Kaplan-Meier survival analysis with a log-rank test for comparing survival curves. Significant differences in the incidence of tumor-free mice were determined using Fisher's exact test (p values <0.05 were considered significant).

Mice were euthanized when their tumor volume reached the limits described above. One mouse in the CAS-024 treatment group was euthanized on day 45 due to weight loss >20%. This mouse had no apparent SC tumor at that time, and was treated as censored data for the survival analysis (not euthanized as of day 45 due to tumor growth) and was not included in the comparison of tumor-free incidence at the end of the study. No other mice were found dead and none were euthanized due to weight loss, tumor ulceration, or impaired mobility. No overt signs of toxicity or weight loss were observed in any of the treatment groups (data not shown).

The CAS-024 and Rituxan treated mice exhibited a rapid response to treatment. Mean tumor volumes of the CAS-024- and Rituxan®-treated groups were significantly lower than that of the human IgG treated group as early as day 4 (after a single injection of drug) and remained lower through day 11. There were no significant differences in mean tumor volumes or mean relative tumor volumes between the CAS-024 and Rituxan® treated groups through day 11.

The hulgG treated mice were euthanized starting on day 11; therefore, comparisons of tumor volumes were not performed for later time points.

The tumors in the mice treated with hulgG grew rapidly and all mice in this group were euthanized by day 15. In contrast, by day 15, the majority of tumors in the CAS-024 and Rituxan treated groups had regressed to the point that no palpable tumor was present. Notably, the response to treatment was durable only in the CAS-024 treated group. By the end of the study, all of the Rituxan-treated mice were euthanized due to growth of their tumors, whereas 10/14 (71%) of the mice in the CAS-024 treated group remained tumor-free. See Table 9. Thus, at the end of the study, the survival curves and the incidence of tumor-free mice in the CAS-024 treated group differed significantly from the hulgG control group and the Rituxan® treated group. Figure 6 shows that CAS-024 was statistically superior to Rituxan in the *in vivo* treatment of this animal model of follicular lymphoma.

15

Table 11.

Median Survival Time and Incidence of Tumor-Free Mice

Treatment Group	Treatment Days and Cumulative Dose	Median Survival Time (Days) ^a	p Value from Log Rank Test ^b	Death (other than for Tumor Size Sacrifice)	Tumor-Free Mice at Day 81 ^c	Fischer's Exact Test (Comparison of tumor-free incidence) ^b
HuIgG	Days 0, 4, 8 600 µg	13	---	0/15	0/15 (0%)	NA
CAS-024 IP	Days 0, 4, 8 600 µg	Undefined^{d,e}	<0.0001	1/15 ^f	10/14 (71%)^f	<0.0001
Rituxan® IP	Days 0, 4, 8 600 µg	43	<0.0001	0/15	0/15 (0%)	NA

^a“Survival” was determined by the day a mouse was euthanized due to tumor growth. Other than one mouse in the CAS-024 dose group (*see* (f)), no mice were euthanized for reasons other than tumor volume reaching the predetermined limit.

20 ^bEach group was compared with the HuIgG treated control group.

^c“Tumor-free” mice had no palpable SC tumors; confirmation of tumor cells absence was not confirmed by histology.

^dThe median survival time is undefined when >50% of the mice are alive at the end of the observation period.

25 ^eBold-faced values are significantly different from those of HuIgG control.

^fOne mouse was euthanized on day 45 due to >20% weight loss. The mouse had no apparent SC tumor at that time and was excluded from the group for the comparison of tumor-free mice at day 81.

In conclusion, CAS-024 and Rituxan were efficacious as single agents in a human tumor (DOHH2) xenograft model in SCID mice. While both agents caused an initial tumor regression in the majority of mice, long-term tumor regression was observed only in the group of mice treated with CAS-024 as tumors relapsed after optimal anti-CD20 treatment. Consequently, CAS-024, a humanized anti-CD37 SMIP, shows significant efficacy in pre-clinical tumor xenograft models including models that show that Rituxan® treatment fails over time. These results therefore suggest that CAS-024 treatment of B cell lymphoma and leukemia patients is beneficial and is a viable alternative treatment in patients who fail Rituxan® treatment.

EXAMPLE 9

IN VITRO EVALUATION OF CAS-024 COMBINED WITH CHEMOTHERAPEUTIC AGENTS

It was previously demonstrated that CAS-006 acts synergistically in combination with the chemotherapeutic agent fludarabine to kill chronic lymphocytic leukemia (CLL) cells *in vitro* (see, e.g., US Patent Application Publication No. 2007/0059306). As CLL cells do not actively divide in cell culture *in vitro*, the data indicate that cell proliferation is not required for the pro-apoptotic effect of CAS-006 or CAS-024 for its synergy with chemotherapeutic agents. The purpose of this study, therefore, was to determine whether CAS-024 and various chemotherapeutic agents were effective on a mantle cell lymphoma (MCL) cell line, Rec-1, that actively grows and divides in cell culture *in vitro* and whether the combination of CAS-024 and a chemotherapeutic agent (drug) would desensitize or enhance the response of mantle cell lymphoma cells to various chemotherapeutic agents. The chemotherapeutic agents tested were doxorubicin, vincristine, and fludarabine, which are used to treat non-Hodgkin's lymphoma and other lymphoid malignancies.

Rec-1 cells, a CD37+ human B cell line established from a patient with mantle cell lymphoma, were tested for growth inhibition in response to crosslinked CAS-024 in the presence or absence of doxorubicin, vincristine, or fludarabine (see Figure 7). CAS-024 was preincubated with anti-human IgG

F(ab)₂ to crosslink the protein. Cells were cultured with medium alone or with medium containing various concentrations of the crosslinked CAS-024 protein, in the presence or absence of various concentrations of doxorubicin, vincristine, or fludarabine. Cultures were incubated for 96 hours and growth inhibition was
5 assessed using an ATP viable cell detection system (i.e., viable cells quantified by ATP release).

The Median Effect/ Combination Index (CI) method of Chou and Talalay (Adv. Enzyme Regul. 22:27, 1984) was used for data analysis. A numerical value, assigned to each drug combination at predefined dose levels,
10 enabled quantitative drug/drug interaction comparisons between different drug combinations. Results were expressed as combination indices (CI) vs. effect level, in which effect level represented percent inhibition of cell growth. The mean CI $\pm$ SEM for each effect level was averaged over three experiments. A CI < 1.0 was considered synergy, CI = 1.0 additivity, and CI > 1.0 antagonism.
15 Values presented are the mean $\pm$ SEM for each effect level, averaging three independent assays.

The combination of CAS-024 with vincristine or fludarabine was synergistic (CI < 1.0) and the combination of CAS-024 and doxorubicin was additive (CI not significantly different from 1.0). None of CAS-024 and
20 chemotherapeutic agent combinations were antagonistic (CI > 1.0) across all effect levels. Therefore, the combination of CAS-024 with each of the three chemotherapeutic agents tested did not desensitize target cells to drug-induced growth inhibition, but instead resulted in synergistic or additive inhibitory effects on target cell growth. A preferred embodiment would be the combination of CAS-
25 024 (SEQ ID NO:253) with vincristine or fludarabine. These data indicate that the efficacy of established chemotherapeutics increase when used in combination with CAS-024.

EXAMPLE 10
PRELIMINARY CLINICAL PHASE 1/2 RESULTS

As provided herein, pre-clinical studies have demonstrated that
5 CD37 SMIP molecules mediate significantly greater direct and natural killer (NK)-
cell mediated killing of chronic lymphocytic leukemia (CLL) cells as compared to
other therapeutic antibodies used in CLL. Hence, a Phase 1/2, open label, dose
escalation study has been initiated in patients with relapsed chronic lymphocytic
leukemia (CLL).

10 Patients with relapsed/refractory CLL or small lymphocytic
lymphoma (SLL) who had adequate organ function, platelets $> 30,000/\text{mm}^3$ were
eligible. Six doses and two different schedules (cohorts 1-10) have/or will be
studied. The planned doses range from 0.03 mg/kg to 10 mg/kg IV once a week
for 4 doses (cohort 1-6 and 9). The second schedule (cohort 7, 8, and 10) will
15 test 3.0, 6.0, or 10.0 mg/kg on days 1, 3 and 5 the first week followed by 3 weekly
doses. Dose escalation and de-escalation is based on Common Toxicity Criteria
Adverse Events (CTC AE) toxicity grades. Patients may receive 2 additional
cycles, if positive biologic effect after first cycle.

Results: To date, 22 patients have been enrolled (cohort 1-7 and 9)
20 and completed treatment (all have received prior fludarabine and rituximab
treatment). Six patients have entered a second cycle and two patients have
entered a third cycle. The patients being treated have gone through a number of
prior regimens (e.g., Cohort 4 patients had from 6 to 10 (median 6) and Cohort 5
had 5 to 13 (median 9.5) prior regimens). Eight of the ten have high risk genomic
25 features [del(17p13.1), n=5 and del(11q22.3), n=3]. No dose limiting toxicities or
serious adverse events have occurred. Mild (grade 1-2) infusion toxicity has
been observed in three patients. Beginning with the 0.3 mg/kg dose, all eight
patients demonstrated evidence of biological activity including patients with
del(17p13.1). Two patients had partial clearing of leukemia cutis, and the median
30 reduction in peripheral lymphocyte count has been 64% (see Figure 5). One
patient had a 99% reduction in peripheral lymphocyte count with no serious
adverse events and a continuing response after 3 months of treatment (see

Figure 6). One patient had an increase in hemoglobin of 40% and a reduction in lymph node size of 36% as determined by CT scan and continues to respond after 3 months of treatment (see Figure 7). Two patients had a significant increase in platelet count.

5 Conclusion: To date, this CD37 SMIP molecule is a well tolerated treatment with minimal infusional toxicity and no observed dose limiting toxicity. There also seems to be any complement involvement since patients with severe drops in lymphocyte counts are not showing signs of tumor lysis syndrome. Encouraging reduction in tumor lymphocyte blood counts, reduction in lymph
10 node/spleen size, clearing of leukemia cutis, and/or partial clearing of marrow disease, and/or improvement in normal hematopoietic function in patients with high risk genomic CLL have already been observed at low, non-saturating doses of CD37 SMIP molecule.

15

EXAMPLE 11

IN VITRO EFFICACY OF CAS024 COMBINED WITH BENDAMUSTINE

This study was to determine the effects of CAS024, bendamustine, and the combination of CAS024 and bendamustine on Rec-1 (a mantle cell
20 lymphoma cell line) and SU-DHL-6 (a diffuse large cell lymphoma line) cells.

The following human cell lines expressing CD37 were used: Rec-1 and SU-DHL-6 (both from DSMZ, Braunschweig, Germany). Bendamustine (TREANDA®) was purchased from the University of Washington Pharmacy (Seattle, WA) and was dissolved in PBS and stored at -20°C until use.

25 Rec-1 and SU-DHL-6 cells were plated at 1×10^4 cells/well in 100 μ L medium in 96 well black-sided, black-bottomed plates. Cells were treated with various concentrations of CAS024 that had been preincubated with anti-human IgG F(ab)'₂ and plates were incubated for 96 hr at 37°C, 5% CO₂ in the presence of serial dilutions of bendamustine. The final volume in each well was 150 μ L.
30 After incubation, plates were cooled to room temperature and labeled with 100 μ L/well of ATPlite detection reagent (Perkin Elmer, Boston, MA). The assay measures cellular ATP as a marker for viable cells. Samples were analyzed by

detection of luminescence using a Topcount NXT (Perkin Elmer, Waltham, MA) plate reader. Data were reduced using a 4-parameter curve fit in Prism (version 4.0, Graphpad Software, San Diego, CA) and the IC₅₀ defined as the concentration resulting in 50% inhibition compared to untreated cultures.

5 For synergy determination the Median Effect/ Combination Index (CI) method was used for data analysis (Chou and Talalay). A numerical value, assigned to each drug combination at predefined dose levels, enables quantitative drug/drug interaction comparisons between different drug combinations. The CI values assign interactions into three categories: synergism, 10 additivity, and antagonism (CI<1.0, =1, or >1.0 respectively). After labeling and data reduction, Combination Index (CI) values were determined using the Calcosyn software package (Biosoft, Cambridge, UK). The results of two separate experiments show that the combination of CAS024 with bendamustine resulted in synergistic inhibitory effects on target cell growth (see, Figure 11). 15 Similar results were obtained showing that the combination of CAS024 with bendamustine also synergistically inhibited SU-DHL-6 cell growth.

 Combination effects of CAS-024 with another alkylating agent, chlorambucil, were also determined using the method described above and the concentrations shown in Figure 12. Unlike bendamustine, chlorambucil in 20 combination with CAS-024 did not result in synergistic inhibitory effects on SU-DHL-6 cell growth (see, Figure 13)

EXAMPLE 12

EFFICACY OF CAS024 COMBINED WITH BENDAMUSTINE IN 25 HUMAN TUMOR XENOGRAFT MODEL

 This study was to compare the efficacy of CAS024 combined with bendamustine against each agent individually administered against subcutaneous DOHH2 human tumor xenografts in SCID mice.

30 *Establishment of tumor xenografts and sorting into treatment groups.* As described above, DOHH2 is a CD20⁺CD37⁺ human B-lymphoblastoid cell line derived from a patient with follicular lymphoma. Five million DOHH2 cells

were injected subcutaneously into the flank of female CB-17 SCID mice. On day 8 post-tumor inoculation, palpable tumors were apparent in majority of mice. The tumor-bearing mice were sorted into five groups with equivalent mean tumor volumes (n=15 per group; 3 cages of 5 mice for each group). The day of the sort was defined as day 0. Tumor diameters were determined with a pair of calipers and tumor volumes were calculated using the formula: $V = \frac{1}{2} [\text{length} \times (\text{width})^2]$. The baseline mean tumor volume was 231 mm³, the median baseline tumor size was 229 mm³, and the range was 201 to 261 mm³.

In vivo treatment. Groups of mice were treated with an injection of 0.2 mL of PBS containing 10 µg hulgG (days 0, 4, 8 IV), 10 µg CAS024 (days 0, 4, 8 IV), 10 mg/kg Bendamustine (0, 2, 4, 7, 9 IP), or 10 µg CAS024 (days 0, 4, 8 IV) AND 10 mg/kg Bendamustine (0, 2, 4, 7, 9 IP).

Monitoring and endpoints. Mice were monitored daily by visual inspection. Weights were determined weekly, and tumor diameters were determined at least 3 times per week (M, W, F) by an observer blinded (see above) to the treatment groups. Tumor volumes were calculated as described above.

Mice were euthanized if their tumor volume reached more than 1500 mm³ (or 1200 mm³ on Fridays). Death was not an endpoint in this study, and unless noted otherwise, "survival" of a mouse was determined by the time it was euthanized due to its tumor volume reaching the predetermined limits. Mice were euthanized if their tumor volume exceeded the parameters noted above, ulceration of a tumor occurs, the tumor inhibits the mobility of the mouse, or if weight loss exceeds 20%.

Statistical analyses. All statistical analyses were performed using GraphPad Prism software. Significant differences in mean tumor volumes and mean relative tumor volumes were determined using a one-way ANOVA for nonparametric data (Kruskal-Wallis test) with Dunn's multiple comparison post test. Significant differences in survival of mice over time were determined using Kaplan-Meier survival analysis with a log-rank test for comparing survival curves. Significant differences in the incidence of tumor-free mice were determined using Fisher's exact test. p values <0.05 were considered significant.

In the Bendamustine treated groups scruffy coats and diarrhea were seen starting around day 6. On day 10, one mouse in the CAS024 + Bendamustine treatment group was euthanized due to $\geq 20\%$ weight loss. This mouse was treated as censored data for the analysis of survival curves. No
5 clinical signs of toxicity were seen in the CAS024 alone treatment group.

All treatments, demonstrated an inhibitory effect on the growth of DOHH2 compared to hulgG. On day 13 (which was the last day all mice were alive) the mean tumor volume and mean relative tumor volume of all the treatment groups were statistically different than the hulgG control group of mice
10 (Figures 14A and 4B). A significant difference in mean tumor volumes and mean relative tumor volumes was also seen between Bendamustine and the CAS024 + Bendamustine combination treatment group. There were no significant differences in mean tumor volumes or mean relative tumor volumes between any two other treatment groups. Mean tumor volumes over time of the four groups
15 are shown in Figure 15.

The tumors in the mice treated with hulgG grew rapidly, and all of the mice in this group were euthanized by day 17. As shown in Figure 16 and summarized in Tables 12 and 13, the survival of mice dosed with any of the treatment groups was prolonged compared to the hulgG treated group ($p \leq$
20 0.0001 for all groups). There was also a significant difference between the survival curves of all three treatment groups and each other with the CAS024/bendamustine combination being superior to either single agent.

None of the hulgG-treated mice were alive (thus none were tumor-free) at the end of the study (day 34) (Figure 17 and Table 12). The incidence of
25 tumor-free mice in the other groups was 0/15 (0%) in the CAS024 and Bendamustine treatment groups and 2/14 (14%) in the CAS024 + Bendamustine combination treatment group. There was no significant difference in the incidence of tumor-free mice between any of the treatment groups.

Table 12. Median Survival Time and Incidence of Tumor-Free Mice at the end of the Observation Period

Treatment Group ^a	Treatment Days	Median Survival Time (Days) ^a	Tumor-Free Incidence at End of Study
hulgG	Days 0, 4, 8	15	0/15 (0%)
CAS024 10 µg	Days 0, 4, 8	17^b	0/15 (0%)
Bendamustine 10 mg/kg	Days 0, 2, 4, 7, 9	17	0/15 (0%)
CAS024 + Bendamustine	Days 0, 4, 8 0, 2, 4, 7, 9	24	2/14 (14%) ^d

^a "Survival" of a mouse was determined by the day it was euthanized due to tumor growth. One mouse in the CAS024 + Bendamustine combo group was euthanized on day 10 due to $\geq 20\%$ weight loss. This mouse was treated as censored data when calculating survival curves. No other mice were euthanized for reasons other than its tumor volume reaching the predetermined limit.

^b Values in bold face indicate that the survival curves of the indicated group are significantly different from those of hulgG control ($p < 0.0001$ for all treatment groups; log rank test).

^c "Tumor-free" mice have no palpable SC tumors. The absence of tumor cells was not confirmed by histology. Study ended on day 34.

^d In the CAS024 + Bendamustine combo group one mouse was euthanized on day 10 due to $\geq 20\%$ weight loss. No other mice were euthanized for toxicity reasons.

Table 13. p Values for Comparison of Survival Curves Between Treated Groups

p Values for Comparison of survival curves (log- rank test)				
	hulgG	TRU-016	Bendamustine	TRU-016 + Bendamustine
hulgG	NA	<0.0001	<0.0001	<0.0001
TRU-016	<0.0001^a	NA	0.0050	0.01
Bendamustine	<0.0001	0.0050	NA	<0.0001
TRU-016 + Bendamustine	<0.0001	0.01	<0.0001	NA

This study shows that CAS024 combined with Bendamustine exhibited inhibitory effects on the growth of DOHH2 tumors in SCID mice greater than that seen with either agent alone.

The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.

These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

SEQUENCE LISTING

<110> Tan, Phillip
 Simon, Sandy A.
 Cervený, Charles G.
 Nilsson, Christy Anne
 Brady, William
 Ledbetter, Jeffrey A.
 Hayden-Ledbetter, Martha S.
 Thompson, Peter A.
 Morales, Cecile

<120> CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL
 CHEMOTHERAPEUTIC THEREOF

<130> EMER-017/01SG 309814-2369

<140> Singapore Patent Application No. 201007096-9
 <141> 2010-09-28

<150> PCT/US2009/040288
 <151> 2009-04-11

<150> US 61/190,067
 <151> 2008-04-11

<160> 293

<170> PatentIn version 3.3

<210> 1
 <211> 1510
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 1
 aagcttgccg ccattggattt tcaagtgcag attttcagct tcttgctaatt cagtgcattca 60
 gtcataattg ccagaggagt cgacatccag atgactcagt ctccagcctc cctatctgca 120
 tctgtgggag agactgtcac catcacatgt cgaacaagtg aaaatgttta cagttatttg 180
 gcttggtatc agcagaaaca gggaaaatct cctcagctcc tggctctctt tgcaaaaacc 240
 ttagcagaag gtgtgccatc aaggttcagt ggcagtggat caggcacaca gttttctctg 300
 aagatcagca gcctgcagcc tgaagattct ggaagttatt tctgtcaaca tcattccgat 360
 aatccgtgga cgttcgggtg aggcaccgaa ctggagatca aaggtggcgg tggctcgggc 420

```

gggtggtgggt cggtggtggcg cggatcgtca gcggtccagc tgcagcagtc tggacctgag 480
tcggaaaagc ctggcgcttc agtgaagatt tcctgcaagg cttctggtta ctcatctact 540
ggctacaata tgaactgggt gaagcagaat aatggaaaga gccttgagtg gattggaaat 600
attgatcctt attatggtgg tactacctac aacoggaagt tcaagggcaa ggccacattg 660
actgtagaca aatcctccag cacagcctac atgcagctca agagtctgac atctgaggac 720
tctgcagtct attactgtgc aagatcggtc ggccctatgg actactgggg tcaaggaacc 780
tcagtcaccg tctcttcaga tctggagccc aaatcttctg acaaaactca cacatctcca 840
ccgtgcccag cacctgaact cttgggtgga ccgtcagctc tcctcttccc cccaaaaccc 900
aaggacaccc tcatgatctc ccggaccctt gaggtcacat gcgtgggtgg ggacgtgagc 960
cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc 1020
aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc 1080
gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc 1140
ctcccagccc ccacgcagaa aaccatctcc aaagccaaag ggagagcccc agaaccacag 1200
gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc 1260
ctgggtcaaag gcttctatcc aagcgacatc gccgtggagt gggagagcaa tgggcaaccg 1320
gagaacaact acaagaccac goctcccgtg ctggactccg acggctcctt cttcctctac 1380
agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg 1440
atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa 1500
tgagtctaga 1510

```

```

<210> 2
<211> 496
<212> PRT
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 2

```

```

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1           5           10          15

```

```

Val Ile Ile Ala Arg Gly Val Asp Ile Gln Met Thr Gln Ser Pro Ala

```

	20		25		30														
Ser	Leu	Ser	Ala	Ser	Val	Gly	Glu	Thr	Val	Thr	Ile	Thr	Cys	Arg	Thr				
	35					40					45								
Ser	Glu	Asn	Val	Tyr	Ser	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Gln	Gly				
	50				55					60									
Lys	Ser	Pro	Gln	Leu	Leu	Val	Ser	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly				
65				70					75					80					
Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Gln	Phe	Ser	Leu				
			85					90						95					
Lys	Ile	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Ser	Gly	Ser	Tyr	Phe	Cys	Gln				
		100						105					110						
His	His	Ser	Asp	Asn	Pro	Trp	Thr	Phe	Gly	Gly	Gly	Thr	Glu	Leu	Glu				
	115						120					125							
Ile	Lys	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly				
	130					135					140								
Ser	Ser	Ala	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Ser	Glu	Lys	Pro				
145					150					155					160				
Gly	Ala	Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ser	Phe	Thr				
				165					170					175					
Gly	Tyr	Asn	Met	Asn	Trp	Val	Lys	Gln	Asn	Asn	Gly	Lys	Ser	Leu	Glu				
		180						185					190						
Trp	Ile	Gly	Asn	Ile	Asp	Pro	Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg				
	195					200						205							
Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr				
	210					215					220								
Ala	Tyr	Met	Gln	Leu	Lys	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr				
225					230					235					240				

Tyr Cys Ala Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr
 245 250 255

Ser Val Thr Val Ser Ser Asp Leu Glu Pro Lys Ser Ser Asp Lys Thr
 260 265 270

His Thr Ser Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 275 280 285

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 290 295 300

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 305 310 315 320

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 325 330 335

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 340 345 350

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 355 360 365

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
 370 375 380

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 385 390 395 400

Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
 405 410 415

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 420 425 430

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 435 440 445

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser

450 455 460
 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 465 470 475 480
 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490 495

<210> 3
 <400> 3
 000

<210> 4
 <400> 4
 000

<210> 5
 <211> 1482
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 5
 atggaagccc cagctcagct tctcttcctc ctgctactct ggctcccaga taccaccgga 60
 gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
 ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180
 ggccaggctc ctaggctcct catctatfff gcaaaaacct tagcagaagg aattccagcc 240
 aggttcagtg gcagtggatc cgggacagac ttcactctca ccatcagcag cctagagcct 300
 gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
 gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt 420
 gggaccggtg aggtgcagct ggtgcagtct ggagcagagg tgaaaaagcc cggagagtct 480
 ctgaagattt cctgtaaggg atccggttac tcattcactg gctacaatat gaactgggtg 540
 cgccagatgc ccgggaaagg cctcgagtgg atgggcaata ttgatcctta ttatgggtgt 600
 actacctaca accggaagtt caagggccag gtcactatct ccgcccacaa gtccatcagc 660
 accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgcatgta ttactgtgca 720

cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctctgat 780
 caggagccca aatcttctga caaaactcac acatctccac cgtgccagc acctgaactc 840
 ctgggtggac cgtcagtcct cctcttcccc ccaaaaccca aggacaccct catgatctcc 900
 cggacccttg aggtcacatg cgtgggtggtg gacgtgagcc acgaagaccc tgaggtcaag 960
 ttcaactggt acgtggacgg cgtggagggtg cataatgcc aagacaaagcc gcgggaggag 1020
 cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg 1080
 aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1140
 accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc 1200
 cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtaaagg cttctatcca 1260
 agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg 1320
 cctcccgtagc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag 1380
 agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcattgaggc tctgcacaac 1440
 cactacacgc agaagagcct ctccctgtct ccgggtaaag ga 1482

<210> 6
 <211> 493
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

 <400> 6

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 290 295 300

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 305 310 315 320

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 325 330 335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 420 425 430

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 435 440 445

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 450 455 460

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 7

<211> 1482
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

 <400> 7
 atggaagccc cagctcagct tctcttctc ctgctactct ggctcccaga taccaccgga 60
 gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
 ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180
 ggccaggctc ctaggctcct catctatttt gcaaaaacct tagcagaagg aattccagcc 240
 aggttcagtg gcagtggatc cgggacagac ttcaactctca ccatcagcag cctagagcct 300
 gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
 gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt 420
 gggagctctg aggtgcagct ggtgcagtct ggagcagagg tgaaaaagcc cggagagtct 480
 ctgaagattt cctgtaaggg atccggttac tcattcactg gctacaatat gaactgggtg 540
 cgccagatgc ccgggaaagg cctcgagtgg atgggcaata ttgatcctta ttatggtggt 600
 actacctaca accggaagtt caagggccag gtcactatct ccgccgaca gtccatcagc 660
 accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
 cgctcagtcg gccctatgga ctactggggc cgcggcacc tggtcactgt ctctctgat 780
 caggagccca aatcttctga caaaactcac acatctccac cgtgcccagc acctgaactc 840
 ctgggtgggac cgtcagtctt cctcttcccc ccaaaacca aggacaccct catgatctcc 900
 cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagacc tgagggtcaag 960
 ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 1020
 cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tctgcacca ggactggctg 1080
 aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1140
 accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gccccatcc 1200
 cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tgggtcaaag cttctatcca 1260
 agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccag 1320
 cctcccgctg tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag 1380

agcagggtggc agcaggggaa cgtcttctca tgctccgtga tgcattgaggc tctgcacaac 1440
 cactacacgc agaagagcct ctccctgtct ccgggtaa at ga 1482

<210> 8
 <211> 493
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> CD37 specific binding protein
 <400> 8

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Glu
 130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
 145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
 165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
 180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
 260 265 270

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 275 280 285

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 290 295 300

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 305 310 315 320

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 325 330 335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys

370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 420 425 430

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 435 440 445

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 450 455 460

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 9
<211> 1482
<212> DNA
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 9
atggaagccc cagctcagct tctcttcctc ctgctactct ggctcccaga taccaccgga 60
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180
ggccaggctc ctaggctcct catctatctt gcaaaaacct tagcagaagg aattccagcc 240
aggttcagtg gcagtggtac cgggacagac ttactctca ccatcagcag cctagagcct 300
gaagatcttg cagtttatta ctgtcaacat cattccgata atccgtggac attcgccaa 360
gggaccaagg tggaaatcaa aggtggcggt ggctcgggcg gtggtggatc tggaggaggt 420

```

gggaccggtg aggtgcagct ggtgcagtct ggagcagagt cgaaaaagcc cggagagtct 480
ctgaagattt cctgtaaggg atccggttac tcattcactg gctacaatat gaactgggtg 540
cgccagatgc ccgggaaagg cctcgagtgg atgggcaata ttgatcctta ttatggtggt 600
actacctaca accggaagtt caagggccag gtcactatct ccgccgacaa gtccatcagc 660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctctgat 780
caggagccca aatcttctga caaaactcac acatctccac cgtgcccagc acctgaactc 840
ctgggtggac cgtcagtcct cctcttcccc ccaaaacca aggacaccct catgatctcc 900
cggacccttg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag 960
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 1020
cagtacaaca gcacgtaccg tgtggtcagc gtctcaccg tctgcacca ggactggctg 1080
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1140
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gccccatcc 1200
cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtaaagg cttctatcca 1260
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccag 1320
cctcccgtgc tggactccga cggtctcttc ttcctctaca gcaagctcac cgtggacaag 1380
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcattgaggc tctgcacaac 1440
cactacacgc agaagagcct ctccctgtct ccgggtaaatt ga 1482

```

```

<210> 10
<211> 493
<212> PRT
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 10

```

```

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1           5           10           15

```

```

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20           25           30

```

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu
 130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Ser Lys Lys Pro Gly Glu Ser
 145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
 165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
 180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr

			245						250							255
Val	Ser	Ser	Asp	Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	
			260					265					270			
Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	
		275					280					285				
Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	
	290					295					300					
Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	
305					310					315					320	
Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	
				325						330				335		
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	
			340					345					350			
Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	
		355					360					365				
Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	
	370					375					380					
Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	
385					390					395					400	
Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	
				405					410					415		
Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	
			420					425					430			
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	
		435					440					445				
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	
	450					455					460					

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 11
 <211> 1482
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 11
 atggaagccc cagctcagct tctcttcctc ctgctactct ggctcccaga taccaccgga 60
 gaaatttgtg tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
 ctctcctgcc gaacaagtca aaatgtttac agctacttag cctggtacca acagaaacct 180
 ggccaggctc ctaggctcct catctatfff gcaaaaacct tagcagaagg aattccagcc 240
 aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct 300
 gaagatffff cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
 gggaccaagg tggaaatcaa aggtggcggt ggctcgggag gtggtggatc tggaggaggt 420
 gggaccggtg aggtgcagct ggtgcagtct ggagcagagg tgaaaaagcc cggagagtct 480
 ctgaagattt cctgtaaggg atccggttac tcattcactg gctacaatat gaactgggtg 540
 cgccagatgc cggggaaagg cctcgagtgg atgggcaata ttgatcctta ttatgggtgt 600
 actacctaca accggaagtt caagggccag gtcactatct ccgccgacaa gtccatcagc 660
 accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
 cgctcagtcg gccctatgga ctactggggc cgcggcaccg tggtcactgt ctctctgat 780
 caggagccca aatcttctga caaaactcac acatctccac cgtgcccagc acctgaactc 840
 ctgggtggac cgtcagtcct cctcttcccc ccaaaaccca aggacaccct catgatctcc 900
 cggaccocctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgagggtcaag 960
 ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 1020
 cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg 1080

aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1140
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc 1200
cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtaaagg cttctatcca 1260
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg 1320
cctcccgtgc tggactccga cggtccttc ttcctctaca gcaagctcac cgtggacaag 1380
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcattgaggc tctgcacaac 1440
cactacacgc agaagagcct ctccctgtct ccgggtaaat ga 1482

<210> 12
<211> 493
<212> PRT
<213> Artificial sequence
<220>
<223> CD37 specific binding protein
<400> 12

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Gln Asn
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly

115		120		125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu				
130		135		140
Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser				
145		150		155
				160
Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn				
		165		170
				175
Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly				
		180		185
				190
Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys				
		195		200
				205
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu				
210		215		220
Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala				
225		230		235
				240
Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr				
		245		250
				255
Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser				
		260		265
				270
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu				
		275		280
				285
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu				
		290		295
				300
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys				
305		310		315
				320
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys				
		325		330
				335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 420 425 430

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 435 440 445

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 450 455 460

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 13
 <211> 1482
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 13
 atggaagccc cagctcagct tctcttctct ctgctactct ggctcccaga taccaccgga 60
 gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120

```

ctctcctgcc gaacaagtga aagtgtttac agctacttag cctggtacca acagaaacct 180
ggccaggctc ctaggctcct catctatttt gcaaaaacct tagcagaagg aattccagcc 240
aggttcagtg gcagtggtac cgggacagac ttcactctca ccatcagcag cctagagcct 300
gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt 420
gggaccggtg aggtgcagct ggtgcagtct ggagcagagg tgaaaaagcc cggagagtct 480
ctgaagattt cctgtaaggg atccggttac tcattcactg gctacaatat gaactgggtg 540
cgccagatgc ccgggaaagg cctcgagtgg atgggcaata ttgatactta ttatggtggt 600
actacctaca accggaagtt caagggccag gtcactatct ccgccgaca gtccatcagc 660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctctgat 780
caggagccca aatcttctga caaaactcac acatctccac cgtgcccagc acctgaactc 840
ctgggtggac cgtcagtcct cctcttcccc ccaaaacca aggacaccct catgatctcc 900
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagacc tgaggtaag 960
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 1020
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg 1080
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1140
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gccccatcc 1200
cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtaaagg cttctatcca 1260
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccag 1320
cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag 1380
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac 1440
cactacacgc agaagagcct ctccctgtct ccgggtaaat ga 1482

```

```

<210> 14
<211> 493
<212> PRT
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

```

<400> 14

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Ser
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu
130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
 260 265 270

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 275 280 285

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 290 295 300

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 305 310 315 320

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 325 330 335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln

420							425					430				
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	
		435					440					445				
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	
	450					455					460					
Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	
465					470					475					480	
His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys				
				485					490							

caggagccca aatcttctga caaaactcac acatctccac cgtgcccagc acctgaactc 840
 ctgggtggac cgtcagtcct cctcttcccc ccaaaaccca aggacaccct catgatctcc 900
 cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag 960
 ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 1020
 cagtacaaca gcacgtaccg tgtggtcagc gtcttcaccg tcttgacca ggactggctg 1080
 aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1140
 accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gccccatcc 1200
 cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtaaagg cttctatcca 1260
 agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccag 1320
 cctcccgtgc tggactccga cggtccttc ttcctctaca gcaagctcac cgtggacaag 1380
 agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcattgaggc tctgcacaac 1440
 cactacacgc agaagagcct ctccctgtct ccgggtaaatt ga 1482

<210> 16

<211> 493

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 16

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu
 130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
 145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
 165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
 180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
 260 265 270

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 275 280 285

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu

290		295		300
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys				
305		310		315 320
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys				
	325		330	335
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu				
	340		345	350
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys				
	355		360	365
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys				
	370		375	380
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser				
385		390		395 400
Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys				
	405		410	415
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln				
	420		425	430
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly				
	435		440	445
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln				
	450		455	460
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn				
465		470		475 480
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys				
	485		490	

<210> 17
 <211> 1479
 <212> DNA

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 17

```
atggaagcac cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccggt      60
gacatccaga tgactcagtc tccagcctcc ctatctgcat ctgtgggaga gactgtcacc      120
atcacatgtc gaacaagtga aaatgtttac agttatttgg cttggtatca gcagaaacag      180
ggaaaatctc ctacagctcct ggtctctttt gcaaaaacct tagcagaagg tgtgccatca      240
aggttcagtg gcagtggatc aggcacacag ttttctctga agatcagcag cctgcagcct      300
gaagattctg gaagttatct ctgtcaacat cattccgata atccgtggac gttcgggtga      360
ggcaccgaac tggagatcaa aggtggcggg ggctcgggag gtgggtgggtc ggggtggcggc      420
ggagctagcg aggtgcagct ggtgcagctt ggagcagagg tgaaaaagcc cggagagtct      480
ctgaggatct cctgtaaggg atccgggttac tcattcactg gctacaatat gaactgggtg      540
cgccagatgc ccgggaaagg cctggagtggt atgggcaata ttgatcctta ttatggtggt      600
actacctaca accggaagtt caagggccag gtcactatct ccgccgacaa gtccatcagc      660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca      720
cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctcagagc      780
gagcccaaata cttctgacaa aactcacaca tctccaccgt gccagcacc tgaactcctg      840
ggtggaccgt cagtcttcct cttcccccca aaaccaagg acaccctcat gatctcccg      900
acccttgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc      960
aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag     1020
tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat     1080
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc     1140
atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccg      1200
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc     1260
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct     1320
cccgctgctg actccgacgg ctcttctctc ctctacagca agctcaccgt ggacaagagc     1380
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac     1440
```

tacacgcaga agagcctctc cctgtctccg ggtaaata

1479

<210> 18

<211> 492

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 18

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
20 25 30

Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Glu Asn
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
50 55 60

Gln Leu Leu Val Ser Phe Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Ser
85 90 95

Ser Leu Gln Pro Glu Asp Ser Gly Ser Tyr Phe Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Glu
130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
145 150 155 160

Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
385 390 395 400

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
405 410 415

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
420 425 430

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
435 440 445

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
450 455 460

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
465 470 475 480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490

<210> 19
<211> 1479
<212> DNA
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 19
atggaagcac cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccggt 60
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180
ggccaggctc ctaggctcct catctatctt gcaaaaacct tagcagaagg aattccagcc 240
aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct 300
gaagatcttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
gggaccaagg tggaaatcaa aggtggcggt ggctcgggcg gtagtggatc tggaggaggt 420
ggagctagcg cgggtccagct gcagcagctt ggacctgagt cggaaaagcc tggcgcttca 480

gtgaagattt cctgcaaggc ttctggttac tcattcactg gctacaatat gaactgggtg 540
 aagcagaata atggaaagag ccttgagtgg attggaaata ttgataccta ttatggtggt 600
 actacctaca accggaagtt caagggcaag gccacattga ctgtagacaa atcctccagc 660
 acagcctaca tgcagctcaa gagtctgaca tctgaggact ctgcagtcta ttactgtgca 720
 agatcgggtcg gccctatgga ctactggggt caaggaacct cagtcaccgt ctctcgagc 780
 gagcccaaat cttctgacaa aactcacaca tctccaccgt gcccagcacc tgaactcctg 840
 ggtggaccgt cagtcttctt cttcccccca aaaccaagg acaccctcat gatctcccg 900
 accctgagg tcacatgcgt ggtgggtggac gtgagccacg aagaccctga ggtcaagttc 960
 aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag 1020
 tacaacagca cgtaccgtgt ggtcagcgtc ctaccgtcc tgcaccagga ctggctgaat 1080
 ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1140
 atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccg 1200
 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
 cccgtgctgg actccgaagg ctcttcttct ctctacagca agctcaccgt ggacaagagc 1380
 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
 tacacgcaga agagcctctc cctgtctccg ggtaaatga 1479

<210> 20

<211> 492

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 20

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn

35	40	45															
Val	Tyr	Ser	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro		
50						55					60						
Arg	Leu	Leu	Ile	Tyr	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Ile	Pro	Ala		
65					70					75					80		
Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser		
				85					90					95			
Ser	Leu	Glu	Pro	Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	His	His	Ser		
			100					105					110				
Asp	Asn	Pro	Trp	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly		
		115					120					125					
Gly	Gly	Gly	Ser	Gly	Gly	Ser	Gly	Ser	Gly	Gly	Gly	Gly	Ala	Ser	Ala		
		130					135					140					
Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Ser	Glu	Lys	Pro	Gly	Ala	Ser		
145					150					155					160		
Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Asn		
				165					170					175			
Met	Asn	Trp	Val	Lys	Gln	Asn	Asn	Gly	Lys	Ser	Leu	Glu	Trp	Ile	Gly		
			180					185					190				
Asn	Ile	Asp	Pro	Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys		
		195					200					205					
Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	Met		
	210					215					220						
Gln	Leu	Lys	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	Ala		
225					230					235					240		
Arg	Ser	Val	Gly	Pro	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr		
				245					250					255			

Val	Ser	Ser	Ser	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	260	265	270
Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	275	280	285
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	290	295	300
Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	305	310	315
Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	325	330	335
Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	340	345	350
Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	355	360	365
Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	370	375	380
Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	385	390	395
Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	405	410	415
Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	420	425	430
Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	435	440	445
Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	450	455	460
Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His			

465

470

475

480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 21

<211> 1479

<212> DNA

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 21

```

atggaagcac cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccggt      60
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc      120
ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct      180
ggccaggctc ctaggctcct catctatfff gcaaaaacct tagcagaagg aattccagcc      240
aggttcagtg gcagtggatc cgggacagac ttcaactctca ccatcagcag cctagagcct      300
gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa      360
gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt      420
ggagctagcc aggtgcagct ggtggagtct ggtggaggcg tggccagcc tgggagggtcc      480
ctgagactct cctgtgcagc ctctggattc accttcagtg gctacaatat gaactgggtc      540
cgccagatgc ccgggaaagg cctggagtgg atgggcaata ttgatcctta ttatggtggt      600
actacctaca accggaagtt caagggccag gtcactatct ccgccgaca gtccatcagc      660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca      720
cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctcagac      780
gagcccaaatt cttctgacaa aactcacaca tctccaccgt gccagcacc tgaactcctg      840
ggtggaccgt cagtcttctt cttcccccca aaaccaagg acaccctcat gatctcccgg      900
acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagtgc      960
aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag     1020
tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat     1080
ggcaaggaggt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc     1140

```

atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccg 1200
 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
 cccgtgctgg actccgacgg ctctttcttc ctctacagca agctcaccgt ggacaagagc 1380
 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
 tacacgcaga agagcctctc cctgtctccg ggtaaatga 1479

<210> 22
 <211> 492
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

 <400> 22

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ala	Ser	Gln	130	135	140
Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	Ser	145	150	155
Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Gly	Tyr	Asn	165	170	175
Met	Asn	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly	180	185	190
Asn	Ile	Asp	Pro	Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys	195	200	205
Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	210	215	220
Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	225	230	235
Arg	Ser	Val	Gly	Pro	Met	Asp	Tyr	Trp	Gly	Arg	Gly	Thr	Leu	Val	Thr	245	250	255
Val	Ser	Ser	Ser	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	260	265	270
Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	275	280	285
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	290	295	300
Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	305	310	315
Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	325	330	335
Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr			

340 345 350
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 355 360 365
 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 370 375 380
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 385 390 395 400
 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 405 410 415
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 420 425 430
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 435 440 445
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 450 455 460
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 465 470 475 480
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 23
 <211> 1503
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 23
 atggaagcac cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccggt 60
 gcgggtccagc tgcagcagtc tggacctgag tcggaaaagc ctggcgcttc agtgaagatt 120
 tctctgcaagg cttctgggta ctcatctact ggctacaata tgaactgggt gaagcagaat 180

aatggaaaga gccttgagtg gattggaaat attgatccctt attatggtgg tactacctac	240
aaccggaagt tcaagggcaa ggccacattg actgtagaca aatcctccag cacagcctac	300
atgcagctca agagtctgac atctgaggac tctgcagtct attactgtgc aagatcggtc	360
ggccctatgg actactgggg tcaaggaacc tcagtcaccg tctcttctgg tggcggtggc	420
tcgggcggtg gtgggtcggg tggcgggcga tcaggaggag gcgggagtgc tagcgaaatt	480
gtgttgacac agtctccagc caccctgtct ttgtctccag gcgaaagagc caccctctcc	540
tgccgaacaa gtgaaaatgt ttacagctac ttagcctggt accaacagaa acctggccag	600
gctcctaggc tcctcatcta ttttgcaaaa accttagcag aaggaattcc agccaggttc	660
agtggcagtg gatccgggac agacttcaact ctccaccatca gcagcctaga gcctgaagat	720
tttgcagttt attactgtca acatcattcc gataatccgt ggacattcgg ccaagggacc	780
aaggtggaag tcaaaggctc gagcgagccc aaatcttctg acaaaactca cacatctcca	840
ccgtgcccag cacctgaact cctgggtgga ccgtcagtct tcctcttccc cccaaaaccc	900
aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtgggtgt ggacgtgagc	960
cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc	1020
aagacaaagc cgcgaggagga gcagtacaac agcacgtacc gtgtgggtcag cgtcctcacc	1080
gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaagggtct caacaaagcc	1140
ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag	1200
gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accagggtcag cctgacctgc	1260
ctgggtcaaag gcttctatcc aagcgacatc gccgtggagt gggagagcaa tgggcagccg	1320
gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt ctctctctac	1380
agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg	1440
atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa	1500
tga	1503

<210> 24
 <211> 500
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

<400> 24

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Ala Val Gln Leu Gln Gln Ser Gly Pro Glu Ser Glu
20 25 30

Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser
35 40 45

Phe Thr Gly Tyr Asn Met Asn Trp Val Lys Gln Asn Asn Gly Lys Ser
50 55 60

Leu Glu Trp Ile Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr
65 70 75 80

Asn Arg Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
85 90 95

Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110

Val Tyr Tyr Cys Ala Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln
115 120 125

Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Ser Glu Ile
145 150 155 160

Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg
165 170 175

Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn Val Tyr Ser Tyr Leu Ala
180 185 190

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Phe
195 200 205

Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
 210 215 220

Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp
 225 230 235 240

Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp Thr Phe
 245 250 255

Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Ser Ser Glu Pro Lys Ser
 260 265 270

Ser Asp Lys Thr His Thr Ser Pro Pro Cys Pro Ala Pro Glu Leu Leu
 275 280 285

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 290 295 300

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 305 310 315 320

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 325 330 335

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 340 345 350

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 355 360 365

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 370 375 380

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 385 390 395 400

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 405 410 415

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

420 425 430
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 435 440 445
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 450 455 460
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 465 470 475 480
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 485 490 495
 Ser Pro Gly Lys
 500

<210> 25
 <211> 1488
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 25
 atggattttc aagtgcagat tttcagcttc ctgctaataca gtgcttcagt cataattgcc 60
 agaggagtcg aaattgtgtt gacacagtct ccagccaccc tgtctttgtc tccaggcgaa 120
 agagccaccc tctcctgccg aacaagtgaa aatgtttaca gctacttagc ctggtaccaa 180
 cagaaacctg gccaggctcc taggctcctc atctatcttg caaaaacctt agcagaagga 240
 attccagcca ggttcagtgg cagtggatcc gggacagact tcaactctcac catcagcagc 300
 ctagagcctg aagatcttgc agtttattac tgtcaacatc attccgataa tccgtggaca 360
 ttcggccaag ggaccaaggt ggaaatcaaa ggtggcggtg gctcgggcgg tgggtggatct 420
 ggaggaggtg gagctagcgc ggtccagctg cagcagtctg gacctgagtc ggaaaagcct 480
 ggcgcttcag tgaagatttc ctgcaaggct tctggttact cattcactgg ctacaatatg 540
 aactgggtga agcagaataa tggaaagagc cttgagtggg ttggaaatat tgatccttat 600
 tatggtggta ctacctaaa ccggaagttc aagggaaggg ccacattgac tgtagacaaa 660

tcctccagca cagcctacat gcagctcaag agtctgacat ctgaggactc tgcagtctat 720
 tactgtgcaa gatcggtcgg ccctatggac tactggggtc aaggaacctc agtcaccgtc 780
 tcctcgagcg agcccaaadc ttctgacaaa actcacacat ctccaccgtg cccagcacct 840
 gaactcctgg gtggaccgtc agtcttctc ttccccccaa aaccaagga caccctcatg 900
 atctcccgga cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag 960
 gtcaagttca actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgchg 1020
 gaggagcagt acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac 1080
 tggctgaatg gcaaggagta caagtgaag gtctccaaca aagccctccc agcccccatc 1140
 gagaaaacca tctccaaagc caaagggcag ccccgagaac cacaggtgta caccctgccc 1200
 ccatcccgga atgagctgac caagaaccag gtcagcctga cctgcctggt caaaggcttc 1260
 tatccaagcg acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag 1320
 accacgcctc ccgtgctgga ctccgacggc tccttcttcc tctacagcaa gtcaccgtg 1380
 gacaagagca ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg 1440
 cacaaccact acacgcagaa gagcctctcc ctgtctccgg gtaaatga 1488

<210> 26
 <211> 495
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

 <400> 26

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1 5 10 15

Val Ile Ile Ala Arg Gly Val Glu Ile Val Leu Thr Gln Ser Pro Ala
 20 25 30

Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr
 35 40 45

Ser Glu Asn Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly
 50 55 60

Gln Ala Pro Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly
 65 70 75 80

Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
 85 90 95

Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln
 100 105 110

His His Ser Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
 115 120 125

Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 130 135 140

Ala Ser Ala Val Gln Leu Gln Gln Ser Gly Pro Glu Ser Glu Lys Pro
 145 150 155 160

Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr
 165 170 175

Gly Tyr Asn Met Asn Trp Val Lys Gln Asn Asn Gly Lys Ser Leu Glu
 180 185 190

Trp Ile Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg
 195 200 205

Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr
 210 215 220

Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
 225 230 235 240

Tyr Cys Ala Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr
 245 250 255

Ser Val Thr Val Ser Ser Ser Glu Pro Lys Ser Ser Asp Lys Thr His
 260 265 270

Thr Ser Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val

275		280		285											
Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr
290					295						300				
Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu
305					310					315					320
Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys
				325					330					335	
Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser
			340					345					350		
Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys
	355						360					365			
Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile
370						375					380				
Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro
385					390					395					400
Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu
				405					410					415	
Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn
			420					425					430		
Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser
		435					440					445			
Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg
450						455					460				
Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu
465					470					475					480
His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	
				485					490					495	

<210> 27
 <211> 1503
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

 <400> 27
 atggaagcac cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccggt 60
 gcggtccagc tgcagcagtc tggacctgag tcggaaaagc ctggcgcttc agtgaagatt 120
 tcctgcaagg cttctgggta ctcatctact ggctacaata tgaactgggt gaagcagaat 180
 aatggaaaga gccttgagtg gattggaaat attgatcctt attatgggtg tactacctac 240
 aaccggaagt tcaagggcaa ggccacattg actgtagaca aatcctccag cacagcctac 300
 atgcagctca agagtctgac atctgaggac tctgcagtct attactgtgc aagatcggtc 360
 ggccctatgg actactgggg tcaaggaacc tcagtcaccg tctcttctgg tggcggtggc 420
 tcgggcggtg gtgggtcggg tggcggcgga tcaggaggag gcgggagtgc tagcgaaatt 480
 gtgttgacac agtctccagc caccctgtct ttgtctccag gcgaaagagc caccctctcc 540
 tgccgaacaa gtgaaaatgt ttacagctac ttagcctggg accaacagaa acctggccag 600
 gtccttaggc tcctcatcta ttttgcaaaa accttagcag aaggaattcc agccagggtc 660
 agtggcagtg gatccgggac agacttcaact ctaccatca gcagcctaga gcctgaagat 720
 tttgcagttt attactgtca acatcattcc gataatccgt ggacattcgg ccaagggacc 780
 aaggttgaaa tcaaaggctc gagcgagccc aaatcttctg acaaaactca cacatgccc 840
 ccgtgcccag cacctgaact cctgggtgga ccgtcagtct tcctcttccc cccaaaaccc 900
 aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc 960
 cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc 1020
 aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc 1080
 gtctgcacc aggactgggt gaatggcaag gagtacaagt gcaagggtct caacaaagcc 1140
 ctcccagccc ccctcgagaa aaccatctcc aaagccaaag ggagccccg agaaccacag 1200
 gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc 1260
 ctggtcaaag gcttctatcc aagcgacatc gccgtggagt gggagagcaa tgggcagccg 1320

gagaacaact acaagaccac gcctcccggtg ctggactccg acggctcctt cttcctctac 1380
agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg 1440
atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa 1500
tga 1503

<210> 28
<211> 500
<212> PRT
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 28

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Ala Val Gln Leu Gln Gln Ser Gly Pro Glu Ser Glu
20 25 30

Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser
35 40 45

Phe Thr Gly Tyr Asn Met Asn Trp Val Lys Gln Asn Asn Gly Lys Ser
50 55 60

Leu Glu Trp Ile Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr
65 70 75 80

Asn Arg Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
85 90 95

Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110

Val Tyr Tyr Cys Ala Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln
115 120 125

Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Ser Glu Ile
 145 150 155 160

Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg
 165 170 175

Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn Val Tyr Ser Tyr Leu Ala
 180 185 190

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Phe
 195 200 205

Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
 210 215 220

Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp
 225 230 235 240

Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp Thr Phe
 245 250 255

Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Ser Ser Glu Pro Lys Ser
 260 265 270

Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 275 280 285

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 290 295 300

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 305 310 315 320

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 325 330 335

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 340 345 350

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

355 360 365
 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 370 375 380
 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 385 390 395 400
 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 405 410 415
 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 420 425 430
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 435 440 445
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 450 455 460
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 465 470 475 480
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 485 490 495
 Ser Pro Gly Lys
 500

<210> 29
 <211> 1479
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 29
 atggaagcac cagcgcagct tctcttctc ctgctactct ggctcccaga taccaccggt 60
 gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
 ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180

```

ggccaggctc ctaggctcct catctatctt gcaaaaacct tagcagaagg aattccagcc 240
aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct 300
gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt 420
ggagctagcg cgggccagct gcagcagctt ggacctgagt cggaaaagcc tggcgcttca 480
gtgaagattt cctgcaaggc ttctgggtac tcattcactg gctacaatat gaactgggtg 540
aagcagaata atggaaagag ccttgagtgg attggaaata ttgatcctta ttatgggtgt 600
actacctaca accggaagtt caagggaag gccacattga ctgtagacaa atcctccagc 660
acagcctaca tgcagctcaa gagtctgaca tctgaggact ctgcagtcta ttactgtgca 720
agatcgggtc gccctatgga ctactggggg caaggaacct cagtcaccgt ctctcagc 780
gagcccaaat cttctgacaa aactcacaca tctccaccgt gccagcacc tgaactcctg 840
ggtggaccgt cagtcttctt cttcccccca aaaccaagg acaccctcat gatctcccg 900
acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 960
aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag 1020
tacaacagca cgtaccgtgt ggtcagcgtc ctaccgtcc tgcaccagga ctggctgaat 1080
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1140
atctccaaag ccaaagggca gcccgcagaa ccacaggtgt acaccctgcc cccatcccg 1200
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
cccgtgctgg actccgacgg ctctctcttc ctctacagca agctcaccgt ggacaagagc 1380
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
tacacgcaga agagcctctc cctgtctccg ggtaaatga 1479

```

<210> 30

<211> 492

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 30

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15
 Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30
 Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45
 Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60
 Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95
 Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110
 Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Ala
 130 135 140
 Val Gln Leu Gln Gln Ser Gly Pro Glu Ser Glu Lys Pro Gly Ala Ser
 145 150 155 160
 Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
 165 170 175
 Met Asn Trp Val Lys Gln Asn Asn Gly Lys Ser Leu Glu Trp Ile Gly
 180 185 190
 Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195 200 205
 Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met

210		215		220															
Gln	Leu	Lys	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	Ala				
225					230					235					240				
Arg	Ser	Val	Gly	Pro	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr				
				245					250					255					
Val	Ser	Ser	Ser	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro				
				260					265					270					
Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe				
		275					280					285							
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val				
	290					295					300								
Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe				
305					310					315					320				
Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro				
				325					330					335					
Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr				
			340					345					350						
Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val				
		355					360					365							
Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala				
	370					375					380								
Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg				
385					390					395					400				
Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly				
				405					410					415					
Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro				
			420					425					430						

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 435 440 445

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 450 455 460

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 465 470 475 480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 31
 <211> 1479
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 31
 atggaagcac cagcgcagct tctcttctct ctgctactct ggctcccaga taccaccggt 60
 gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
 ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180
 ggccaggctc ctaggctcct catctatctt gcaaaaacct tagcagaagg aattccagcc 240
 aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct 300
 gaagatcttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
 gggaccaagg tggaaatcaa aggtggcggt ggctcgggcg gtggtggatc tggaggaggt 420
 ggagctagcg cggtcagct gcagcagtct ggacctgagt cggaaaagcc tggcgcttca 480
 gtgaagattt cctgcaaggc ttctggttac tcattcactg gctacaatat gaactgggtg 540
 aagcagaata atggaaagag ccttgagtgg attggaaata ttgatcctta ttatggtggt 600
 actacctaca accggaagtt caagggcaag gccacattga ctgtagacaa atcctccagc 660
 acagcctaca tgcagctcaa gagtctgaca tctgaggact ctgcagtcta ttactgtgca 720
 agatcggtcg gccctatgga ctactggggt caaggaacct cagtcaccgt ctctcgagc 780
 gagcccaa atctctgacaa aactcacaca tgcccaccgt gccagcacc tgaactcctg 840

```

ggtggaccgt cagtcttcct cttcccccca aaacccaagg acaccctcat gatctcccgg      900
acccttgagg tcacatgcgt ggtggtggac gtgagccaag aagaccctga ggtcaagttc      960
aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag    1020
tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat    1080
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc    1140
atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccgg    1200
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc    1260
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct    1320
cccgtgctgg actccgacgg ctcttctctc ctctacagca agctcaccgt ggacaagagc    1380
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac    1440
tacacgcaga agagcctctc cctgtctccg ggtaaatga                          1479

```

```

<210> 32
<211> 492
<212> PRT
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 32

```

```

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1           5           10           15

```

```

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
          20           25           30

```

```

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
          35           40           45

```

```

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
          50           55           60

```

```

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65           70           75           80

```

```

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

```


Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 305 310 315 320

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 325 330 335

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 340 345 350

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 355 360 365

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 370 375 380

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 385 390 395 400

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 405 410 415

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 420 425 430

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 435 440 445

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 450 455 460

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 465 470 475 480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 33
 <211> 1479
 <212> DNA
 <213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 33

```
atggaagcac cagcgagct tctcttcctc ctgctactct ggctcccaga taccaccggt      60
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc      120
ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct      180
ggccaggctc ctaggctcct catctatfff gcaaaaacct tagcagaagg aattccagcc      240
aggttcagtg gcagtggatc cgggacagac ttcaacttca ccatcagcag cctagagcct      300
gaagattttg cagtttatta ctgtcaacat caticcgata atccgtggac attcggccaa      360
gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt      420
ggagctagcc aggtgcagct ggtggagtct ggtggaggcg tggccagcc tgggaggtcc      480
ctgagactct cctgtgcagc ctctggattc accttcagtg gctacaatat gaactgggtc      540
cgccagatgc cggggaaagg cctggagtgg atgggcaata ttgatcctta ttatggtggt      600
actacctaca accggaagtt caagggccag gtcactatct ccgccgaca gtccatcagc      660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca      720
cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctcagc      780
gagcccaaatt cttctgacaa aactcacaca tgcccaccgt gccagcacc tgaactcctg      840
ggtggaccgt cagtcttctt cttcccccca aaaccaagg acaccctcat gatctcccgg      900
acccctgagg tcacatgctt ggtggtggac gtgagccacg aagaccctga ggtcaagttc      960
aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag     1020
tacaacagca cgtaccgtgt ggtcagcgtc ctaccgtcc tgcaccagga ctggctgaat     1080
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagccccat cgagaaaacc     1140
atctccaaag ccaaagggca gcccagagaa ccacaggtgt acaccctgcc cccatcccgg     1200
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc     1260
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct     1320
cccgtgctgg actcagacgg ctctttcttc ctctacagca agctcaccgt ggacaagagc     1380
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac     1440
tacacgcaga agagcctctc cctgtctccg ggtaaatga                               1479
```

<210> 34
 <211> 492
 <212> PRT
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 34

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Gln
 130 135 140

Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser
 145 150 155 160

Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Asn
 165 170 175

Met	Asn	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly	180	185	190
Asn	Ile	Asp	Pro	Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys	195	200	205
Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	210	215	220
Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	225	230	235
Arg	Ser	Val	Gly	Pro	Met	Asp	Tyr	Trp	Gly	Arg	Gly	Thr	Leu	Val	Thr	245	250	255
Val	Ser	Ser	Ser	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Cys	Pro	260	265	270
Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	275	280	285
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	290	295	300
Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	305	310	315
Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	325	330	335
Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	340	345	350
Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	355	360	365
Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	370	375	380
Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg			

385 390 395 400

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
420 425 430

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
450 455 460

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490

<220>
<223> CD37 specific binding protein

cgccagatgc ccgggaaagg cctggagtgg atgggcaata ttgatcctta ttatggtggt 600
 actacctaca accggaagtt caagggccag gtcactatct ccgccgacaa gtccatcagc 660
 accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
 cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctcagagc 780
 gagcccaaat cttctgacaa aactcacaca tgcccaccgt gcccagcacc tgaactcctg 840
 ggtggaccgt cagtcttcct cttcccccca aaaccaagg acaccctcat gatctcccg 900
 acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 960
 aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag 1020
 tacaacagca cgtaccgtgt ggtcagcgtc ctaccgtcc tgcaccagga ctggctgaat 1080
 ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1140
 atctccaaag ccaaagggca gcccgcagaa ccacaggtgt acaccctgcc cccatcccg 1200
 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
 cccgtgctgg actccgacgg ctctctcttc ctctacagca agctcacctg ggacaagagc 1380
 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
 tacacgcaga agagcctctc cctgtctccg ggtaaatga 1479

<210> 36
 <211> 492
 <212> PRT
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 36

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Gln
130 135 140

Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser
145 150 155 160

Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Asn
165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
245 250 255

Val Ser Ser Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro

260	265	270
Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe		
275	280	285
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val		
290	295	300
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe		
305	310	315
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro		
	325	330
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr		
	340	345
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val		
	355	360
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala		
	370	375
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg		
385	390	395
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly		
	405	410
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro		
	420	425
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser		
	435	440
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln		
	450	455
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His		
465	470	475
		480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490

<210> 37
<211> 1476
<212> DNA
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 37
atggaagcac cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccggt 60
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180
ggccaggctc ctaggctcct catctatctt gcaaaaacct tagcagaagg aattccagcc 240
aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct 300
gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
gggaccaagg tggaaatcaa aggtggcggt ggctcgggcg gtggtggatc tggaggaggt 420
ggggctagcg aggtgcagct ggtggagtct ggtggaggct tggtcagcc tggagggtcc 480
ctgagactct cctgtgcagc ctctggatcc accttcagtg gctacaatat gaactgggtc 540
cgccagatgc cggggaaagg cctggagtgg atgggcaata ttgatactta ttatggtggt 600
actacctaca accggaagtt caagggccag gtcactatct ccgccgaca gtccatcagc 660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctcagc 780
gagcccaaat cttctgacaa aactcacaca tctccaccgt gccagcacc tgaactcctg 840
ggtggaccgt cagtcttcct cttccccca aaaccaagg acaccctcat gatctcccg 900
acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 960
aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag 1020
tacaacagca cgtaccgtgt ggtcagcgtc ctaccgtcc tgcaccagga ctggtgaa 1080
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1140
atctccaaag ccaaagggca gccccgaga ccacaggtgt acaccctgcc cccatcccg 1200

gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
cccggtgctgg actccgacgg ctcccttcttc ctctacagca agctcaccgt ggacaagagc 1380
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
tacacgcaga agagcctctc cctgtctccg ggtaaa 1476

<210> 38
<211> 492
<212> PRT
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 38

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Glu

130		135		140
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser				
145		150		155
				160
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Asn				
		165		170
				175
Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly				
		180		185
				190
Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys				
		195		200
				205
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu				
		210		215
				220
Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala				
		225		230
				235
Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr				
		245		250
				255
Val Ser Ser Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro				
		260		265
				270
Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe				
		275		280
				285
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val				
		290		295
				300
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe				
		305		310
				315
				320
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro				
		325		330
				335
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr				
		340		345
				350

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 355 360 365

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 370 375 380

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 385 390 395 400

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 405 410 415

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 420 425 430

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 435 440 445

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 450 455 460

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 465 470 475 480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 39

<211> 1476

<212> DNA

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 39

atggaagcac cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccggt 60

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120

ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtacca acagaaacct 180

ggccaggctc ctaggctcct catctatctt gcaaaaacct tagcagaagg aattccagcc 240

```

aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct 300
gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt 420
ggggctagcg aggtgcagct ggtggagtct ggtggaggct tggtcagcc tggagggtcc 480
ctgagactct cctgtgcagc ctctggattc accttcagtg gctacaatat gaactgggtc 540
cgccagatgc cgggaaagg cctggagtgg atgggcaata ttgatcctta ttatggtggt 600
actacctaca accggaagtt caagggccag gtcactatct ccgccgaca gtccatcagc 660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
cgctcagtcg gccctatgga ctactggggc cgcggcacc tggtcactgt ctctcgagc 780
gagcccaaat cttctgacaa aactcacaca tgcccaccgt gcccagcacc tgaactcctg 840
ggtggaccgt cagtcttcct cttccccca aaaccaagg acaccctcat gatctcccg 900
accctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 960
aactggtacg tggacggcgt ggagggtgat aatgccaaga caaagccgcg ggaggagcag 1020
tacaacagca cgtaccgtgt ggtcagcgtc ctaccgtcc tgcaccagga ctggctgaat 1080
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1140
atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccg 1200
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
cccgtgctgg actccgacgg ctcttcttct ctctacagca agctcaccgt ggacaagagc 1380
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
tacacgcaga agagcctctc cctgtctccg ggtaaa 1476

```

<210> 40

<211> 492

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 40

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro

1	5	10	15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser	20	25	30
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn	35	40	45
Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro	50	55	60
Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala	65	70	75
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser	85	90	95
Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser	100	105	110
Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly	115	120	125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Glu	130	135	140
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser	145	150	155
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Asn	165	170	175
Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly	180	185	190
Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys	195	200	205
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu	210	215	220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro
 260 265 270

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
 275 280 285

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 290 295 300

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 305 310 315 320

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 325 330 335

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 340 345 350

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 355 360 365

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 370 375 380

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 385 390 395 400

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 405 410 415

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 420 425 430

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser

435 440 445

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
450 455 460

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
465 470 475 480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490

acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 960
 aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag 1020
 tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 1080
 ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1140
 atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccgg 1200
 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
 cccgtgctgg actccgacgg ctctctcttc ctctacagca agctcaccgt ggacaagagc 1380
 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
 tacacgcaga agagcctctc cctgtctccg ggtaaa 1476

<210> 42
 <211> 492
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

 <400> 42

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Glu
 130 135 140

Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser
 145 150 155 160

Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Asn
 165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
 180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro
 260 265 270

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
 275 280 285

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 290 295 300

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe

305 310 315 320
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 325 330 335
 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 340 345 350
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 355 360 365
 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 370 375 380
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 385 390 395 400
 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 405 410 415
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 420 425 430
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 435 440 445
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 450 455 460
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 465 470 475 480
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 43

<211> 1476

<212> DNA

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 43
atggaagcac cagcgagct tctcttcctc ctgctactct ggtcccaga taccaccggt 60
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc 120
ctctcctgcc gaacaagtga aaatgtttac agctacttag cctggtagca acagaaacct 180
ggccaggctc ctaggctcct catctatctt gcaaaaacct tagcagaagg aattccagcc 240
aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct 300
gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa 360
gggaccaagg tggaaatcaa aggtggcggg ggtcggggcg gtgggtggatc tggaggaggt 420
ggggctagcg aggtgcagct ggtggagtct ggtggaggct ctgtccagcc tggagggtcc 480
ctgagactct cctgtgcagc ctctggatct accttcagtg gctacaatat gaactgggtc 540
cgccagatgc ccgggaaagg cctggagtgg atgggcaata ttgatcctta ttatggtggt 600
actacctaca accggaagtt caagggccag gtcactatct ccgccgaca gtccatcagc 660
accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
cgctcagtcg gccctatgga ctactggggc cgcggcaccg tggtcactgt ctctcgagc 780
gagcccaaat cttctgacaa aactcacaca tgcccaccgt gccagcacc tgaactcctg 840
ggtggaccgt cagtcttcct ctcccccca aaaccaagg acaccctcat gatctcccg 900
accctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 960
aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagcccg ggaggagcag 1020
tacaacagca cgtaccgtgt ggtcagcgtc ctaccgtcc tgcaccagga ctggctgaat 1080
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 1140
atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccg 1200
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc 1260
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1320
ccgtgctgg actcgcagc ctctctcttc ctctacagca agctcaccgt ggacaagagc 1380
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1440
tacacgcaga agagcctctc cctgtctccg ggtaaa 1476

<210> 44

<211> 492
 <212> PRT
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 44

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Glu
 130 135 140

Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser
 145 150 155 160

Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Asn
 165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly

180	185	190
Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys		
195	200	205
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu		
210	215	220
Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala		
225	230	235
Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr		
	245	250
Val Ser Ser Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro		
	260	265
Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe		
	275	280
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val		
	290	295
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe		
305	310	315
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro		
	325	330
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr		
	340	345
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val		
	355	360
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala		
	370	375
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg		
385	390	395
		400

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
405 410 415

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
420 425 430

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
435 440 445

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
450 455 460

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
465 470 475 480

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490

<210> 45

<211> 1482

<212> DNA

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 45

```

atggaagccc cagctcagct tctcttcctc ctgctactct ggctcccaga taccaccgga      60
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccaggcga aagagccacc      120
ctctcctgcc gagcaagtca aagtgtttac agctacttag cctggtacca acagaaacct      180
ggccaggctc ctaggctcct catctatfff gcaaaaacct tagcagaagg aattccagcc      240
aggttcagtg gcagtggatc cgggacagac ttactctca ccatcagcag cctagagcct      300
gaagattttg cagtttatta ctgtcaacat cattccgata atccgtggac attcggccaa      360
gggaccaagg tggaaatcaa aggtggcggg ggctcgggcg gtggtggatc tggaggaggt      420
gggaccggtg aggtgcagct ggtgcagtct ggagcagagg tgaaaaagcc cggagagtct      480
ctgaagattt cctgtaaggg atccggttac tcattcactg gctacaatat gaactgggtg      540
cgccagatgc ccgggaaagg cctcgagtgg atgggcaata ttgatcctta ttatgggtgt      600

```

actacctaca accggaagtt caagggccag gtcactatct ccgcgcgacaa gtccatcagc 660
 accgcctacc tgcaatggag cagcctgaag gcctcggaca ccgccatgta ttactgtgca 720
 cgctcagtcg gccctatgga ctactggggc cgcggcaccc tggtcactgt ctctctgat 780
 caggagccca aatcttctga caaaactcac acatctccac cgtgcccagc acctgaactc 840
 ctgggtggac cgtcagtctt cctcttcccc ccaaaacca aggacaccct catgatctcc 900
 cggacccttg aggtcacatg cgtgggtggtg gacgtgagcc acgaagacc tgaggtcaag 960
 ttcaactggt acgtggacgg cgtggaggtg cataatgcc agacaaagcc gcgggaggag 1020
 cagtacaaca gcacgtaccg tgtggtcagc gtctcaccg tctgcacca ggactggctg 1080
 aatggcaagg agtacaagtg caaggtctcc aacaaagccc tccagcccc catcgagaaa 1140
 accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gccccatcc 1200
 cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtaaagg cttctatcca 1260
 agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccag 1320
 cctcccgctg tggactccga cggctccttc ttctctaca gcaagctcac cgtggacaag 1380
 agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcattgaggc tctgcacaac 1440
 cactacacgc agaagagcct ctccctgtct ccgggtaa at ga 1482

<210> 46
 <211> 493
 <212> PRT
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 46

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro

50		55		60											
Arg 65	Leu 66	Leu 67	Ile 68	Tyr 69	Phe 70	Ala 71	Lys 72	Thr 73	Leu 74	Ala 75	Glu 76	Gly 77	Ile 78	Pro 79	Ala 80
Arg 85	Phe 86	Ser 87	Gly 88	Ser 89	Gly 90	Ser 91	Gly 92	Thr 93	Asp 94	Phe 95	Thr 96	Leu 97	Thr 98	Ile 99	Ser 100
Ser 105	Leu 106	Glu 107	Pro 108	Glu 109	Asp 110	Phe 111	Ala 112	Val 113	Tyr 114	Tyr 115	Cys 116	Gln 117	His 118	His 119	Ser 120
Asp 125	Asn 126	Pro 127	Trp 128	Thr 129	Phe 130	Gly 131	Gln 132	Gly 133	Thr 134	Lys 135	Val 136	Glu 137	Ile 138	Lys 139	Gly 140
Gly 145	Gly 146	Gly 147	Ser 148	Gly 149	Gly 150	Gly 151	Gly 152	Ser 153	Gly 154	Gly 155	Gly 156	Gly 157	Thr 158	Gly 159	Glu 160
Val 165	Gln 166	Leu 167	Val 168	Gln 169	Ser 170	Gly 171	Ala 172	Glu 173	Val 174	Lys 175	Lys 176	Pro 177	Gly 178	Glu 179	Ser 180
Leu 185	Lys 186	Ile 187	Ser 188	Cys 189	Lys 190	Gly 191	Ser 192	Gly 193	Tyr 194	Ser 195	Phe 196	Thr 197	Gly 198	Tyr 199	Asn 200
Met 205	Asn 206	Trp 207	Val 208	Arg 209	Gln 210	Met 211	Pro 212	Gly 213	Lys 214	Gly 215	Leu 216	Glu 217	Trp 218	Met 219	Gly 220
Asn 225	Ile 226	Asp 227	Pro 228	Tyr 229	Tyr 230	Gly 231	Gly 232	Thr 233	Thr 234	Tyr 235	Asn 236	Arg 237	Lys 238	Phe 239	Lys 240
Gly 245	Gln 246	Val 247	Thr 248	Ile 249	Ser 250	Ala 251	Asp 252	Lys 253	Ser 254	Ile 255	Ser 256	Thr 257	Ala 258	Tyr 259	Leu 260
Gln 265	Trp 266	Ser 267	Ser 268	Leu 269	Lys 270	Ala 271	Ser 272	Asp 273	Thr 274	Ala 275	Met 276	Tyr 277	Tyr 278	Cys 279	Ala 280
Arg 285	Ser 286	Val 287	Gly 288	Pro 289	Met 290	Asp 291	Tyr 292	Trp 293	Gly 294	Arg 295	Gly 296	Thr 297	Leu 298	Val 299	Thr 300
Val 305	Ser 306	Ser 307	Asp 308	Gln 309	Glu 310	Pro 311	Lys 312	Ser 313	Ser 314	Asp 315	Lys 316	Thr 317	His 318	Thr 319	Ser 320

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 275 280 285

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 290 295 300

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 305 310 315 320

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 325 330 335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 420 425 430

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 435 440 445

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 450 455 460

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

<210> 47
 <211> 1500
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 47
 aagcttgccg ccatggaagc cccagcgcag cttctcttcc tctgctact ctggctccca 60
 gataccaccg gagaaattgt gttgacacag tctccagcca ccctgtcttt gtctccaggc 120
 gaaagagcca ccctctcctg ccgagcaagt gaaaatgttt acagctactt agcctggtac 180
 caacagaaac ctggccaggc tcttaggctc ctcatctatt ttgcaaaaac ctagcagaa 240
 ggaattccag ccaggttcag tggcagtggg tccgggacag acttcactct caccatcagc 300
 agcctagagc ctgaagatct tgcagtttat tactgtcaac atcattccga taatccgtgg 360
 acattcggcc aagggaacca ggtggaaatc aaaggtggcg gcggctcggg cggtgggtga 420
 tctggaggag gtgggaccgg tgaggtgcag ctggtgcagt ctggagcaga ggtgaaaaag 480
 cccggagagt ctctgaagat ttctgtgaag ggatccggtt actcattcac tggctacaat 540
 atgaactggg tgcgccagat gcccgggaaa ggctcagat ggatgggcaa tattgatcct 600
 tattatggtg gtactaccta caaccggaag ttcaagggcc aggtcactat ctccgcgcac 660
 aagtccatca gcaccgccta cctgcaatgg agcagcctga aggcctcgga caccgccatg 720
 tattactgtg cacgctcagt cggcccttct gactactggg gccagggcac cctgggtcact 780
 gtctcctctg atcaggagcc caaatcttct gacaaaactc acacatctcc accgtgcccc 840
 gcacctgaac tcttgggtgg accgtcagtc ttctcttcc ccccaaaacc caaggacacc 900
 ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac 960
 cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag 1020
 ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac 1080
 caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc 1140
 cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc 1200
 ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctgggtcaaa 1260

ggcttctatc caagcgacat cgcctgggag tgggagagca atgggcagcc ggagaacaac 1320
 tacaagacca cgcctcccgt gctggactcc gacggctcct tcttctctta cagcaagctc 1380
 accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag 1440
 gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa atgatctaga 1500

<210> 48
 <211> 493
 <212> PRT
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 48

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
 115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu
 130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
 145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
 165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
 180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
 260 265 270

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 275 280 285

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 290 295 300

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 305 310 315 320

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 325 330 335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys

355 360 365
 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 385 390 395 400
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 420 425 430
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 435 440 445
 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 450 455 460
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 465 470 475 480
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 49
 <400> 49
 000

<210> 50
 <400> 50
 000

<210> 51
 <211> 1381
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 51
 aagcttgccg ccattggaagc cccagcgcag cttctcttcc tcctgctact ctggctccca 60

gataccaccg gagaaattgt gttgacacag tctccagcca cctgtcttt gtctccaggc	120
gaaagagcca cctctctctg ccgagcaagt gaaaatgttt acagctactt agcctggtac	180
caacagaaac ctggccaggc tcttaggctc ctcatctatt ttgcaaaaac cttagcagaa	240
ggaattccag ccaggttcag tggcagtgga tccgggacag acttcactct caccatcagc	300
agcctagagc ctgaagattt tgcagtttat tactgtcaac atcattccga taatccgtgg	360
acattcggcc aagggaacaa ggtggaaatc aaagggtggcg gtggctcggg cgggtggtgga	420
tctggaggag gtgggaccgg tgagggtgcag ctggtgcagt ctggagcaga ggtgaaaaag	480
cccggagagt ctctgaagat ttctgtgaag ggatccggtt actcattcac tggctacaat	540
atgaactggg tgcgccagat gcccgggaaa ggctcagagt ggatgggcaa tattgatcct	600
tattatggtg gtactaccta caaccggaag ttcaagggcc aggtcactat ctccgccgac	660
aagtccatca gcaccgccta cctgcaatgg agcagcctga aggcctcgga caccgccatg	720
tattactgtg cacgctcagt cggccctttc gactcctggg gccagggcac cctggtcact	780
gtctcctctg atcaggagcc caaatcttct gacaaaactc acacatctcc accgtgccca	840
gcacctgaac tcttgggtgg accgtcagtc ttctctttcc ccccaaaacc caaggacacc	900
ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac	960
cctgagggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaaag	1020
ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac	1080
caggactggc tgaatggcaa ggagtacaag tgcaaggctt ccaacaaagc cctcccagcc	1140
cccctcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc	1200
ctgcccccat cccgggatga gctgaccaag aaccagggtc gcctgacctg cctggtcaaa	1260
ggctttctatc caagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac	1320
tacaagacca cgctcccgt gctggactcc gacggctcct tcttctctca cagcaagctc	1380
a	1381

<210> 52
 <211> 493
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> CD37 specific binding protein

<400> 52

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu
130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
 260 265 270

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 275 280 285

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 290 295 300

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 305 310 315 320

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 325 330 335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln

	420		425		430										
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly
		435					440					445			
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln
	450					455					460				
Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn
465					470					475					480
His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys			
				485					490						

<210> 53
 <400> 53
 000

<210> 54
 <400> 54
 000

<210> 55
 <400> 55
 000

<210> 56
 <400> 56
 000

<210> 57
 <400> 57
 000

<210> 58
 <400> 58
 000

<210> 59
 <400> 59
 000

<210> 60

<400> 60
000

<210> 61
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 61

Arg Ala Ser Glu Asn Val Tyr Ser Tyr Leu Ala
1 5 10

<210> 62
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 62

Arg Thr Ser Glu Asn Val Tyr Ser Tyr Leu Ala
1 5 10

<210> 63
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 63

Gly Tyr Asn Met Asn
1 5

<210> 64
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 64

Phe Ala Lys Thr Leu Ala Glu
1 5

<210> 65

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 65

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
1 5 10 15

Gly

<210> 66

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 66

Gln His His Ser Asp Asn Pro Trp Thr
1 5

<210> 67

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 67

Ser Val Gly Pro Phe Asp Tyr
1 5

<210> 68

<211> 7

<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 68

Ser Val Gly Pro Phe Asp Ser
1 5

<210> 69
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 69

Ser Val Gly Pro Met Asp Tyr
1 5

<210> 70
<400> 70
000

<210> 71
<400> 71
000

<210> 72
<400> 72
000

<210> 73
<400> 73
000

<210> 74
<400> 74
000

<210> 75
<400> 75
000

<210> 76
<400> 76
000

<210> 77
 <400> 77
 000

<210> 78
 <400> 78
 000

<210> 79
 <211> 1500
 <212> DNA
 <213> Artificial sequence

<220>
 <223> CD37 specific binding protein

<400> 79
 aagcttgccg ccatggaagc cccagcgcag cttctcttcc tcctgctact ctggctccca 60
 gataccaccg gagaaattgt gttgacacag tctccagcca ccctgtcttt gtctccaggc 120
 gaaagagcca ccctctcctg ccgagcaagt gaaaatgttt acagctactt agcctggtac 180
 caacagaaaac ctggccaggc toctaggctc ctcatctatt ttgcaaaaac cttagcagaa 240
 ggaattccag ccaggttcag tggcagtggg tccgggacag acttcactct caccatcagc 300
 agcctagagc ctgaagattt tgcagtttat tactgtcaac atcattccga taatccgtgg 360
 acattcggcc aagggaccaa ggtggaaatc aaaggtggcg gtggctcggg cggtggtgga 420
 tctggaggag gtgggaccgg tgaggtgcag ctggtgcagt ctggagcaga ggtgaaaaag 480
 cccggagagt ctctgaagat ttctgttaag ggatccggtt actcattcac tggctacaat 540
 atgaactggg tgcgccagat gcccgggaaa ggcctcgagt ggatgggcaa tattgatcct 600
 tattatggtg gtactaccta caaccggaag ttcaagggcc aggtcactat ctccgcgcag 660
 aagtccatca gcaccgccta cctgcaatgg agcagcctga aggcctcgga caccgccatg 720
 tattactgtg cacgctcagt cggccctttc gacctctggg gcagaggcac cctgggtcact 780
 gtctcctctg atcaggagcc caaatcttct gacaaaactc acacatctcc accgtgcccc 840
 gcacctgaac tcctgggtgg accgtcagtc ttctcttcc ccccaaaacc caaggacacc 900
 ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac 960
 cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag 1020
 ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac 1080

caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc 1140
 cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc 1200
 ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctgggtcaaa 1260
 ggctttctatc caagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac 1320
 tacaagacca cgcctcccgt gctggactcc gacggctcct tcttctctta cagcaagctc 1380
 accgtggaca agagcaggtg gcagcagggg aacgtttctt catgctccgt gatgcatgag 1440
 gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa atgatctaga 1500

<210> 80
 <211> 493
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> CD37 specific binding protein
 <400> 80

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
 100 105 110

Asp	Asn	Pro	Trp	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly
		115					120					125			
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Thr	Gly	Glu
	130					135					140				
Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Glu	Ser
145					150					155					160
Leu	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Asn
				165					170					175	
Met	Asn	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly
			180					185					190		
Asn	Ile	Asp	Pro	Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys
		195					200					205			
Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu
	210					215					220				
Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala
225					230					235					240
Arg	Ser	Val	Gly	Pro	Phe	Asp	Leu	Trp	Gly	Arg	Gly	Thr	Leu	Val	Thr
				245					250					255	
Val	Ser	Ser	Asp	Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser
			260					265					270		
Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu
		275					280					285			
Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu
	290					295					300				
Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys
305					310					315					320
Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys
				325					330					335	

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 420 425 430

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 435 440 445

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 450 455 460

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 81

<211> 1494

<212> DNA

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 81

aagcttgccg ccatggaagc cccagctcag cttctcttcc tctgtctact ctggctccca 60

gataccaccg gagaaattgt gttgacacag tctccagcca ccctgtcttt gtctccaggc 120

gaaagagcca ccctctcctg ccgagcaagt gaaaatgttt acagctactt agcctggtac	180
caacagaaac ctggccaggc tcctaggctc ctcatctatt ttgcaaaaac cttagcagaa	240
ggaattccag ccaggttcag tggcagtgga tccgggacag acttcactct caccatcagc	300
agcctagagc ctgaagatfff tgcagtttat tactgtcaac atcattccga taatccgtgg	360
acattcggcc aagggaccaa ggtggaaatc aaaggtggcg gtggctcggg cgggtggtgga	420
tctggaggag gtggggctag cgaggtgcag ctggtgcagt ctggagcaga ggtgaaaaag	480
cccggagagt ctctgaagat ttctgttaag ggatccggtt actcattcac tagctacaat	540
atgaactggg tgcgccagat gcccgggaaa ggcctggagt ggatgggcaa tattgatcct	600
tattatggtg gtactaacta cgcccagaag ttccagggcc aggtcactat ctccgccgac	660
aagtccatca gcaccgccta cctgcaatgg agcagcctga aggcctcgga caccgccatg	720
tattactgtg cacgctcagt cggccctatg gactactggg gccgcggcac cctggtcact	780
gtctcctctg atcaggagcc caaatcttct gacaaaactc acacatctcc accgtgcca	840
gcacctgaac tcctgggtgg accgtcagtc ttctcttcc ccccaaaacc caaggacacc	900
ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac	960
cctgagggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag	1020
ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac	1080
caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc	1140
cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc	1200
ctgcccccat cccgggatga gctgaccaag aaccagggtca gcctgacctg cctggtcaaa	1260
ggcttctatc caagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac	1320
tacaagacca cgctcccggt gctggactcc gacggctcct tcttctctta cagcaagctc	1380
accgtggaca agagcagggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag	1440
gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa atga	1494

<210> 82
 <211> 493
 <212> PRT
 <213> Artificial sequence

 <220>

<223> CD37 specific binding protein

<400> 82

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Glu
130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr Asn
165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln
195 200 205

Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	210	215	220	
Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	225	230	235	240
Arg	Ser	Val	Gly	Pro	Met	Asp	Tyr	Trp	Gly	Arg	Gly	Thr	Leu	Val	Thr	245	250	255	
Val	Ser	Ser	Asp	Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	260	265	270	
Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	275	280	285	
Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	290	295	300	
Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	305	310	315	320
Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	325	330	335	
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	340	345	350	
Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	355	360	365	
Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	370	375	380	
Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	385	390	395	400
Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	405	410	415	

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
420 425 430

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
435 440 445

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
450 455 460

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490

<210> 83
<211> 1476
<212> DNA
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 83
aagcttgccg ccatggaagc cccagcgcag cttctcttcc tcctgctact ctggctccca 60
gataccaccg gagaaattgt gttgacacag tctccagcca ccctgtcttt gtctccaggc 120
gaaagagcca ccctctcctg ccgagcaagt gagaatgttt acagctactt agcctggtac 180
caacagaaaac ctggccaggc tcttaggctc ctcacttatt ttgcaaaaac cttagcagaa 240
gggattccag ccagattcag tggcagtggt tccgggacag acttcactct caccatcagc 300
agcctagagc ctgaagattt tgcagtttat tactgtcaac atcattccga taatccgtgg 360
acattcggcc aagggaccaa ggtggaaatc aaagggtggc gtggctcggg cggtggtgga 420
tctggaggag gtgggagcgg aggaggagct agcgaggtgc agctggtgca gtctggagca 480
gaggtgaaaa agcccggaga gtctctgaag atttcctgta agggatccgg ttactcattc 540
actggctaca atatgaactg ggtgcgccag atgcccggga aaggcctcga atggatgggc 600
aatattgate cttattatgg tgggtactacc tacaaccgga agttcaaggg ccaggtcact 660
atctccgccg acaagtccat cagcaccgcc tacctgcaag gagcagcctg aaggcctcgg 720
acaccgccat gtattactgt gcacgctcag tcggcccttt cgactcctgg ggccagggca 780

ccctggtcac tgtctcgagt tgtccaccgt gccagcacc tgaactcctg ggtggaccgt 840
 cagtcttcct cttcccccca aaaccaagg acaccctcat gatctcccg acccctgagg 900
 tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc aactggtacg 960
 tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag tacaacagca 1020
 cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat ggcaaggagt 1080
 acaagtgcaa ggtctccaac aaagccctcc cagcccccac cgagaaaacc atctccaaag 1140
 ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccg gatgagctga 1200
 ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatccaagc gacatcgccg 1260
 tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct cccgtgctgg 1320
 actccgacgg ctcttcttct ctctacagca agctcaccgt ggacaagagc aggtggcagc 1380
 aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac tacacgcaga 1440
 agagcctctc cctgtctccg ggtaaatagac tctaga 1476

<210> 84

<211> 485

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 84

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn
 35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65 70 75 80

Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	85	90	95	
Ser	Leu	Glu	Pro	Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	His	His	Ser	100	105	110	
Asp	Asn	Pro	Trp	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly	115	120	125	
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	130	135	140	
Gly	Ala	Ser	Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	145	150	155	160
Pro	Gly	Glu	Ser	Leu	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	165	170	175	
Thr	Gly	Tyr	Asn	Met	Asn	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	180	185	190	
Glu	Trp	Met	Gly	Asn	Ile	Asp	Pro	Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	195	200	205	
Arg	Lys	Phe	Lys	Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	210	215	220	
Thr	Ala	Tyr	Leu	Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	225	230	235	240
Tyr	Tyr	Cys	Ala	Arg	Ser	Val	Gly	Pro	Phe	Asp	Ser	Trp	Gly	Gln	Gly	245	250	255	
Thr	Leu	Val	Thr	Val	Ser	Ser	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	260	265	270	
Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	275	280	285	

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 290 295 300

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 305 310 315 320

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 325 330 335

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 340 345 350

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 355 360 365

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 370 375 380

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 385 390 395 400

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 405 410 415

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 420 425 430

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 435 440 445

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 450 455 460

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 465 470 475 480

Leu Ser Pro Gly Lys
 485

<210> 85
 <211> 1494

<212> DNA
 <213> Artificial sequence
 <220>
 <223> CD37 specific binding protein

<400> 85
 aagcttgccg ccatggaagc cccagctcag cttctcttcc tctgctact ctggctccca 60
 gataccaccg gagaaattgt gttgacacag tctccagcca ccctgtcttt gtctccaggc 120
 gaaagagcca ccctctcctg ccgaacaagt gaaaatgttt acagctactt agcctggtac 180
 caacagaaaac ctggccaggc tcttaggtct ctcattctatt ttgcaaaaac cttagcagaa 240
 ggaattccag ccagggttcag tggcagtgga tccgggacag acttcactct caccatcagc 300
 agcctagagc ctgaagatct tgcagtttat tactgtcaac atcattccga taatccgtgg 360
 acattcggcc aagggaacca ggtggaaatc aaaggtggcg gtggctcggg cgggtggtgga 420
 tctggaggag gtgggaccgg tgaggtgcag ctggtgcagt ctggagcaga ggtgaaaaag 480
 cccggagagt ctctgaagat ttctgtgaag ggatccggtt actcattcac tggctacaat 540
 atgaactggg tgcgccagat gcccgggaaa ggcctggagt ggatgggcaa tattgatcct 600
 tattatggtg gtactaccta caaccggaag ttcaagggcc aggtcactat ctccgccgac 660
 aagtccatca gcaccgccta cctgcaatgg agcagcctga aggcctcgga caccgccatg 720
 tattactgtg caagctcagt cggccctatg gactactggg gccgcggcac cctggtcact 780
 gtctcctctg atcaggagcc caaatcttct gacaaaactc acacatctcc accgtgcccc 840
 gcacctgaac tcttgggtgg accgtcagtc ttctcttcc ccccaaaacc caaggacacc 900
 ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac 960
 cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag 1020
 ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac 1080
 caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc 1140
 cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc 1200
 ctgcccccat cccgggatga gctgaccaag aaccagggtc gcctgacctg cctggtcaaa 1260
 ggcttctatc caagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac 1320
 tacaagacca cgctcccggt gctggactcc gacggctcct tcttctcta cagcaagctc 1380
 accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag 1440

gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa atga

1494

<210> 86

<211> 493

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 86

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn
35 40 45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60

Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100 105 110

Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Glu
130 135 140

Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
145 150 155 160

Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
 165 170 175

Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
 180 185 190

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195 200 205

Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
 210 215 220

Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
 225 230 235 240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
 245 250 255

Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
 260 265 270

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 275 280 285

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 290 295 300

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 305 310 315 320

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 325 330 335

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 340 345 350

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 355 360 365

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 370 375 380

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
385 390 395 400

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
405 410 415

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
420 425 430

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
435 440 445

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
450 455 460

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490

<210> 87
<211> 1494
<212> DNA
<213> Artificial sequence

<220>
<223> CD37 specific binding protein

<400> 87
aagcttgccg ccattggaagc cccagctcag cttctcttcc tctgctact ctggctccca 60
gataccaccg gtgaaattgt gttgacacag tctccagcca ccctgtcttt gtctccaggc 120
gaaagagcca ccctctcctg ccgaacaagt gaaaatgttt acagctactt agcctggtag 180
caacagaaac ctggccaggc tctaggctc ctcatttatt ttgcaaaaac cttagcagaa 240
ggaattccag ccagggttcag tggcagtgga tccgggacag acttcactct caccatcagc 300
agcctagagc ctgaagattt tgcagtttat tactgtcaac atcattccga taatccgtgg 360
acattcgggc aagggaacaa ggtggaaatc aaaggtggcg gtggctcggg cgggtggtgga 420
tctggaggag gtggggctag cgaggtgcag ctggtgcagt ctggagcaga ggtgaaaaag 480

```

cccggagagt ctctgaggat ttctgtgaag ggatccgggtt actcattcac tggctacaat 540
atgaactggg tgcgccagat gcccgggaaa ggcctggagt ggatgggcaa tattgatcct 600
tattatggtg gtactaccta caaccggaag ttcaagggcc aggtcactat ctccgccgac 660
aagtccatca gcaccgccta cctgcaatgg agcagcctga aggcctcgga caccgccatg 720
tattactgtg cacgctcagt cggccctatg gactactggg gccgcggcac cctggtcact 780
gtctcctctg atcaggagcc caaatcttct gacaaaactc acacatctcc accgtgcca 840
gcacctgaac tcctgggttg accgtcagtc ttctcttcc cccaaaacc caaggacacc 900
ctcatgatct cccggacccc tgaggtcaca tgcgtgggtg tggacgtgag ccacgaagac 960
cctgaggcca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag 1020
ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac 1080
caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc 1140
cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc 1200
ctgcccccat cccgggatga gctgaccaag aaccaggcca gctgacctg cctgggtcaaa 1260
ggcttctatc caagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac 1320
tacaagacca cgctcccggt gctggactcc gacggctcct tcttctctta cagcaagctc 1380
accgtggaca agagcagggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag 1440
gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa atga 1494

```

<210> 88

<211> 493

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 88

```

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1           5           10           15

```

```

Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
          20           25           30

```

Leu	Ser	Pro	Gly	Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Thr	Ser	Glu	Asn
		35					40					45			
Val	Tyr	Ser	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro
	50					55					60				
Arg	Leu	Leu	Ile	Tyr	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Ile	Pro	Ala
65					70					75					80
Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser
				85					90					95	
Ser	Leu	Glu	Pro	Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	His	His	Ser
			100						105				110		
Asp	Asn	Pro	Trp	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly
		115					120					125			
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ala	Ser	Glu
	130						135					140			
Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Glu	Ser
145					150					155					160
Leu	Arg	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Asn
				165					170					175	
Met	Asn	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly
			180					185					190		
Asn	Ile	Asp	Pro	Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys
		195					200					205			
Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu
	210						215				220				
Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala
225					230					235					240
Arg	Ser	Val	Gly	Pro	Met	Asp	Tyr	Trp	Gly	Arg	Gly	Thr	Leu	Val	Thr
				245					250					255	

Val	Ser	Ser	Asp	Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser
			260					265					270		
Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu
		275					280					285			
Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu
	290					295					300				
Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys
305					310					315					320
Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys
				325						330				335	
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu
			340					345					350		
Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys
		355					360					365			
Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys
	370					375					380				
Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser
385					390					395					400
Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys
				405					410					415	
Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln
			420					425					430		
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly
		435					440					445			
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln
	450					455					460				

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 465 470 475 480

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 89
 <211> 45
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 89
 gagcccaaatt cttgtgacaa aactcacaca tgtccaccgt gccca 45

<210> 90
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 90

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
 1 5 10 15

<210> 91
 <211> 45
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 91
 gagcccaaatt cttctgacaa aactcacaca tgtccaccgt gccca 45

<210> 92
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 92

Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro
1				5					10					15

<210> 93

<211> 45

<212> DNA

<213> Artificial sequence

<220>

<223> Hinge region

<400> 93

gagcccaaatt cttctgacaa aactcacaca tgtccaccgt gctca

45

<210> 94

<211> 15

<212> PRT

<213> Artificial sequence

<220>

<223> Hinge region

<400> 94

Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Ser
1				5					10					15

<210> 95

<211> 45

<212> DNA

<213> Artificial sequence

<220>

<223> Hinge region

<400> 95

gagcccaaatt cttgtgacaa aactcacaca tgtccaccga gctca

45

<210> 96

<211> 15

<212> PRT

<213> Artificial sequence

<220>

<223> Hinge region

<400> 96

Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Ser Ser
 1 5 10 15

<210> 97
 <211> 45
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 97
 gagcccaaatt cttctgacaa aactcacaca tctccaccga gccca 45

<210> 98
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 98

Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro
 1 5 10 15

<210> 99
 <211> 45
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 99
 gagcccaaatt cttctgacaa aactcacaca tctccaccga gctca 45

<210> 100
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 100

Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Ser
 1 5 10 15

<210> 101
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 101
gagcccaaatt cttgtgacaa aactcacaca tctccaccgt gccca

45

<210> 102
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 102

Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Pro
1				5					10				15	

<210> 103
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 103
gagcccaaatt cttgtgacaa aactcacaca tctccaccgt gctca

45

<210> 104
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 104

Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Ser
1				5					10				15	

<210> 105
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 105
gagcccaaat cttctgacaa aactcacaca tctccaccgt gccca

45

<210> 106
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 106

Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Pro
1				5					10				15	

<210> 107
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 107
gagcccaaat cttctgacaa aactcacaca tctccaccgt gctca

45

<210> 108
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 108

Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Ser
1				5					10				15	

<210> 109
<211> 45

<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 109
gagcccaaatt cttgtgacaa aactcacaca tctccaccga gccca

45

<210> 110
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 110

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser Pro
1 5 10 15

<210> 111
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 111
gagcccaaatt cttgtgacaa aactcacaca tctccaccga gctca

45

<210> 112
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 112

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser Ser
1 5 10 15

<210> 113
<400> 113
000

<210> 114
 <400> 114
 000

<210> 115
 <211> 19
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 115

Val	Pro	Ser	Thr	Pro	Pro	Thr	Pro	Ser	Pro	Ser	Thr	Pro	Pro	Thr	Pro
1				5					10					15	

Ser Pro Ser

<210> 116
 <211> 6
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 116

Val	Pro	Pro	Pro	Pro	Pro
1				5	

<210> 117
 <211> 186
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 117	
gagctcaaaa ctctctcgg ggatacgacc catacgtgtc cccgctgtcc tgaaccgaag	60
tcttgcgata cgctccgcc atgtccacgg tgcccagagc ccaaatacatg cgatacgccc	120
ccaccgtgtc cccgctgtcc tgaaccaaag tcatgcgata cccaccacc atgtccaaga	180
tgccca	186

<210> 118
 <211> 62
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 118

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys
 1 5 10 15

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
 20 25 30

Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu
 35 40 45

Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
 50 55 60

<210> 119
 <211> 45
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 119
 gagcccaaat cttctgacac acctccccca tgcccacggt gcccc

45

<210> 120
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Hinge region

<400> 120

Glu Pro Lys Ser Ser Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
 1 5 10 15

<210> 121
 <211> 45

<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 121
gagcccaaat cttgtgacac acctccccca tccccacggt cccca

45

<210> 122
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 122

Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Ser Pro Arg Ser Pro
1 5 10 15

<210> 123
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 123
gagcccaaat cttctgacac acctccccca tccccacggt cccca

45

<210> 124
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 124

Glu Pro Lys Ser Ser Asp Thr Pro Pro Pro Ser Pro Arg Ser Pro
1 5 10 15

<210> 125
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Hinge region

<400> 125
gagcccaaatt cttgtgacac acctccccca tccccacggt gccca

45

<210> 126
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 126

Glu	Pro	Lys	Ser	Cys	Asp	Thr	Pro	Pro	Pro	Ser	Pro	Arg	Cys	Pro
1			5					10					15	

<210> 127
<211> 58
<212> PRT
<213> Artificial sequence

<220>
<223> Hinge region

<400> 127

Glu	Ser	Pro	Lys	Ala	Gln	Ala	Ser	Ser	Val	Pro	Thr	Ala	Gln	Pro	Gln
1			5					10					15		

Ala	Glu	Gly	Ser	Leu	Ala	Lys	Ala	Thr	Thr	Ala	Pro	Ala	Thr	Thr	Arg
			20				25						30		

Asn	Thr	Gly	Arg	Gly	Gly	Glu	Glu	Lys	Lys	Lys	Glu	Lys	Glu	Lys	Glu
		35				40					45				

Glu	Gln	Glu	Glu	Arg	Glu	Thr	Lys	Thr	Pro
	50				55				

<210> 128
<211> 11
<212> PRT
<213> Artificial sequence

<220>

<223> CDR

<400> 128

Arg Thr Ser Gln Asn Val Tyr Ser Tyr Leu Ala
1 5 10

<210> 129

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 129

Arg Thr Ser Glu Ser Val Tyr Ser Tyr Leu Ala
1 5 10

<210> 130

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 130

Arg Ala Ser Gln Ser Val Tyr Ser Tyr Leu Ala
1 5 10

<210> 131

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 131

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10

<210> 132

<211> 11

<212> PRT

<213> Artificial sequence

<220>
<223> CDR

<400> 132

Arg Ala Ser Gln Ser Val Ser Tyr Tyr Leu Ala
1 5 10

<210> 133
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 133

Ser Tyr Met Asn Met
1 5

<210> 134
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 134

Ser Tyr Trp Ile Gly
1 5

<210> 135
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 135

Ala Ala Ser Ser Leu Gln Ser
1 5

<210> 136
<211> 7

<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 136

Gly Ala Ser Thr Arg Ala Thr
1 5

<210> 137
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 137

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 138
<211> 17
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 138

Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15

Gly

<210> 139
<211> 17
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 139

Arg Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe Gln
 1 5 10 15

Gly

<210> 140
 <211> 30
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 140

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 20 25 30

<210> 141
 <211> 30
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 141

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser
 20 25 30

<210> 142
 <211> 30
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 142

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser
 20 25 30

<210> 143
 <211> 30
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 143

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Thr Val Lys Ile Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr
 20 25 30

<210> 144
 <211> 30
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 144

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr
 20 25 30

<210> 145
 <211> 30
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 145

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15

Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr
 20 25 30

<210> 146
 <211> 30
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 146

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 20 25 30

<210> 147
 <211> 14
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 147

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly
 1 5 10

<210> 148
 <400> 148
 000

<210> 149
 <400> 149
 000

<210> 150
 <211> 14
 <212> PRT
 <213> Artificial sequence

<220>
<223> Framework region

<400> 150

Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly
1 5 10

<210> 151
<211> 14
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 151

Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
1 5 10

<210> 152
<400> 152
000

<210> 153
<400> 153
000

<210> 154
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 154

Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu
1 5 10 15

Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 155
<211> 32
<212> PRT
<213> Artificial sequence

<220>
 <223> Framework region

 <400> 155

 Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu
 1 5 10 15

 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

 <210> 156
 <211> 32
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> Framework region

 <400> 156

 Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu
 1 5 10 15

 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

 <210> 157
 <211> 32
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> Framework region

 <400> 157

 Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu
 1 5 10 15

 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr
 20 25 30

 <210> 158
 <211> 32
 <212> PRT
 <213> Artificial sequence

<220>
<223> Framework region

<400> 158

Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	Gln
1				5					10					15	

Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg
			20					25					30		

<210> 159
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 159

His	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	Gln
1				5					10					15	

Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg
			20					25					30		

<210> 160
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 160

Arg	Phe	Val	Phe	Ser	Leu	Asp	Thr	Ser	Val	Ser	Thr	Ala	Tyr	Leu	Gln
1				5					10					15	

Ile	Ser	Ser	Leu	Lys	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg
			20					25					30		

<210> 161
<211> 11
<212> PRT
<213> Artificial sequence

<220>
 <223> Framework region

 <400> 161

 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1 5 10

<210> 162
 <211> 11
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

 <400> 162

 Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser
 1 5 10

<210> 163
 <211> 11
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

 <400> 163

 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 1 5 10

<210> 164
 <400> 164
 000

<210> 165
 <400> 165
 000

<210> 166
 <400> 166
 000

<210> 167
 <400> 167
 000

<210> 168
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 168

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
1 5 10

<210> 169
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 169

Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser
1 5 10

<210> 170
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 170

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys
20

<210> 171
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 171

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys
20

<210> 172

<211> 23

<212> PRT

<213> Artificial sequence

<220>

<223> Framework region

<400> 172

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 173

<400> 173

000

<210> 174

<400> 174

000

<210> 175

<211> 23

<212> PRT

<213> Artificial sequence

<220>

<223> Framework region

<400> 175

Asn Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 176
<400> 176
000

<210> 177
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 177

Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 178
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 178

Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 179
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 179

Ala Ile Arg Met Thr Gln Ser Pro Phe Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 180
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 180

Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 181
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 181

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 182
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 182

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr

1	5	10	15
---	---	----	----

<210> 183
 <400> 183
 000

<210> 184
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 184

Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr
1				5					10					15

<210> 185
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 185

Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Val	Pro	Lys	Leu	Leu	Ile	Tyr
1				5					10					15

<210> 186
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Framework region

<400> 186

Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Arg	Leu	Ile	Tyr
1				5					10					15

<210> 187
 <211> 15
 <212> PRT
 <213> Artificial sequence

<220>
<223> Framework region

<400> 187

Trp	Phe	Gln	Gln	Lys	Pro	Gly	Lys	Val	Pro	Lys	His	Leu	Ile	Tyr
1				5					10					15

<210> 188
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 188

Trp	Phe	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Ser	Leu	Ile	Tyr
1				5					10					15

<210> 189
<400> 189
000

<210> 190
<400> 190
000

<210> 191
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 191

Trp	Tyr	Gln	Gln	Lys	Pro	Ala	Lys	Ala	Pro	Lys	Leu	Phe	Ile	Tyr
1				5					10					15

<210> 192
<400> 192
000

<210> 193
<400> 193
000

<210> 194
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 194

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys
20 25 30

<210> 195
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 195

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
20 25 30

<210> 196
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 196

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 197
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 197

Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr
1				5				10						15	

Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Val	Ala	Thr	Tyr	Tyr	Cys
			20					25					30		

<210> 198
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 198

Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe	Thr
1				5				10						15	

Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys
			20					25					30		

<210> 199
<400> 199
000

<210> 200
<400> 200
000

<210> 201
<400> 201
000

<210> 202
<400> 202
000

<210> 203
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 203

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 204
<400> 204
000

<210> 205
<211> 32
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 205

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 206
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 206

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> 207
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 207

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
1 5 10

<210> 208
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 208

Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
1 5 10

<210> 209
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 209

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> 210
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Framework region

<400> 210

Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys

1 5 10

<210> 211
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 211

Ser Val Gly Pro Met Asp Tyr
1 5

<210> 212
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 212

Ser Val Gly Pro Phe Asp Tyr
1 5

<210> 213
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 213

Ser Val Gly Pro Met Asp Val
1 5

<210> 214
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 214

Ser Val Gly Pro Phe Asp Ser
1 5

<210> 215
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 215

Ser Val Gly Pro Phe Asp Pro
1 5

<210> 216
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 216

Ser Val Gly Pro Phe Gln His
1 5

<210> 217
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 217

Ser Val Gly Pro Phe Asp Val
1 5

<210> 218
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> CDR

<400> 218

Ser Val Gly Pro Phe Asp Ile
1 5

<210> 219

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 219

Ser Val Gly Pro Phe Asp Leu
1 5

<210> 220

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> CDR

<400> 220

Gln His His Ser Asp Asn Pro Trp Thr
1 5

<210> 221

<211> 1530

<212> DNA

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 221

aagcttgccg ccatggaagc cccagctcag cttctcttcc tctgctact ctggctccca
60

gataccaccg gagaggtgca gctggtgcag tctggagcag aggtgaaaaa gcccggagag
120

tctctgaaga tttcctgtaa gggctccggt tactcattca ctggctacaa tatgaactgg
180

gtgcgccaga tgcccgggaa aggcctcgag tggatgggca atattgatcc ttattatggc
 240
 ggtactacct acaaccggaa gttcaagggc caggtcacta tctccgccga caagtccatc
 300
 agcaccgcct acctgcaatg gagcagcctg aaggcctcgg acaccgccat gtattactgt
 360
 gcacgctcag tcggcccttt cgactcctgg ggccagggca ccctggtcac tgtctcctct
 420
 ggggggtggag gctctgggtg cggtggctct ggcgagggtg gatccgggtg cggcggatct
 480
 ggcggggggtg gctctgaaat tgtgttgaca cagtctccag ccaccctgtc tttgtctcca
 540
 ggcgaaagag ccaccctctc ctgccgagca agtgaaaatg tttacagcta cttagcctgg
 600
 taccaacaga aacctggcca ggctcctagg ctctcatct attttgcaa aaccttagca
 660
 gaaggaattc cagccagggt cagtggcagt ggctccggga cagacttcac tctcaccatc
 720
 agcagcctag agcctgaaga ttttgcagtt tattactgtc aacatcattc cgataatccg
 780
 tggacattcg gccaaaggac caaggtggaa atcaaagggtg atcaggagcc caaatcttct
 840
 gacaaaactc acacatctcc accgtgcccc gcacctgaac tcctgggtgg accgtcagtc
 900
 ttctctttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
 960
 tgcgtgggtg tggacgtgag ccacgaagac cctgagggtc agttcaactg gtacgtggac
 1020
 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
 1080
 cgtgtgggtc gcgtctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
 1140
 tgcaagggtc ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa
 1200
 gggcagcccc gagaaccaca ggtgtacacc ctgccccat cccgggatga gctgaccaag
 1260

aaccaggtca gcctgacctg cctgggtcaaa ggcttctatc caagcgacat cgccgtggag
1320

tgggagagca atgggcagcc ggagaacaac tacaagacca cgctctccgt gctggactcc
1380

gacggctcct tcttctctta cagcaagctc accgtggaca agagcaggtg gcagcagggg
1440

aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
1500

ctctccctgt ctccgggtaa atgatctaga
1530

<210> 222

<211> 503

<212> PRT

<213> Artificial sequence

<220>

<223> CD37 specific binding protein

<400> 222

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15

Asp Thr Thr Gly Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
20 25 30

Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser
35 40 45

Phe Thr Gly Tyr Asn Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly
50 55 60

Leu Glu Trp Met Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr
65 70 75 80

Asn Arg Lys Phe Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile
85 90 95

Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala
100 105 110

Met Tyr Tyr Cys Ala Arg Ser Val Gly Pro Phe Asp Ser Trp Gly Gln
 115 120 125

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
 130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 145 150 155 160

Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro
 165 170 175

Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Val Tyr Ser
 180 185 190

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 195 200 205

Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser
 210 215 220

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 225 230 235 240

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro
 245 250 255

Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Asp Gln Glu
 260 265 270

Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys Pro Ala Pro
 275 280 285

Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 290 295 300

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 305 310 315 320

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 325 330 335

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
340 345 350

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
355 360 365

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
370 375 380

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
385 390 395 400

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
405 410 415

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
420 425 430

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
435 440 445

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
450 455 460

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
465 470 475 480

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
485 490 495

Leu Ser Leu Ser Pro Gly Lys
500

<210> 223

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Linker sequence

<400> 223

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1 5 10 15
 Val Ile Ile Ala Arg Gly Val
 20

<210> 224
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker sequence

<400> 224
 Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15
 Asp Thr Thr Gly
 20

<210> 225
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker sequence

<400> 225
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
 1 5 10 15

<210> 226
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker sequence

<400> 226
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser
 1 5 10 15

<210> 227
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker sequence

<400> 227
Gly Gly Gly Gly Ser Gly Gly Ser Gly Ser Gly Gly Gly Gly Ala Ser
1 5 10 15

<210> 228
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker sequence

<400> 228
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly
1 5 10 15

<210> 229
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker sequence

<400> 229
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Gly Ser
20 25

<210> 230
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Hinge sequence

<400> 230
Cys Pro Pro Cys Pro
1 5

<210> 231
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Hinge sequence

<400> 231
 Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys Pro
 1 5 10 15

<210> 232
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hinge sequence

<400> 232
 Asp Leu Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys
 1 5 10 15
 Pro

<210> 233
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hinge sequence

<400> 233
 Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys
 1 5 10 15
 Pro

<210> 234
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hinge sequence

<400> 234
 Gly Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro
 1 5 10 15
 Cys Pro

<210> 235
 <211> 18
 <212> PRT

<213> Artificial Sequence

<220>

<223> Hinge sequence

<400> 235

Gly	Ser	Ser	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro
1				5					10					15	
Cys	Pro														

<210> 236

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> variable light chain region

<400> 236

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5					10					15	
Glu	Thr	Val	Thr	Ile	Thr	Cys	Arg	Thr	Ser	Glu	Asn	Val	Tyr	Ser	Tyr
		20						25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Gln	Gly	Lys	Ser	Pro	Gln	Leu	Leu	Val
		35					40					45			
Ser	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50					55					60				
Ser	Gly	Ser	Gly	Thr	Gln	Phe	Ser	Leu	Lys	Ile	Ser	Ser	Leu	Gln	Pro
65					70					75				80	
Glu	Asp	Ser	Gly	Ser	Tyr	Phe	Cys	Gln	His	His	Ser	Asp	Asn	Pro	Trp
				85					90					95	
Thr	Phe	Gly	Gly	Gly	Thr	Glu	Leu	Glu	Ile	Lys					
			100					105							

<210> 237

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> variable light chain region

<400> 237

Glu	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly
1				5					10					15	
Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Thr	Ser	Glu	Asn	Val	Tyr	Ser	Tyr
			20					25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile
		35					40					45			
Tyr	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly
	50					55					60				

```

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65          70          75          80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp
          85          90          95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100          105

```

```

<210> 238
<211> 107
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> variable light chain region

```

```

<400> 238
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1          5          10          15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Val Tyr Ser Tyr
          20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
          35          40          45
Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65          70          75          80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp
          85          90          95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100          105

```

```

<210> 239
<211> 107
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> variable light chain region

```

```

<400> 239
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1          5          10          15
Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Gln Asn Val Tyr Ser Tyr
          20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
          35          40          45
Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65          70          75          80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp
          85          90          95

```

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 240
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> variable light chain region

<400> 240
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Ser Val Tyr Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Asp Asn Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 241
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> variable heavy chain region

<400> 241
Ala Val Gln Leu Gln Gln Ser Gly Pro Glu Ser Glu Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30
Asn Met Asn Trp Val Lys Gln Asn Asn Gly Lys Ser Leu Glu Trp Ile
35 40 45
Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
100 105 110
Thr Val Ser Ser
115

<210> 242
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> variable heavy chain region

<400> 242
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30
 Asn Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe
 50 55 60
 Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 243
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> variable heavy chain region

<400> 243
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30
 Asn Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe
 50 55 60
 Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Val Gly Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 244
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> variable heavy chain region

<400> 244
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30
 Asn Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe
 50 55 60
 Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Val Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 245
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> variable heavy chain region

<400> 245
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30
 Asn Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe
 50 55 60
 Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Val Gly Pro Phe Asp Ser Trp Gly Gln Gly Thr Leu Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 246
 <211> 217
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> human IgG1 CH2 and CH3 regions

<400> 246
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 1 5 10 15
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 20 25 30
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 35 40 45
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 50 55 60
 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 65 70 75 80
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 85 90 95
 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 100 105 110
 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
 115 120 125
 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 130 135 140
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 145 150 155 160
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 165 170 175
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 180 185 190
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 195 200 205
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 210 215

<210> 247
 <211> 473
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD37 specific binding protein

<400> 247
 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Tyr
 20 25 30

Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Gln	Gly	Lys	Ser	Pro	Gln	Leu	Leu	Val
	35						40					45			
Ser	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50					55					60				
Ser	Gly	Ser	Gly	Thr	Gln	Phe	Ser	Leu	Lys	Ile	Ser	Ser	Leu	Gln	Pro
65					70					75					80
Glu	Asp	Ser	Gly	Ser	Tyr	Phe	Cys	Gln	His	His	Ser	Asp	Asn	Pro	Trp
				85					90					95	
Thr	Phe	Gly	Gly	Gly	Thr	Glu	Leu	Glu	Ile	Lys	Gly	Gly	Gly	Gly	Ser
			100					105					110		
Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	Ala	Val	Gln	Leu	Gln
	115						120					125			
Gln	Ser	Gly	Pro	Glu	Ser	Glu	Lys	Pro	Gly	Ala	Ser	Val	Lys	Ile	Ser
	130					135					140				
Cys	Lys	Ala	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Asn	Met	Asn	Trp	Val
145					150					155					160
Lys	Gln	Asn	Asn	Gly	Lys	Ser	Leu	Glu	Trp	Ile	Gly	Asn	Ile	Asp	Pro
				165					170					175	
Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys	Gly	Lys	Ala	Thr
			180					185					190		
Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	Met	Gln	Leu	Lys	Ser
	195						200					205			
Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Ser	Val	Gly
	210					215					220				
Pro	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Asp
225					230					235					240
Leu	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Pro
				245					250					255	
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys
			260				265						270		
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val
		275					280					285			
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr
	290					295					300				
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu
305					310					315					320
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His
				325					330					335	
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys
			340					345					350		
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln
	355						360					365			
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu
	370					375					380				
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro
385					390					395					400
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn
				405					410					415	
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu
			420					425					430		
Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val
		435					440					445			
Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln
	450					455					460				

Lys Ser Leu Ser Leu Ser Pro Gly Lys
 465 470

<210> 248

<211> 473

<212> PRT

<213> Artificial Sequence

<220>

<223> CD37 specific binding protein

<400> 248

Glu	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly
1				5					10					15	
Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Thr	Ser	Glu	Asn	Val	Tyr	Ser	Tyr
			20					25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile
		35				40					45				
Tyr	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly
	50					55					60				
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro
65					70					75					80
Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	His	His	Ser	Asp	Asn	Pro	Trp
				85					90					95	
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly	Gly	Gly	Gly	Ser
			100					105					110		
Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Thr	Gly	Glu	Val	Gln	Leu	Val
			115				120					125			
Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Glu	Ser	Leu	Lys	Ile	Ser
			130				135					140			
Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Asn	Met	Asn	Trp	Val
145					150					155					160
Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly	Asn	Ile	Asp	Pro
				165					170					175	
Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys	Gly	Gln	Val	Thr
			180					185					190		
Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	Gln	Trp	Ser	Ser
			195				200					205			
Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg	Ser	Val	Gly
			210				215				220				
Pro	Met	Asp	Tyr	Trp	Gly	Arg	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Asp
225					230					235					240
Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Pro
				245					250					255	
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys
			260					265					270		
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val
		275					280					285			
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr
		290				295					300				
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu
305					310					315					320
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His

```

          325          330          335
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
          340          345          350
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
          355          360          365
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
          370          375          380
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
385          390          395          400
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
          405          410          415
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
          420          425          430
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
          435          440          445
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
          450          455          460
Lys Ser Leu Ser Leu Ser Pro Gly Lys
465          470

```

<210> 249

<211> 473

<212> PRT

<213> Artificial Sequence

<220>

<223> CD37 specific binding protein

<400> 249

```

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1          5          10          15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Val Tyr Ser Tyr
          20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
          35          40          45
Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65          70          75          80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp
          85          90          95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser
          100          105          110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu Val Gln Leu Val
          115          120          125
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser
          130          135          140
Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn Met Asn Trp Val
145          150          155          160
Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asn Ile Asp Pro
          165          170          175
Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys Gly Gln Val Thr
          180          185          190

```

Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser
 195 200 205
 Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser Val Gly
 210 215 220
 Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Asp
 225 230 235 240
 Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys Pro
 245 250 255
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 260 265 270
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 275 280 285
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 290 295 300
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 305 310 315 320
 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 325 330 335
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 340 345 350
 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 355 360 365
 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
 370 375 380
 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 385 390 395 400
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 405 410 415
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 420 425 430
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 435 440 445
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 450 455 460
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 465 470

<210> 250

<211> 473

<212> PRT

<213> Artificial Sequence

<220>

<223> CD37 specific binding protein

<400> 250

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Val Tyr Ser Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly

50		55		60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro				
65		70		75
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp				
	85		90	
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser				
	100		105	
Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu Val Gln Leu Val				
	115		120	
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser				
	130		135	
Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn Met Asn Trp Val				
	145		150	
Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asn Ile Asp Pro				
	165		170	
Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys Gly Gln Val Thr				
	180		185	
Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser				
	195		200	
Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser Val Gly				
	210		215	
Pro Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Asp				
	225		230	
Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys Pro				
	245		250	
Ala Pro Glu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys				
	260		265	
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val				
	275		280	
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr				
	290		295	
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu				
	305		310	
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His				
	325		330	
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys				
	340		345	
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln				
	355		360	
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu				
	370		375	
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro				
	385		390	
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn				
	405		410	
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu				
	420		425	
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val				
	435		440	
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln				
	450		455	
Lys Ser Leu Ser Leu Ser Pro Gly Lys			460	
465		470		

<210> 251
 <211> 480
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD37 specific binding protein

<400> 251
 Ala Val Gln Leu Gln Gln Ser Gly Pro Glu Ser Glu Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30
 Asn Met Asn Trp Val Lys Gln Asn Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
 100 105 110
 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly
 115 120 125
 Gly Gly Ser Gly Gly Gly Gly Ser Ala Ser Glu Ile Val Leu Thr Gln
 130 135 140
 Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
 145 150 155 160
 Cys Arg Thr Ser Glu Asn Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln
 165 170 175
 Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu
 180 185 190
 Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
 195 200 205
 Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr
 210 215 220
 Tyr Cys Gln His His Ser Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr
 225 230 235 240
 Lys Val Glu Ile Lys Gly Ser Ser Glu Pro Lys Ser Ser Asp Lys Thr
 245 250 255
 His Thr Ser Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 260 265 270
 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 275 280 285
 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 290 295 300
 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 305 310 315 320
 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 325 330 335
 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 340 345 350

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
 355 360 365
 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 370 375 380
 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
 385 390 395 400
 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 405 410 415
 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 420 425 430
 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
 435 440 445
 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 450 455 460
 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 465 470 475 480

<210> 252

<211> 472

<212> PRT

<213> Artificial Sequence

<220>

<223> CD37 specific binding protein

<400> 252

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Glu Asn Val Tyr Ser Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser
 100 105 110
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Ala Val Gln Leu Gln
 115 120 125
 Gln Ser Gly Pro Glu Ser Glu Lys Pro Gly Ala Ser Val Lys Ile Ser
 130 135 140
 Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Asn Met Asn Trp Val
 145 150 155 160
 Lys Gln Asn Asn Gly Lys Ser Leu Glu Trp Ile Gly Asn Ile Asp Pro
 165 170 175
 Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys Gly Lys Ala Thr
 180 185 190
 Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser
 195 200 205
 Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Val Gly

210	215	220
Pro Met Asp Tyr Trp	Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ser	
225	230	235
Glu Pro Lys Ser Ser	Asp Lys Thr His Thr Ser Pro Pro Cys Pro Ala	240
	245	250
Pro Glu Leu Leu Gly Gly	Pro Ser Val Phe Leu Phe Pro Pro Lys Pro	255
	260	265
Lys Asp Thr Leu Met Ile Ser	Arg Thr Pro Glu Val Thr Cys Val Val	270
	275	280
Val Asp Val Ser His Glu Asp	Pro Glu Val Lys Phe Asn Trp Tyr Val	285
	290	295
Asp Gly Val Glu Val His Asn	Ala Lys Thr Lys Pro Arg Glu Glu Gln	300
305	310	315
Tyr Asn Ser Thr Tyr Arg	Val Val Ser Val Leu Thr Val Leu His Gln	320
	325	330
Asp Trp Leu Asn Gly Lys Glu Tyr	Lys Cys Lys Val Ser Asn Lys Ala	335
	340	345
Leu Pro Ala Pro Ile Glu Lys Thr	Ile Ser Lys Ala Lys Gly Gln Pro	350
	355	360
Arg Glu Pro Gln Val Tyr Thr	Leu Pro Pro Ser Arg Asp Glu Leu Thr	365
	370	375
Lys Asn Gln Val Ser Leu Thr Cys	Leu Val Lys Gly Phe Tyr Pro Ser	380
385	390	395
Asp Ile Ala Val Glu Trp Glu Ser	Asn Gly Gln Pro Glu Asn Asn Tyr	400
	405	410
Lys Thr Thr Pro Pro Val Leu Asp	Ser Asp Gly Ser Phe Phe Leu Tyr	415
	420	425
Ser Lys Leu Thr Val Asp Lys Ser	Arg Trp Gln Gln Gly Asn Val Phe	430
	435	440
Ser Cys Ser Val Met His Glu Ala	Leu His Asn His Tyr Thr Gln Lys	445
	450	455
Ser Leu Ser Leu Ser Pro Gly Lys		460
465	470	

<210> 253

<211> 483

<212> PRT

<213> Artificial Sequence

<220>

<223> CD37 specific binding protein

<400> 253

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu	
1	5
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr	10
	15
	20
Asn Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met	25
	30
	35
Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe	40
	45
	50
Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr	55
	60
65	70
	75
	80

Leu	Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	
				85					90					95		
Ala	Arg	Ser	Val	Gly	Pro	Phe	Asp	Ser	Trp	Gly	Gln	Gly	Thr	Leu	Val	
			100					105					110			
Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	
		115					120					125				
Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Glu	Ile	Val	
	130					135					140					
Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly	Glu	Arg	Ala	
145					150					155					160	
Thr	Leu	Ser	Cys	Arg	Ala	Ser	Glu	Asn	Val	Tyr	Ser	Tyr	Leu	Ala	Trp	
			165					170					175			
Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile	Tyr	Phe	Ala	
			180					185					190			
Lys	Thr	Leu	Ala	Glu	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	
	195						200					205				
Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro	Glu	Asp	Phe	
	210					215					220					
Ala	Val	Tyr	Tyr	Cys	Gln	His	His	Ser	Asp	Asn	Pro	Trp	Thr	Phe	Gly	
225					230				235						240	
Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly	Asp	Gln	Glu	Pro	Lys	Ser	Ser	
			245						250					255		
Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	
		260						265					270			
Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	
	275						280					285				
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	
	290					295					300					
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	
305					310					315					320	
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	
				325					330					335		
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	
		340						345					350			
Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	
	355						360					365				
Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	
	370					375					380					
Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	
385					390					395					400	
Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	
			405						410					415		
Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	
			420					425					430			
Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	
	435						440					445				
Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	
	450					455				460						
His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	
465					470					475					480	
Pro	Gly	Lys														

<210> 254
 <211> 473
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD37 specific binding protein

<400> 254
 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Val Tyr Ser Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser
 100 105 110
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu Val Gln Leu Val
 115 120 125
 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser
 130 135 140
 Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn Met Asn Trp Val
 145 150 155 160
 Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asn Ile Asp Pro
 165 170 175
 Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys Gly Gln Val Thr
 180 185 190
 Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser
 195 200 205
 Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser Val Gly
 210 215 220
 Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Asp
 225 230 235 240
 Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys Pro
 245 250 255
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 260 265 270
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 275 280 285
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 290 295 300
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 305 310 315 320
 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 325 330 335
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 340 345 350
 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln

<210> 258
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Hinge region

<400> 258
Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
1 5 10 15

<210> 259
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Hinge region

<400> 259
Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Ser Pro
1 5 10 15

<210> 260
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Hinge region

<400> 260
Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Ser Pro Arg Cys Pro
1 5 10 15

<210> 261
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Hinge region

<400> 261
Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Ser Pro
1 5 10 15

<210> 262
 <211> 493
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD37 specific binding protein

<400> 262

```

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
 1          5          10          15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
 20          25          30
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn
 35          40          45
Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50          55          60
Arg Leu Leu Ile Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala
 65          70          75          80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85          90          95
Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser
100          105          110
Asp Asn Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115          120          125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ala Ser Glu
130          135          140
Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser
145          150          155          160
Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr Asn
165          170          175
Met Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly
180          185          190
Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Gly Tyr Ala Gln Lys Phe Gln
195          200          205
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu
210          215          220
Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala
225          230          235          240
Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr
245          250          255
Val Ser Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
260          265          270
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
275          280          285
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
290          295          300
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
305          310          315          320
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
325          330          335
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
340          345          350
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys

```


<220>

<223> CD37 specific binding protein

<400> 266

Glu	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly
1				5					10					15	
Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Glu	Asn	Val	Tyr	Ser	Tyr
			20					25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile
			35				40					45			
Tyr	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly
	50					55					60				
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro
65					70					75					80
Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	His	His	Ser	Asp	Asn	Pro	Trp
				85					90					95	
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly	Gly	Gly	Gly	Ser
			100					105					110		
Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Thr	Gly	Glu	Val	Gln	Leu	Val
			115					120					125		
Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Glu	Ser	Leu	Lys	Ile	Ser
			130				135					140			
Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Asn	Met	Asn	Trp	Val
145					150					155					160
Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly	Asn	Ile	Asp	Pro
				165					170					175	
Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys	Gly	Gln	Val	Thr
			180					185					190		
Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	Gln	Trp	Ser	Ser
			195				200					205			
Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg	Ser	Val	Gly
			210				215				220				
Pro	Phe	Asp	Pro	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Asp
225					230					235					240
Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Pro
				245					250					255	
Ala	Pro	Glu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	
			260					265					270		
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val
			275				280					285			
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr
			290				295				300				
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu
305					310					315					320
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His
				325					330					335	
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys
			340					345					350		
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln
			355				360					365			
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu
			370				375				380				
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro
385					390					395					400

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 405 410 415
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 420 425 430
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 435 440 445
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 450 455 460
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 465 470

<210> 267

<211> 473

<212> PRT

<213> Artificial Sequence

<220>

<223> CD37 specific binding protein

<400> 267

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Val Tyr Ser Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Phe Ala Lys Thr Leu Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His His Ser Asp Asn Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser
 100 105 110
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Gly Glu Val Gln Leu Val
 115 120 125
 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser
 130 135 140
 Cys Lys Gly Ser Gly Tyr Ser Phe Thr Gly Tyr Asn Met Asn Trp Val
 145 150 155 160
 Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asn Ile Asp Pro
 165 170 175
 Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys Gly Gln Val Thr
 180 185 190
 Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser
 195 200 205
 Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser Val Gly
 210 215 220
 Pro Met Glu His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Asp
 225 230 235 240
 Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Cys Pro
 245 250 255
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys

<400> 269

Glu	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly
1				5					10					15	
Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Glu	Asn	Val	Tyr	Ser	Tyr
			20					25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile
		35					40					45			
Tyr	Phe	Ala	Lys	Thr	Leu	Ala	Glu	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly
	50					55					60				
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro
65					70					75					80
Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	His	His	Ser	Asp	Asn	Pro	Trp
				85					90					95	
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Gly	Gly	Gly	Gly	Ser
			100					105					110		
Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Thr	Gly	Glu	Val	Gln	Leu	Val
			115					120					125		
Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Glu	Ser	Leu	Lys	Ile	Ser
			130				135					140			
Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr	Asn	Met	Asn	Trp	Val
145					150					155					160
Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	Gly	Asn	Ile	Asp	Pro
				165					170					175	
Tyr	Tyr	Gly	Gly	Thr	Thr	Tyr	Asn	Arg	Lys	Phe	Lys	Gly	Gln	Val	Thr
			180					185					190		
Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr	Leu	Gln	Trp	Ser	Ser
		195					200					205			
Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg	Ser	Val	Gly
	210					215					220				
Pro	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser	Asp
225				230						235					240
Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Cys	Pro
				245					250					255	
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys
			260					265					270		
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val
		275					280						285		
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr
	290					295					300				
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu
305					310					315					320
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His
				325					330					335	
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys
			340					345					350		
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln
		355					360					365			
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu
	370					375					380				
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro
385					390					395					400
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn
			405						410					415	
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu

<223> Xaa = Lys or Arg

<220>

<221> VARIANT

<222> 40

<223> Xaa = Asn or Met

<220>

<221> VARIANT

<222> 41

<223> Xaa = Asn or Pro

<220>

<221> VARIANT

<222> 44

<223> Xaa = Ser or Gly

<220>

<221> VARIANT

<222> 48

<223> Xaa = Ile or Met

<220>

<221> VARIANT

<222> 67

<223> Xaa = Lys or Gln

<220>

<221> VARIANT

<222> 68, 72

<223> Xaa = Ala or Val

<220>

<221> VARIANT

<222> 70

<223> Xaa = Leu or Ile

<220>

<221> VARIANT

<222> 71, 91

<223> Xaa = Thr or Ser

<220>

<221> VARIANT

<222> 76

<223> Xaa = Ser or Ile

<220>

<221> VARIANT

<222> 81

<223> Xaa = Met or Leu

<220>

<221> VARIANT

<222> 83
 <223> Xaa = Leu or Trp

<220>
 <221> VARIANT
 <222> 84
 <223> Xaa = Lys or Ser

<220>
 <221> VARIANT
 <222> 87
 <223> Xaa = Thr or Lys

<220>
 <221> VARIANT
 <222> 88
 <223> Xaa = Ser or Ala

<220>
 <221> VARIANT
 <222> 89
 <223> Xaa = Glu or Ser

<220>
 <221> VARIANT
 <222> 93
 <223> Xaa = Val or Met

<220>
 <221> VARIANT
 <222> 103
 <223> Xaa = Met or Phe

<220>
 <221> VARIANT
 <222> 105
 <223> Xaa = Tyr or Ser

<220>
 <221> VARIANT
 <222> 111
 <223> Xaa = Ser or Leu

<400> 270
 Xaa Val Gln Leu Xaa Gln Ser Gly Xaa Glu Xaa Xaa Lys Pro Gly Xaa
 1 5 10 15
 Ser Xaa Lys Ile Ser Cys Lys Xaa Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30
 Asn Met Asn Trp Val Xaa Gln Xaa Gly Lys Xaa Leu Glu Trp Xaa
 35 40 45
 Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe
 50 55 60
 Lys Gly Xaa Xaa Thr Xaa Xaa Xaa Asp Lys Ser Xaa Ser Thr Ala Tyr
 65 70 75 80

Xaa	Gln	Xaa	Xaa	Ser	Leu	Xaa	Xaa	Xaa	Asp	Xaa	Ala	Xaa	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Ser	Val	Gly	Pro	Xaa	Asp	Xaa	Trp	Gly	Gln	Gly	Thr	Xaa	Val
			100					105					110		
Thr	Val	Ser	Ser												
			115												

<210> 271
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Consensus light chain sequence

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Asp or Glu

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Gln or Val

<220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Met or Leu

<220>
 <221> VARIANT
 <222> 13
 <223> Xaa = Ala or Leu

<220>
 <221> VARIANT
 <222> 15
 <223> Xaa = Val or Pro

<220>
 <221> VARIANT
 <222> 18
 <223> Xaa = Thr or Arg

<220>
 <221> VARIANT
 <222> 19
 <223> Xaa = Val or Ala

<220>
 <221> VARIANT
 <222> 21

<223> Xaa = Ile or Leu

<220>

<221> VARIANT

<222> 22, 72

<223> Xaa = Thr or Ser

<220>

<221> VARIANT

<222> 25

<223> Xaa = Thr or Ala

<220>

<221> VARIANT

<222> 40

<223> Xaa = Gln or Pro

<220>

<221> VARIANT

<222> 42

<223> Xaa = Lys or Gln

<220>

<221> VARIANT

<222> 43, 60

<223> Xaa = Ser or Ala

<220>

<221> VARIANT

<222> 45

<223> Xaa = Gln or Arg

<220>

<221> VARIANT

<222> 48, 58

<223> Xaa = Val or Ile

<220>

<221> VARIANT

<222> 49

<223> Xaa = Ser or Tyr

<220>

<221> VARIANT

<222> 70

<223> Xaa = Gln or Asp

<220>

<221> VARIANT

<222> 74

<223> Xaa = Lys or Thr

<220>

<221> VARIANT

<222> 79
 <223> Xaa = Gln or Glu

<220>
 <221> VARIANT
 <222> 83
 <223> Xaa = Ser or Phe

<220>
 <221> VARIANT
 <222> 84
 <223> Xaa = Gly or Ala

<220>
 <221> VARIANT
 <222> 85
 <223> Xaa = Ser or Val

<220>
 <221> VARIANT
 <222> 87
 <223> Xaa = Phe or Tyr

<220>
 <221> VARIANT
 <222> 100
 <223> Xaa = Gly or Gln

<220>
 <221> VARIANT
 <222> 103
 <223> Xaa = Glu or Lys

<220>
 <221> VARIANT
 <222> 104
 <223> Xaa = Leu or Val

<400> 271
 Xaa Ile Xaa Xaa Thr Gln Ser Pro Ala Thr Leu Ser Xaa Ser Xaa Gly
 1 5 10 15
 Glu Xaa Xaa Thr Xaa Xaa Cys Arg Xaa Ser Glu Asn Val Tyr Ser Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Xaa Gly Xaa Xaa Pro Xaa Leu Leu Xaa
 35 40 45
 Xaa Phe Ala Lys Thr Leu Ala Glu Gly Xaa Pro Xaa Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Xaa Phe Xaa Leu Xaa Ile Ser Ser Leu Xaa Pro
 65 70 75 80
 Glu Asp Xaa Xaa Xaa Tyr Xaa Cys Gln His His Ser Asp Asn Pro Trp
 85 90 95
 Thr Phe Gly Xaa Gly Thr Xaa Xaa Glu Ile Lys
 100 105

<210> 272
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 272
Gly Gly Gly Gly Ser
1 5

<210> 273
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 273
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10

<210> 274
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 274
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 275
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 275
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20

<210> 276
<211> 4

<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 276
Gly Ser Gly Ser
1

<210> 277
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 277
Gly Ser Gly Ser Gly Ser
1 5

<210> 278
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 278
Gly Ser Gly Ser Gly Ser Gly Ser
1 5

<210> 279
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 279
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser
1 5 10

<210> 280
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 280
Gly Gly Ser Gly Gly Ser
1 5

<210> 281
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 281
Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5

<210> 282
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 282
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10

<210> 283
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 283
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10 15

<210> 284
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Linker peptide

<400> 284
Gly Gly Gly Ser
1

<210> 285
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 285
Gly Gly Gly Ser Gly Gly Gly Ser
1 5

<210> 286
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 286
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10

<210> 287
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 287
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10 15

<210> 288
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker peptide

<400> 288
 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 1 5 10 15
 Gly Gly Gly Ser
 20

<210> 289
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker peptide

<400> 289
 Gly Gly Gly Gly Gly Ser
 1 5

<210> 290
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker peptide

<400> 290
 Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser
 1 5 10

<210> 291
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker peptide

<400> 291
 Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
 1 5 10 15
 Gly Ser

<210> 292
 <211> 24
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Linker peptide

<400> 292

Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
1 5 10 15
Gly Ser Gly Gly Gly Gly Gly Ser
20

<210> 293

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Linker peptide

<400> 293

Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
1 5 10 15
Gly Ser Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser
20 25 30

CLAIMS

1. A composition comprising a CD37-specific binding molecule and bendamustine.
2. The composition of claim 1, wherein the CD37-specific binding molecule is a CD37-specific antibody or SMIP.
3. The composition of claim 1, wherein the CD37-specific molecule is a humanized antibody or humanized SMIP.
4. The composition of any one of claims 1 to 3, wherein the CD37-specific binding molecule competes with G28-1 mAb in CD37-specific binding.
5. The composition of claim 1, wherein the CD37-specific binding protein comprises a light chain CDR1 as set forth in SEQ ID NO:61 or 62, a light chain CDR2 as set forth in SEQ ID NO:64, and a light chain CDR3 as set forth in SEQ ID NO:66; and
a heavy chain CDR1 as set forth in SEQ ID NO:63, a heavy chain CDR2 as set forth in SEQ ID NO:65, and a heavy chain CDR3 as set forth in SEQ ID NO:67, 68 or 69.
6. The composition of claim 1, wherein the CD37-specific binding protein comprises, from amino terminus to carboxy terminus:
 - (i) a humanized heavy chain variable region,
 - (ii) a linker,
 - (iii) a humanized light chain variable region,
 - (iv) an IgG1 hinge, and

- (v) a human IgG1 CH2 region, and
- (vi) a human IgG1 CH3 region.

7. The composition of claim 1, wherein the CD37-specific binding molecule comprises, from amino terminus to carboxy terminus:

- (i) a heavy chain variable region comprising a heavy chain CDR3 as set forth in SEQ ID NO:67 or 68;
- (ii) a linker;
- (iii) a light chain variable region comprising a light chain CDR1 as set forth in SEQ ID NO:61;
- (iv) an IgG1 hinge; and
- (v) a human IgG1 CH2 region, and
- (vi) a human IgG1 CH3 region.

8. The composition of claim 1, wherein the CD37-specific binding molecule comprises, from amino terminus to carboxy terminus:

- (i) a heavy chain variable region comprising a heavy chain CDR1 as set forth in SEQ ID NO:63, a heavy chain CDR2 as set forth in SEQ ID NO:65, and a heavy chain CDR3 as set forth in SEQ ID NO:67 or 68;
- (ii) a linker;
- (iii) a light chain variable region comprising a light chain CDR1 as set forth in SEQ ID NO:61, a light chain CDR2 as set forth in SEQ ID NO:64, and a light chain CDR3 as set forth in SEQ ID NO:66;
- (iv) an IgG1 hinge; and
- (v) a human IgG1 CH2 region, and
- (vi) a human IgG1 CH3 region.

9. The composition of claim 8, wherein the CD37-specific binding molecule is a humanized CD37-specific binding molecule that comprises from amino

terminus to carboxyl terminus:

- (i) a humanized heavy chain variable region,
- (ii) a linker as set forth in SEQ ID NO:229,
- (iii) a humanized light chain variable region,
- (iv) an IgG1 hinge,
- (v) a human IgG1 CH2 region, and
- (vi) a human IgG1 CH3 region,

wherein

(a) the humanized heavy chain variable region comprising from amino terminus to carboxyl terminus: a human heavy chain FR1, a heavy chain CDR1 as set forth in SEQ ID NO:63, a human heavy chain FR2, a heavy chain CDR2 as set forth in SEQ ID NO:65, a human heavy chain FR3, a heavy chain CDR3 as set forth in SEQ ID NO:67, 68 or 69, and a human heavy chain FR4, and

(b) the humanized light chain variable region comprises from amino terminus to carboxyl terminus: a human light chain FR1, a light chain CDR1 as set forth in SEQ ID NO:61 or 62, a human light chain FR2, a light chain CDR2 as set forth in SEQ ID NO:64, a human light chain FR3, and a light chain CDR3 as set forth in SEQ ID NO:66, and a human light chain FR4.

10. Use of a CD37-specific binding molecule and bendamustine in the manufacture of a medicament for reducing B-cells or treating a disease associated with aberrant B-cell activity.

11. The use of claim 10, wherein the disease associated with aberrant B-cell activity is a B-cell lymphoma, a B-cell leukemia, a B-cell myeloma, a disease characterized by autoantibody production, or a disease characterized by inappropriate T-cell stimulation associated with a B-cell pathway.

12. The use of claim 11, wherein the disease characterized by autoantibody production is idiopathic inflammatory myopathy, rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis, an autoimmune disease, dermatomyositis, polymyositis, or Waldenstrom's macroglobinemia.

13. The use of claim 10, wherein the disease associated with aberrant B-cell activity is selected from the group consisting of chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), and hairy cell leukemia.

14. The use of claim 10, wherein the CD37-specific binding molecule and bendamustine are administered concurrently.

15. The use of claim 10, wherein the CD37-specific binding molecule and bendamustine are administered sequentially.

16. The use of claim 10, wherein the CD37-specific binding molecule and bendamustine are formulated together.

17. The use of claim 10, wherein the CD37-specific binding molecule is a CD37-specific antibody or SMIP.

18. The use of claim 10, wherein the CD37-specific molecule is a humanized antibody or a humanized SMIP.

19. The use of claim 10, wherein the CD37-specific binding molecule competes with G28-1 mAb in CD37-specific binding.

20. The use of claim 10, wherein the CD37-specific binding molecule is a humanized CD37-specific binding molecule that comprises from amino

terminus to carboxyl terminus:

- (i) a humanized heavy chain variable region,
- (ii) a linker as set forth in SEQ ID NO:229,
- (iii) a humanized light chain variable region,
- (iv) an IgG1 hinge,
- (v) a human IgG1 CH2 region, and
- (vi) a human IgG1 CH3 region, wherein

(a) the humanized heavy chain variable region comprising from amino terminus to carboxyl terminus: a human heavy chain FR1, a heavy chain CDR1 as set forth in SEQ ID NO:63, a human heavy chain FR2, a heavy chain CDR2 as set forth in SEQ ID NO:65, a human heavy chain FR3, a heavy chain CDR3 as set forth in SEQ ID NO:67, 68 or 69, and a human heavy chain FR4, and

(b) the humanized light chain variable region comprises from amino terminus to carboxyl terminus: a human light chain FR1, a light chain CDR1 as set forth in SEQ ID NO:61 or 62, a human light chain FR2, a light chain CDR2 as set forth in SEQ ID NO:64, a human light chain FR3, and a light chain CDR3 as set forth in SEQ ID NO:66, and a human light chain FR4.